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Genetic factors are known to play an important role in smoking behaviours. The work 
presented in this thesis was part of a research project aimed at investigating genetic factors 
involved in nicotine dependence (ND) and smoking cessation; more specifically, the aim of 
my work was to test the hypothesis that these complex traits may be influenced by genetic 
variation affecting 7 nicotinic acetylcholine receptors (nAChR) function. A secondary goal of 
my PhD project was to investigate genetic susceptibility to cluster headache (CH), a form of 
primary headache clinically well distinguished from other forms of migraine, and 
characterized by a very high prevalence of smoking addiction. Previous epidemiological 
studies indicated the importance of complex genetic factors in CH, but genetic studies were 
extremely limited and inconclusive; therefore, we decided to perform a genome-wide study 
to investigate genetic factors involved in this disorder, and their possible relationship to 
nicotine dependence.   
 Role of 7 nAChR in nicotine dependence: 
Numerous studies highlighted the role of nAChRs in nicotine addiction; genetic studies 
pointed to significant SNP associations within the CHRNA5-CHRNA3-CHRNB4 and CHRNB3-
CHRNA6 gene clusters. CHRNA7, encoding the 7 subunit of homopentameric nAChR, has a 
still uncertain role in nicotine dependence, although it is implicated in a wide range of 
phenotypes and psychiatric conditions. CHRFAM7A, a hybrid gene containing a partial 
duplication of CHRNA7, is possibly involved in modulating 7 nAChR function. We conducted 
a genetic study in order to investigate the role of genetic variation at CHRNA7 and 
CHRFAM7A in smoking phenotypes, as well as to test the hypothesis that 7 nAChR variation 
may modulate the efficacy of varenicline in smoking cessation. The study was performed on 
a collection of 408 regular tobacco smokers, recruited at  smoking cessation centers, 
including a subgroup of 142 individuals treated with varenicline, a drug approved by US Food 
and Drug Administration for use as smoking cessation aid. We determined the copy number of 
both CHRNA7 and CHRFAM7A, as well as the genotype of the CHRFAM7A exon 62bp 




resequenced the CHRNA7 proximal promoter region in order to test the effect of common 
and rare variants involved in CHRNA7 transcription regulation. Our results point to a role for 
CHRNA7 promoter variants in tobacco addiction mechanisms; moreover, our study provides 
the first evidence that CHRFAM7A copy number variation could affect the response to 
varenicline treatment.  
 Genetic analysis of cluster headache: 
Family and twin studies have indicated a genetic component for CH, but its molecular 
genetic background is still largely unexplored. Smoking is the most consistent lifetime habit 
reported in CH patients, as over 80% of CH patients have a prolonged history of tobacco 
usage. However, it is still unknown if tobacco use could be an environmental trigger for CH in 
genetically predisposed subjects, or if specific genetic risk factors for CH may also predispose 
individuals to smoking addiction. Given the unknown CH pathophysiology, we decided to 
take a hypothesis-free genome-wide approach, using the Infinium PsychArray (Illumina); this 
particular SNP array combines both common highly-informative genome-wide tag SNPs and 
SNPs in coding regions of genes with an enrichment in genetic variants associated with 
common psychiatric conditions. Genotyping data from a sample of 99 CH cases and 359 
controls were used to perform a genome wide case-control association analysis for common 
SNPs. Even if no genome-wide significant loci were reported, this analysis led to the 
identification of a suggestive association with a common variant of the PACAP receptor gene 
(ADCYAP1R1). No evidence for an overlap with the strongest  and most replicated risk 
variants for migraine or nicotine dependence was detected. Furthermore, we performed a 
gene-based association analysis considering rare protein altering variants in 745 candidate 
genes with a possible role in CH.  This analysis provided evidence of association for a rare 
potentially damaging missense variant in the MME gene, encoding for the metallo-
endopeptidase neprilysin. ADCYAP1R1 and MME both represent very interesting candidate 
genes for CH,  as their gene products are known to have an important function in pain 
mechanisms; thus, our study provides the first evidence that genetic variation in genes 
related to pain processing might have a role in CH susceptibility. 
 







1.1 Biological mechanisms 
Tobacco use is the main cause of preventable morbidities and deaths worldwide1,2. Cigarette 
smoking is associated with increased risk of the four main death causes: lung cancer, 
cardiovascular diseases, cerebral infarction and chronic obstructive pulmonary disease. 
According to the World Health Organization (WHO), cigarette consumption causes more 
than 6 million deaths each year worldwide. The number of smokers, even if in decline, 
remains over 1.1 billion people around the world and Europe has the highest prevalence of 
tobacco smoking among adults (28%).  
Despite cigarette smoking related risks are well known in Western countries, only about 30% 
of smokers attempt to quit smoking each year and, among these, only 5% maintain smoking 
abstinence within one year2. The tobacco epidemic can be explained by the fact that tobacco 
use represents a form of drug dependence, and specifically, dependence to nicotine, which 
is the primary compound responsible for tobacco reinforcement3.   
The process that leads to the development of nicotine addiction involves different areas in 
the brain in which several different nicotinic acetylcholine receptor (nAChR) subunits (Figure 
1.1) are located.  





Figure 1.1: Model of neuronal mechanisms involved in smoking dependence. Nicotinic acetylcholine receptor (nAChR) 
subunits are located in different brain areas involved in ND mechanisms. Nicotine intake and reinforcement are caused by 
activation of VTA neurons in the midbrain that project to limbic areas (including the hypothalamus)  and the prefrontal 
cortex. Cholinergic innervation from both the pedunculopontine tegmental nucleus (PPTg), in the caudal mesencephalic 
tegmentum,  and the laterodorsal tegmental nucleus (LDTg) projects into VTA neurons. Withdrawal symptoms involve 
distinct neural circuits including the extended amygdala and brain stress systems, hippocampus, hypothalamus, substantia 
nigra pars compacta (SNpc), and/or the habenula–interpeduncular (HB–IPN) system. The transition from prefrontal cortex 
control (which regulates the hippocampus and amygdala) to dorsal striatum control determines the switch from voluntary 
to compulsive nicotine use(Changeux et al. 2010)3. 
 
Nicotine binds and activates nicotinic acetylcholine receptors (nAChRs) and induces the 
activation of mesolimbic dopamine (DA) system neurons that trigger the process leading to 
tobacco addiction development. The activation of mesolimbic DA system is the principal 
cause of reward for both natural stimuli (for example drinks or food) and drugs4, and, thus, it 
is considered a major contributor to dependence development.  
The mesolimbic DA system includes cell bodies in the ventral tegmental area (VTA) and their 
projections to the ventral striatum, which comprises the nucleus accumbens (NAc) as well as 
other telencephalic areas such as the amygdala, hippocampus and prefrontal cortex.  The 
activation of nAChRs by nicotine binding causes the stimulation of dopaminergic neurons in 
the VTA leading to increased DA concentration in the NAc which is critical for the primary 
reinforcing effects of tobacco use, and contributes to the development of tobacco 




addiction5. In vivo studies showed that blockage of dopamine release in the NAc with 
antagonist peptides or lesions reduces the rewarding effects of nicotine, as shown by 
decreased self-administration in animals6-8. 
Withdrawal symptoms are regulated by different neural circuits including habenula, 
amygdala and the hypothalamus. Studies performed on animal models showed that neurons 
in the VTA receive inhibitory projections from the habenula and an elevated DA turnover is 
induced in Nac and prefrontal cortex after habenular lesion. It is supposed that cigarette 
consumption leads to increased habenular activity to compensate for elevated DA release. 
Withdrawal would then lead to non-compensated habenular hyperactivity, and therefore to 
a disappointment state, driving repeated cigarette consumption9. 
Dependence represents the end point of a series of stages in which individuals seek and 
voluntarily smoke cigarettes owing to its reinforcing effects; this leads to loss of control of 
cigarette consumption and smoke becomes habitual and, ultimately, compulsive. Neuronal 
mechanisms underlying conscious control have been investigated and a model has been 
proposed: the global neuronal workspace (GNW) model. This model proposes that several 
cortical areas interact through a complex network of neuronal axons to maintain voluntary 
control. Under this hypothesis the hippocampus, amygdala and dorsal striatum are regulated 
by the prefrontal cortex (Figure 1.1) and this mechanism underpins the control and 
inhibition of behavior. It has been suggested that nicotine prolonged use could alter 
prefrontal cortex functions disrupting inhibitory control to resist cigarette consumption thus 
leading to compulsive cigarette smoke that characterizes the final step of ND3. 
 
1.2 Nicotinic acetylcholine receptors 
1.2.1 Protein structure 
NAChRs are receptor proteins that are activated by the endogenous neurotransmitter 
acetylcholine and exogenous substance nicotine. They are expressed in the central and 
peripheral nervous system, muscle, and many other tissues of many organisms, including 
humans.  NAChRs consist of 5 subunits assembled to delimit a central pore that allows cation 
flow down an electrochemical gradient (mainly influx of Na+ and Ca++, and efflux of K+). The 
mammalian nervous system expresses twelve neuronal subunits, nine alpha (α2–α10) and 
three beta subunits (β2–β4), and five muscular subunits (α1, β1, γ, δ, and ε). The different 




combinations of subunits lead to several pentameric receptor subtypes with different 
pharmacological properties, including binding affinity, and distribution in the nervous 
system5. Only the α7 and α9 subunits are capable of forming homomeric receptors.  
Each subunit consists of one single polypeptide chain organized into transmembrane 
structure shared by all subunits. In particular, it is characterized by an amino-terminal 
glycosylated domain carrying one or more highly conserved cysteine bridges, facing the 
extracellular space; three transmembrane segments called M1, M2, and M3 linked by short 
loops, a large and variable intracellular domain and another transmembrane segment M410 
(Figure 1.2).  The cysteine bridge, in the N-terminal fragment, is important in maintaining the 
correct folding of the chain and in the ligand binding 11,12. Furthermore, other two conserved 
amino acid, tyrosine and tryptophan, are involved in the ligand binding, establishing weak 
links with acetylcholine.  
 
Figure 1.2: Neuronal nicotine receptor section. 
 
The number of binding sites is different between homopentameric and heteromeric 
receptors: the first receptor type contains five identical acetylcholine-binding sites, while the 
heteropentameric receptors have only two acetylcholine-binding sites. In this case the two 
alpha subunits (a2–a4 or a6) contain the main component of the acetylcholine-binding site 
while the binding site complementary component is carried by two beta subunits (b2 or b4). 




The fifth subunit (a5, b3, b2 or b4), is not directly involved in acetylcholine binding, but it 
influences receptor affinity for the ligand and receptor localization in the neuronal 
membrane.  
Based on agonist exposure, the nAChR can be found in three different conformational states: 
closed, open and desensitized13. Agonist binding causes the activation of the receptor which 
changes its state from closed to open.  In this state, the permeability to Na+ and Ca++ 
increases, leading to neuronal depolarization and excitation. After this step, the receptor 
becomes closed again and it is desensitized. Only when the agonist dissociates from the 
receptor the activation-desensitization cycle can restart14-16. 
1.2.2 Localization and function of neuronal nAChRs  
Nicotine acetylcholine receptors are located both on the presynaptic, postsynaptic and the 
preterminal membrane. Presynaptically, nicotine acetylcholine receptors regulate different 
neurotransmission pathways, including the serotonergic and cholinergic pathways17-21. The 
activation of nAChRs at the presynaptic level initiates an intracellular Ca++ signal enhancing 
neurotransmitter release17,22-27.  Properly localized Ca++ signals lead to the start of 
intracellular signaling that alters synaptic transmission28,29. Moreover, it was reported that 
timed presynaptic nAChRs activity, which precedes glutamatergic electrical stimulation, 
increases glutamate release and raises long-term synaptic potentiation30,31.  
NAChRs are also localized in the preterminal membrane where they regulate excitability 
along fibers as well as neurotransmitter release. Preterminal localization of nAChRs, just 
before the presynaptic membrane, indirectly modulates neurotransmitter release through 
activation of voltage-gated channels and induction of local action potentials32,33.  Dendritic 
and somatic location of nAChRs have a role in synaptic plasticity modulation. 
Postsinaptically, nAChRs have also a role in depolarization and in initiation of intracellular 
Ca++ signal 30,31.  
In the central nervous system, nicotine acetylcholine receptors are widely distributed, 
therefore their activation influences several molecular mechanisms in different brain areas 
that could be involved in tobacco addiction3 (Figure 1.1).  NAChRs share a common basic 
structure but they are also distinguished in different subtypes (based on different subunit 
combinations), with distinct functional and pharmacological properties34. 




In the central nervous system it is possible to discriminate 2 different classes of nAChRs 
based on their binding affinity: one class of receptors that binds nicotine and nicotinic 
agonists with high affinity (nM affinity) and another class of receptors that bind nicotine with 
low affinity (µM affinity) and the antagonist α-bungarotoxin with high affinity35. Heteromeric 
receptors consisting of different combinations of α2- α6 and β2- β4 belong to the receptor 
class showing high affinity for nicotine but no sensitivity for α-bungarotoxin, while 
homomeric or heteromeric receptors consisting of the α7, α9, α8, α7– α8, or α9– α10 belong 
to the second class of receptors36.  
It was reported that nicotine, in the brain, causes a post-transcriptional up-regulation of 
high-affinity receptors, and this effect could be considered another mechanism through 
which nicotine leads to addiction development37.  
In the brain, the most expressed nicotine acetylcholine receptors are α4β2* (the asterisk 
indicates the presence of other subunits in the pentameric receptor) and α7. The former are 
particularly expressed by dopaminergic neurons in the VTA18,34,35. Generally, in these 
neurons, α4 and β2 assemble with α3, α5, α6 or β3 subunits, forming several nicotine 
acetylcholine receptor subtypes that differ in subcellular localization, activation rates, ligand 
affinity, ionic permeability, and pharmacological profile5. α7 receptors are localized in the 
hippocampus,  cortex, and subcortical limbic areas, and to a lower extent, in the thalamus 
and basal ganglia regions34.  
Studies performed on animal models (rats and mice) revealed that the α3 subunit is located 
in the pineal gland, medial temporal lobes and cerebellum, while the α5 subunit is localized 
in the striatum and cerebral cortex38-41. Both are also expressed in the ventral tegmental 
area, in the substantia nigra and in the hippocampus.  
Given the different distribution of nAChRs subtypes in the central nervous system, nicotine 
binding causes several different effects depending on the brain region involved. In the 
prefrontal cortex and hippocampus nicotine binding enhances memory and concentration, 
while in the mesolimbic pathway nicotine modulates the positive reinforcement and 
gratification mechanisms that lead to the development of addiction3,34 (Figure 1.1).  
 




1.2.3 α7 nAChRs 
CHRNA7 encodes the α7 subunit of the neuronal nicotinic acetylcholine receptor, which 
forms a homopentameric chloride channel receptor. This receptor is characterized by fast 
activation, rapid desensitization, high Ca++ permeability, and specific binding for selective 
ligands which include the antagonist α-bungarotoxin42. CHRNA7 is widely expressed in both 
the brain and periphery with many important roles in cognition and the immune system. α7 
receptors are localized both pre- and post-synaptically; in the brain, presynaptic a7nAChRs 
are found in glutamatergic and GABAergic terminals in the hippocampus and other regions, 
where Ca++ influx leads to the release of many different types of neurotransmitters11. 
α7nAChR are localized also in the postsynaptic density (PSD)43,44 where Ca++ influx modulates 
CREB phosphorylation, causing alterations in gene expression29. 
1.3 The genetics of nicotine dependence 
Nicotine dependence (ND) is considered a multifactorial trait determined by a complex 
interaction of several genetic factors, each having a modest effect, and environmental 
influences45. Family and twin studies highlighted the importance of genetics in tobacco 
addiction and in different aspects of smoking behavior (including the number of cigarettes 
smoked daily and the dependence level), estimating a heritability greater than 60%45,46. 
Furthermore it has been shown that the ability to quit smoking is also influenced by robust 
heritable factors47. It has been estimated that 50% of the risk for a failed attempt at smoking 
cessation can be attributed to genetic factors 48,49. Interestingly, it was also reported that 
heritable influence on ability to quit smoking overlaps only in part with genetic influences 
underlying tobacco addiction 47. Therefore, analysis of ND is complicated, since several genes 
and environmental factors are involved in smoking phenotypes, and the different smoking-
related traits could be attributed to different genetic underpinnings. In recent years, 
researchers have used several approaches to investigate the contribution of genetic factors 
to ND. Experimental methods for genetic studies of ND have evolved from genome-wide 
linkage studies to candidate gene association studies and from genome-wide association 
studies (GWAS) to targeted sequencing. The first three approaches rely on genotyping of 
genetic markers, which are polymorphic variants with a known position in the genome, such 
as microsatellites and single base changes named Single-Nucleotide Polymorphisms (SNPs).  
In the next coming years, whole-exome and whole-genome sequencing studies are expected 




to become the main methods to analyze the contribution of rare and common variants 
involved in complex disorders/traits50.  
To understand the complex aspects of tobacco addiction, researchers have used different 
measures of ND in genetic studies. One of these is the level of ND, calculated by Fagerstrom 
test for ND (FTND)51. It is a questionnaire, containing six items of which three are yes/no 
items with a score from 0 to 1 and three are multiple-choice items with a score from 0 to 3. 
The sum of each items represents the total score spanning from 0 to 10 and provides a 
measure of ND: 1-2 = low dependence, 3-4 = low to moderate dependence, 5-7 = moderate 
dependence, > 8 = high dependence52. Others nicotine addiction related phenotypes include 
smoking quantity, referred to the number of cigarettes smoked per day (CPD) and smoking 
cessation, based on success or failure of smokers that attempt to quit. Furthermore, some 
genetic studies have also considered the age of smoking initiation as an additional 
phenotypic trait5.  
1.3.1 Linkage analysis 
Genetic linkage analysis is a powerful method to identify the chromosomal position of genes 
related to disease. For several years, linkage analysis has been the main approach for genetic 
mapping of both Mendelian and complex disorders showing familial aggregation53,54. Linkage 
analysis is the process of determining the approximate chromosomal location of  disease-
causing variants by looking for evidence of co-segregation across generations with other 
markers whose locations are already known. Co-segregation is a tendency for two or more 
genes to be inherited together, and hence for individuals with the same trait to share alleles 
at the marker locus. The degree of linkage is a function of how close the loci are to each 
other, with widely spaced loci on the same chromosome behaving as if they were unlinked, 
thereby making it possible to estimate the location of variant involved in a specific disease 
relative to one or more known markers.  
Linkage studies are focused on related individuals of large multigenerational families or a 
consistent number of small nuclear families (including father, mother, and their children). 
This approach allows to detect large candidate regions (in the order of Mb), spanning many 
genes, and its success may be hampered by genetic and phenotypic heterogeneity of the 
trait.  




The linkage analyses used to map genes for monogenic disorders are said to be parametric, 
and in this case the data can be analysed only if a specific genetic model is assumed. This 
type of linkage is used in the study of Mendelian diseases occurring within multigenerational 
families containing different affected individuals, from which it is possible to infer the 
inheritance model of the locus disease. Instead, to analyzed complex diseases, 
nonparametric methods may be used, that do not require the pre-specification of a genetic 
model. Nonparametric linkage studies are usually based on the analysis of large samples of 
affected sib-pairs. The aim is to obtain genome-wide marker data and then identify 
chromosomal regions that have been shared by affected sib pairs more often than would be 
predicted by random Mendelian segregation.  
In 2008, Li et al. published a comprehensive review including more than 20 genome-wide 
linkage analysis of smoking behaviors55. The linkage studies were performed across several 
populations using different nicotine addiction phenotypes, CPD, FTND, ever-smoking, 
habitual smoking, or maximum number of cigarettes smoked in a day (24h). In this study 13 
regions, located on chromosomes 3–7, 9–11, 17, 20, and 22, have been identified to be 
suggestively or significantly linked with various ND measures in at least two independent 
samples. Three genes that encode for nicotine acetylcholine receptors are located in these 
suggestive or significant regions: CHRNA10 (11p15), CHRNA2(8p21–22), and CHRNA4 
(20q13.2–q13.3). In 2009, Hardin et al performed a genome-wide linkage study of nicotine 
withdrawal sensitivity in 158 pedigrees with 432 individuals56. This study identified a linked 
locus in the same region previously reported to be linked to FTND57.  More recently, a meta-
analysis of 15 genome-wide linkage scans of smoking phenotypes was performed58. This 
study, including 3404 families with 10253 individuals, detected a genome-wide suggestive 
linkage on chromosome 17q24.3–q25.3. The same region has been also detected in one 
sample reported in Li et al. 200855. Futhermore, the metanalysis performed by Han et al., 
provided a genome-wide suggestive linkage in 5q33.1–5q35.2, and a genome-wide 
significant linkage in 20q13.12–q13.3258. These results confirmed the previous finding 
showed in Li et al. (2008), even if, in this metanalysis, the regions detected on chromosomes 
5 and 20 are larger.  




1.3.2 Association studies 
Linkage analyses have limited power to detect susceptibility factors in complex disease, and 
have been largely supplanted by the alternative of association studies. The purpose of 
association studies is to detect an allelic association between specific genetic variants and 
the studied trait in closely unrelated individuals within a population.   For example, if allele 
A1 at locus A is found to be significantly more frequent in people affected by a specific 
disorder than would be expected from the individual population frequencies of A1 and the 
disease gene, the allele A1 is positively associated with disease and, thus, it is a disease 
susceptibility allele. 
To investigate disease associations, case-control studies can be performed in which genetic 
variants are genotyped in affected individuals (cases) and controls. Different methods can be 
used to measure the disease risk for each tested genetic variant, notably the odds ratio (the 
odds of being affected of individuals carrying a specific variant divided by the odds of being 
affected of individuals without the variant). Association between genetic variants and 
disease could be interpreted in different ways. Genetic variants associated with disease 
might be directly involved in the disorder, or they may be in Linkage disequilibrium (LD) with 
the variant contributing to disease risk. The LD describes any non-random association of 
alleles at different loci in a specific population.   
Notably, the association identified in case-control analysis could also represents a false 
positive caused by chance or problems related to the use of inappropriate statistical 
methods or population stratification. As a result of population stratification, different 
subgroups within a broad population often have significantly different frequencies of a 
genetic variant, and this can confound genetic analyses. To minimize problems arising from 
population stratification, cases and controls used in association studies should have the 
same population ancestry.  
Generally, the density of SNPs required for association studies is higher compared to linkage 
studies, but association studies allow to detect a candidate genetic region with a better 
resolution. Association studies do not require large families with several affected members, 
but can be carried out on unrelated case and control individuals or using nuclear families 
(e.g. trios: a proband and parents). Furthermore, association approaches are more 
appropriate to identify susceptibility genes involved in common and complex traits in which 
the risk of any given susceptibility variant is relatively small59.  




Association studies results are normally expressed as P values or –log10(P), a strong 
association is observed when p-value is very low.  Generally, a p value < 0.05  is taken as the 
threshold of statistical significance. However, the significance threshold must be corrected 
by the number of independent statistical tests performed; thus, testing for association using 
a large number of markers increases the required number of tests and the significance 
threshold should be more stringent.   
Genetic association studies may be focussed on testing for association between variants 
within pre-specified genes of interest and phenotypic traits (candidate gene approach), or 
they may be extended to the whole genome. Genome-wide association studies (GWAS) 
involve the analysis of a large number of SNP markers throughout the entire genome.  
1.3.2.1 Candidate-gene association studies 
Candidate gene studies are focused on the study of genes that could be related to the trait 
or disease. The first step of candidate gene analysis is the selection of a putative candidate 
gene and, generally, it is based on its known biological, physiological, or functional relevance 
to the trait being investigated. Furthermore, a positional-candidate approach can be used to 
further investigate a putative region of interest arising from genome-wide linkage mapping 
or GWAS. 
In ND, some biological pathways that regulate the intake of nicotine, its effects in central 
nervous system, and its metabolism are well known, but others are not60. Candidate genes 
studies have been carried out to investigate the contribution of  genes involved in those 
pathways: 
 Dopaminergic system  
Several studies focused on the dopaminergic system, considered the main contributor in 
development of drug addiction. Different studies identified statistically significant 
association with several variants and haplotypes in regions encompassing the dopamine 
receptor genes  DRD2, DRD1,  DRD4 and smoking-related behaviours61-64. Significant 
associations with smoking cessation and others nicotine addiction traits, have also been 
reported for genes involved in dopamine metabolism, including dopamine β-hydroxylase 
(DBH)61,65-67 DOPA decarboxylase (DDC)68,69 and catechol-O-methyl transferase (COMT)70,71. 
Interestingly these genes, except DBH and DDC, are within or close to a modest linkage peak 




and received support from GWAS72. Furthermore, the dopamine transporter gene, SLC6A3, 
has been implicated in smoking cessation in a meta-analysis performed on 2155 subjects73. 
However, a more recent meta-analysis, which assessed eight studies, didn’t confirm this 
result74. Several candidate gene studies also examined the OPRM1 gene, encoding for the 
endogenous opioids receptor. OPRM1 A118G variant seems to be involved in increasing 
susceptibility to smoking behaviours, especially to ND, but less to smoking initiation and 
cessation75. 
 GABAergic systems 
Different candidate gene association studies were performed on the region on chromosome 
9, showing a “suggestive” linkage results for smoking-related behaviour in previous studies76-
79. Several candidate genes were analysed, and among these, the GABAB receptor subunit 2 
(GABBR2) gene. Variants in this gene were significantly associated with ND, in subjects of 
European and African origin77. Another candidate gene in the GABAergic system is the 
GABAA receptor-associated protein (GABARAP) gene, located on chromosome 17 in a 
“suggestive” linkage region for tobacco addiction58. Lou et al. reported two polymorphisms 
in GABARAP (rs222843 and rs17710) showing association with ND in European-American 
smokers80. Furthermore, variants in the GABAA receptor subunits alpha 2 (GABRA2) and 4 
(GABRA4) located on the chromosome 4p cluster, have been associated to smoking 
behaviour and alcoholism61,81,82.  
 Serotonergic systems 
The serotonergic system may be involved in tobacco addiction, since nicotine intake leads to 
an increased release of serotonin in the brain and nicotine withdrawal behaviours are 
related to a reduction of serotonergic neurotransmission83. Candidate genes studies 
reported a statistically significant association for variants in genes encoding for serotonin 
transporter (SLC6A4)84-86 and serotonin receptor (HTR3A – HTR5A), with different smoking 
phenotypes61,87. 
 Glutamatergic system 
The increase of glutamate release is very critical in drug dependence. Analysis of genes 
involved in the glutamatergic system showed that variants in GRIN3A and GRIN2B, encoding 




for ionotropic glutamate receptors, are significantly associated with FTND88,89.  In a GWAS 
performed by Vink et al. in 200990, a suggestive association with smoking-related 
phenotypes was reported also in other genes of the glutamatergic system, including GRIK2, 
GRIN2A, GRM8 and SLC1A2 genes, however, candidate genes studies did not replicate this 
result90. 
The formation of glutamatergic synapses can be regulated by neurexins, cell-adhesion 
molecules that play a role in synapse formation and maintenance. Interestingly, genes 
encoding for Neurexin 1 (NRXN1) and neurexin 3 (NRXN3) have been both associated to 
nicotine addiction91-93.  
 Nicotinic receptors  
Different candidate-gene studies have been performed to analyse the association with 
nAChR subunit genes with ND behaviours. These studies, carried out by either case-control 
or family-based designs, identified a prominent association between several neuronal 
nAChRs genes and tobacco addiction phenotypes94. Statistically significant results were 
identified for gene clusters on chromosomes 15, encompassing CHRNA5, CHRNA3, CHRNB4 
and for gene clusters on chromosomes 8, including CHRNB3 and CHRNA6 with ND95,96. These 
findings represent also the major discoveries from GWAS of ND97,98. Candidate gene studies 
also identified significant association for variants in other genes encoding nicotine receptors 
subunits (CHRNB1, CHRNA4, CHRNA2 and CHRNB2) with tobacco addiction89,99-101. GWAS of 
ND did not find significant association for variants within these genes, however CHRNB1 and 
CHRNA4 are reported to be close to linkage peaks50.  Genetic variants in CHRNA3 and 
CHRNA5 have also been shown to have a role in smoking cessation and in response to 
pharmachological smoking cessation treatments102-104. In particular, the rs16969968 non-
synonymous SNP in CHRNA5, the variant with strongest association to ND implicated by 
GWAS, has an effect on NTR efficacy but not on varenicline efficacy in smoking cessation105 
 Nicotine metabolism pathway  
CYP2A6 is the enzyme involved in metabolic inactivation of nicotine to cotinine. Several 
studies found that variants in the CYP2A6 gene, causing a reduced enzyme activity,  are 
associated with CPD, FTND, and other smoking-related behaviours 61,106,107. Furthermore, 
CYP2A6 variants, have also been shown to have an effect on smoking cessation maintenance 




and on response to cessation pharmacotherapy. Genotypes related to fast nicotine 
metabolism are associated to decreased smoking cessation success and to a higher response 
to NRT compared to slow nicotine metabolism genotypes108. 
1.3.2.2 Genome-wide association studies (GWAS) 
In contrast to candidate gene studies, genome-wide association studies (GWAS) are based 
on  a ‘hypothesis-free’ approach. 
GWAS began to really take off in the mid-2000s because of two technological developments. 
First, in the last years, the creation of public international projects, including the HapMap 
Project (http://hapmap.ncbi.nlm.nih.gov/) and the 1000 Genome Project 
(http://www.1000genomes.org/) allowed to determine the common patterns of human 
genome variation characterizing SNPs, their frequencies and the degree of LD in DNA 
samples from different populations. Knowledge of the LD pattern between SNPs has very 
important practical implications109. By analysing a non-redundant group of representative 
SNPs (SNPs tags), it is possible to impute the genotype of the other common variants in high 
LD with them. All SNPs in high LD belong to a group of SNPs called “haplotype block” and the 
tag SNPs are the variants sufficient to discriminate between all the haplotypes in the block. 
The most widely used measure of LD is the square of the correlation coefficient (r2), which 
can range from 0 to 1 (1 when the two SNPs are in complete LD and perfectly correlated 
with each other). Based on empirical studies, it has been shown that most of the information 
on common human variability, represented by ten million SNPs in the human genome, can 
be obtained by analysing 200000 up to 1000000 tag SNPs110,111. 
Secondly, an important contribution to the spread of the whole genome association studies 
was given by the development of microarray platforms. SNP arrays enable to genotype 
hundreds or thousands of SNPs across the human genome at the same time and provide 
information about both copy number and genotype. Currently, companies such as Illumina 
and Affimetrix produce standard SNPs panels, by which it is possible to generate millions of 
genotypes with only one hybridization reaction, obtaining good quality data in brief time. 
Furthermore, GWAS depend on the availability of large samples of cases and controls. 
GWAS projects have been designed to identify common variants on the assumption that 
common complex disorders are often caused by common variants (the “common disease-
common variants” hypothesis)59. Under this hypothesis, different combinations of common 




variants at multiple loci increase disease risk in specific individuals. It was supported by 
known associations of common variants with complex diseases, for example in the 1990s the 
Apoε4 allele was found to be a susceptibility factor for Alzheimer's disease112 and the factor 
V Leiden was associated to venous thrombosis113.  
The bulk of GWAS have focused on case-controls studies in which panels of affected 
individuals and matched controls are genotyped at hundreds of thousands of common SNPs 
(where the minor allele usually has a frequency of at least 0.05). SNPs in which allele 
frequencies are significantly different in cases than in controls are identified as associated 
with the studied trait (Figure 1.3). 
 
Figure 1.3: Outline of a genome-wide association (GWA) scan. Using HapMap data, representative SNPs are selected that 
will differentiate the common haplotypes at each locus. In this example, three common haplotypes (A,B and C) at locus 1 
are tagged by four SNPs (with strong colour if present, or grey if absent). But just two SNPs (purple and blue) are sufficient 
to discriminate between the three haplotypes. Similarly, the two haplotypes at locus 2 can be distinguished by either the 
red or blue SNPs. Tag SNPs are then genotyped in case-control association study using microarrays, and the alleles 
frequencies for each SNP are compared in the two groups. The significant results need then to be confirmed in an 
independent study.   
 




In GWAS studies hundreds of thousands of common SNPs are investigated and therefore a 
huge numbers of association tests are carried out, hence stringent statistical significance 
thresholds are required to assess the significance of individual results. One way of setting a 
stringent genome wide significance threshold is to divide the standard p-value of 0.05 by the 
number of tests (Bonferroni correction). If one million of independent variants are tested in 
a GWAS, for example, a stringent P value would then be 0.05/1000000 = 5*10-8. In any case, 
initial significant or promising GWAS results need to be confirmed by independent studies to 
gain additional confidence. 
GWAS data can be visualized using two different types of plots (Figure 1.4): 
 The Quantile-quantile (Q-Q) plot is used to explore the presence of systematic errors 
that may result in spurious association, such as stratification population. A Q-Q plot is a 
scatterplot created by plotting all observed p-values ranked from the smallest (the most 
significant) to the largest against the expected null distribution under the hypothesis of 
no disease association. Each p-value is converted to its negative log value. If there is no 
association, the plot of the observed versus expected results will form a 45° straight line. 
Deviation from the 45° reference line indicates a generalized shift of observed results 
from expected results for any level of statistical significance. Such a generalized shift 
indicates the presence of a systematic error such as population stratification, and these 
association results are likely spurious. A clean QQ plot, on the other hand, should show a 
straight line that sharply curves at the end (indicating few true association signals 
amongst thousands of unassociated variants) (Figure 1.4). 
 The “Manhattan plot” is used to display GWA results according to their genomic position 
(x axis) and statistical significance (y axis, the negative log10P scale helps reveal signals of 
particular interest) (Figure 1.4 B).    
 




Figure 1.4: Visualizing genome-wide association (GWA) data. (A,B) Example of QQ plot visualizing observed GWAS results 
against theoretical expectation. The expected null distribution is a straight line (blue). (A) A problematic result showing a 
generalized shift of observed results from expected null results for any level of statistical significance. It indicates a 
systematic error such as population stratification. (B) The expected and observed results show similarity; for limited 
number of SNPs statistical significance values are higher than expected indicating true association. (C) An example of 
Manhattan plot summarizing GWAS results. The red horizontal line at position 7.3 on the vertical scale indicates the 
threshold of statistical significance in this particular example.       
 
In recent years, a large number of GWAS have been performed, leading to the identification 
of hundreds of significantly associated variants to individual complex diseases (available in 
the GWAS catalog, https://www.ebi.ac.uk/gwas/). However, almost all of the identified 
susceptibility variants are of weak effect: even the cumulative contributions of the identified 
variants are usually quite small. That is, the available GWAS data can explain only a small 
proportion of the genetic variance of complex diseases. This observation has raised the issue 
of the “missing heritability”, that is the fact that SNPs associations cannot account for a large 




proportion of the estimated heritability of a trait114. Several explanations have been put 
forward to justify the missing heritability. One of these is the evidence that GWAS with 
sample size of a few thousand cases and controls are well suited to identify susceptibility 
variants with odds ratio of 1.5 or more, but they are missing many true susceptibility factors 
of weaker effects (odds ratio <= 1.2). Much larger numbers of cases and controls are thus 
warranted to detect these weaker effect variants, either in single studies or in meta-analysis. 
Furthermore, a major limitation of GWAS is that they are focused only on the analysis of 
common variants. However, susceptibly to complex diseases could be also partly due to the 
contribution of a heterogeneous set of rare variants, individually with strong effects. In order 
to track down these specific rare variants whole-genome sequencing would be required. In 
addition, the proportion of heritability explained by known GWA variants does not take into 
account possible genetic interactions between loci and between genes and environmental 
components. 
1.3.2.2.1 Results from GWAS on nicotine dependence  
In recent years, several GWAS, using sets of about 500000 SNPs and including large numbers 
of participants, have shown that the strongest genetic contribution for smoking traits comes 
from variation in the nAChR subunit genes. The most prominent associations were found for 
variants in the CHRNA5–CHRNA3–CHRNB4 gene cluster and in the CHRNB3/CHRNA6 gene 
cluster, converging with previous candidate-gene studies results of nicotine receptors genes 
98,115-117.  
The importance of the CHRNA5/A3/B4 gene cluster in several aspects of ND was highlighted 
by three GWAS meta-analyses 72,97,118. In this gene cluster three groups of risk variants for 
heavy smoking and ND have been identified. One group is marked by the non-synonymous 
SNP rs16969968 located in exon 5 of the CHRNA5 gene, which causes a substitution of amino 
acid asparagine with aspartic acid at position 398 (D398N). Homozygous individuals for the 
rs16969968 minor allele (A) are about twice as likely to develop tobacco addiction, in a 
recessive model of inheritance61. rs16969968 is tightly linked to rs55853698, rs2036527, and 
rs1051730, which are also found to be significant associated to smoking phenotypes, 
including both CPD and FTND score. The second associated variant group is tagged by 
rs588765, located on CHRNA5 intron 1. This polymorphism regulates CHRNA5 expression: 
the C/C genotype is associated to low gene expression while the T/T genotype is related to 




an increased expression of CHRNA5 that is associated to higher risk for ND119-121. The third 
risk variants group is marked by rs578776, located on the 3′-untranslated region (UTR) of 
CHRNA3. The correlation between 16969968, rs588765 and rs578776 is very low, suggesting 
that they represent independent contributions to ND (Figure 1.5). The GWAS meta-analyses 
of smoking dependence did not identify SNPs in the CHRNB4 receptor subunit gene that 
could contribute to the genetic association signal for heavy smoking 72,97,118. Therefore, to 
date, it is not clear if common variants in CHRNB4 contribute to tobacco addiction, however, 
a possible role of this gene in ND can be hypothesized, given the high LD patterns existing 
across CHRNA5, CHRNA3, and CHRNB4.   
The GWAS performed by Bierut et al. (2007) in 1050 cases and 879 controls, showed also a 
suggestive association for rs13277254 in CHRNB3 with ND115. This variant is in LD with two 
other SNPs located on chromosome 8p11 (rs6474412, and rs13280604) that showed a 
statistically significant association with CPD in a genome-wide association meta-analyses 
performed in 31266 smokers by Thorgeirsson et al.97 Furthermore, another variant on 
CHRNB3 (rs1451240), has been associated to CPD in a GWAS of ND performed by Rice et 
al122.  All these variants (rs13277254, rs6474412, rs1451240, rs13280604) belong to the 
same LD block including CHRNB3 and CHRNA6 genes122.  GWAS of tobacco addiction also 
detected statistically significant associations in the region on chromosome 19q13.2 
encompassing the following genes: CYP2A6, CYP2A7, CYP2B6, EGLN2, RAB4B, and NUMBL123. 
The association between CYP2A6 and ND is also supported by candidate gene studies124. 
 





Figure 1.5: CHRNA5-CHRNA3-CHRNB4 gene cluster on chromosome 15 in the human genome. Triangles represent SNPs: 
SNPs with the same colour are highly correlated with each other but not with SNPs in other colours. SNP position is not 
drawn to scale (Wang et al. 2012)
121
. 
1.3.3 Targeted sequencing studies 
Complex traits could be due to a complex interplay of several rare and common variants 
conferring different individual risk and collectively involving a large number of different 
genes125. Rare genetic variants cannot be detected by GWAS and, thus, the use of next-
generation sequencing approaches could help to understand the contribution of rare 
variants in complex traits susceptibility. 
In the ND field, one of the first analysis of rare variants was performed by Wessel et al. in 
201096. In this study, researchers tested the contribution of common and rare variants in 11 
nAChR genes to severity of ND (FTND score) in 448 smokers. They observed a significant 
association for both common and rare variants in CHRNA5 and CHRNB2, and only for rare 
variants in CHRNA4 with the FTND score.  
More recently, Olfson et al., reported that common and rare CHRNA5 coding variants are 
independently associated with nicotine addiction susceptibility126. 
In order to investigate the role of CHRNA4 rare variants on ND, Xie et al. sequenced all 
CHRNA4 coding region in 209 smokers and 183 control subjects127. The sequencing of 
CHRNA4 exon 5 was also performed in additional 1000 smokers and 1000 control subjects. 
They identified that functional rare variants in CHRNA4 could reduce the risk of ND. 
Moreover, an effect in reducing risk for tobacco addiction has been also observed for 
missense rare variants at conserved residues in CHRNB4. In vitro study of the two variants 




contributing most to CHRNB4 association (T375I and T91I) and a variant in CHRNA3 (R37H) in 
strong linkage with T91I reveals that the minor allele of each polymorphism increase cellular 
response to nicotine128.  Slimak et al. investigated the contribution of allelic variants of β4 to 
nicotine receptor activity in the medial habenula (MHb) in mice129. They found that 2 
previously associated variants (β4A90I and β4T374I), and another variant (β4D447Y) in 
CHRNB4, significantly increased nicotine-evoked current amplitudes, while the variant 
β4R348C, showed decrease nicotine currents. Moreover, they reported that habenular 
expression of the β4 gain-of-function allele T374I resulted in strong aversion to nicotine in 
mice, while transduction with the β4 loss-of function allele R348C do not induce nicotine 
aversion.  More recently, a targeted sequencing study was performed in 30 candidate genes 
previously involved in tobacco addiction to test both the single and the cumulative effects of 
rare and common variants in 3088 African Americans and 1430 European American 
smokers130. After Bonferroni correction, no common variant showed statistically significant 
association with FTND, indexed CPD and smoking status. However rare variants in NRXN1, 
CHRNA9, CHRNA2, NTRK2, GABBR2, GRIN3A, DNM1, NRXN2, NRXN3 and ARRB2 showed 
statistically significant association with smoking status in African American smokers. In 
European American smokers a significant increase of rare variants in NRXN1, CHRNA9, 
TAS2R38, GRIN3A, DBH, ANKK1/DRD2, NRXN3, and CDH13 was reported. A significant 
cumulative effect of rare and common variants in ND susceptibility was identified in CHRNA9 
in European American smokers.  
1.3.4 CHRNA7 and CHRFAM7A gene  
CHRNA7 is located on chromosome 15q13.3 which is one the most unstable regions of the 
human genome. The proximal region of the long arm of chr15 (15q11-q13) is a well-known 
hotspot for CNVs, given the existence of highly homologous low copy repeats (LCRs). The 
pathogenic role of 15q13.3 microdeletions has been proven for many neurodevelopmental 
and psychiatric conditions (including idiopathic generalized epilepsy, intellectual disability, 
autism and schizophrenia)131-134. Strong evidence supporting CHRNA7 as the major candidate 
gene responsible for the clinical phenotypes associated to the 15q13.3 deletion, derives 
from the identification of subjects with smaller deletions comprising only the entire CHRNA7 
gene, and conveying most or all of the phenotypic alterations associated with the larger 
15q13.3 recurrent deletions134-136. Conversely, the reciprocal microduplication involving 




CHRNA7 has a less certain clinical significance compared with the deletions, as it is identified 
across the same spectrum of neuropsychiatric phenotype observed with the microdeletions, 
but without the same high penetrance, and it is also common in the general population with 
an estimated frequency of 1 in 180137. 
A chimeric gene called CHRFAM7A is present at 1.6 Mb centromeric to CHRNA7; it derives 
from the fusion between a partial duplication of CHRNA7, including exons 5 through 10 and 
exons A–E of the FAM7A gene138 (Figure 1.6). The formation of CHRFAM7A is human-specific 
and the duplication is evolutionary new: CHRNA7 and CHRFAM7A are highly homologous in 
their duplicated portion (99.9%). CHRFAM7A is present in variable number of copies; some 
individuals have only one copy of CHRFAM7A and rare subjects have no copies. The 
translation start site of CHRFAM7A is in exon B and it is in frame through the CHRNA7 
sequence, leading to a peptide subunit, called dupα7, that is a truncated form of CHRNA7 
missing the 5’ acetylcholine binding site139,140. The dupα7 transcript has been identified in 
brain, immune cells, and the HL-60 cell line141, although its translation product and function 
are still unknown. In vitro studies indicate that CHRFAM7A assembles with α7 subunits, 
causing a decrease of acetylcholine-stimulated current thus dupα7 may act as a dominant 
negative regulator of α7nAChRs function140,141. 
CHRFAM7A also harbors a polymorphic 2bp deletion within exon 6, rs67158670 -/TG (Δ2bp), 
which is never observed in the homologous CHRNA7 sequence and it is predicted to result in 
a truncated protein. However, since there are two methionine codons in exon 6, it is likely 
that translation could start from one of these methionine leading to a shorter dupα7 peptide 
139,140.  
 





Figure 1.6: CHRNA7/CHRFAM7A gene cluster on human chromosome 15q13.3. a) Representation of CHRNA7 and 
CHRFAM7A on 15q13.3: Exons 5-10 of CHRNA7 are duplicated in a duplicon of about 300kb at 1.6 Mb centromeric to 
CHRNA7. The duplicon is fused to a partial duplication of a second gene, ULK4. b) Exon organisation of the transcripts 
encoded by CHRNA7 and CHRFAM7A RefSeq NM_000746.3 and NM_139320.1. c) Putative translation products from 
CHRNA7, CHRFAM7A, and CHRFAM7AΔ2bp mRNAs. In green and yellow (the colour indicates the different domains) are 
represented the α7 amino acid sequence. In red and in blue are represented the alternative amino acids from CHRFAM7A 




The CHRFAM7A  Δ2bp allele has been associated to schizophrenia142 and to the P50 sensory 
gating deficit, a possible endophenotype for schizophrenia143. The P50 is an 
electroencephalographic event-related potential wave occurring about 50 ms after a 
stimulus, that often is an acoustic click. The P50 response is used to measure sensory gating, 
by paired-click paradigm144. This non-invasive technique consists in emitting an auditory click 
sound, followed by a successive click emitted about 500 ms after the first one. Usually, for 
an individual with normal sensory gating the second sound is redundant, and, thus, the 
response, related to the second click (measured by electroencephalographic wave 
amplitude), is decreased. Comparing the amplitude of the second auditory stimulus with the 
first one, it is possible to measure the reduction percentage. Normal subjects have an 
amplitude reduction of about 80%, while schizophrenic subjects show a reduction of only 10-
20%145. 
Analysis of the frequency of the CHRFAM7A Δ2bp allele in a cohort of schizophrenic 
individuals (N=70) and controls subjects (N=77) revealed that, while no difference was 




detected among cases and control, the Δ2bp allele seemed to confer risk to P50 sensory 
gating deficit, as genotypes with at least one Δ2bp allele are more frequent in individuals 
with the P50 abnormality compared to individuals with normal P50146. The association of 
Δ2bp allele with P50 sensory gating deficit was also highlighted by a successive study on 
families with schizophrenia or bipolar disorder143. Furthermore, association analysis in a 
Caucasian group (317 schizophrenic patients and 192 controls), in an African Americans 
group (66 schizophrenic patients and 60 controls), and in an Hispanic group (13 
schizophrenic patients and 37 controls) confirmed an effect of the Δ2bp variant with 
schizophrenia in Caucasian individuals and in African American subjects142. Another study 
also reported an association between the CHRFAM7A Δ2bp allele and idiopathic generalized 
epilepsy147.  A mild effect of CHRFAM7A copy number with psychiatric disorder was also 
identified: the absence of CHRFAM7A showed a slightly association with schizophrenia and 
bipolar disorder when considered as a joint psychiatric phenotype148. 
Moreover, a study on a sample of patients with major psychiatric disorders (schizophrenia 
bipolar disorder and major depression) showed an altered ratio of CHRFAM7A/CHRNA7 
expression measured in postmortem prefrontal cortex, mainly due to overexpression of 
CHRFAM7A in this region149.  
Multiple independent studies have also suggested an important role of CHRNA7 in 
schizophrenia. In particular, SNPs in the promoter region  of CHRNA7 have been associated 
to the P50 inhibitory deficit150, and to schizophrenia151,152. Interestingly, some of these 
variants have been reported to reduce CHRNA7 promoter activity in in-vitro functional 
studies150. Furthermore, several studies reported a decreased CHRNA7 expression in 
multiple regions of post-mortem brain in schizophrenic individuals, including the 
hippocampus153, cortex154,155, and the reticular thalamic nucleus156.  
1.3.4.1 Role of CHRNA7-CHRFAM7A loci in ND  
The genetic contribution of CHRNA7 gene in ND has not been extensively studied, however, 
several neurobiological evidences support a significant role for the homomeric α7 nAChR in 
tobacco addiction.  
As previously described, CHRNA7 has been strongly associated with schizophrenia and with 
the specific schizophrenia endophenotype P50.  Schizophrenic individuals have a very high 
risk for tobacco dependence, with a prevalence of around 80%, nearly three times the rate in 




the general population and higher than the elevated rates of smoking in patients with other 
psychiatric disorders157,158. A study performed on individuals with schizophrenia from 
Canada, showed a statistically significant association between the D15S1360 marker in 
CHRNA7 intron 2 and smoking risk159. However, no association was found between the 
polymorphism rs149637464 in CHRNA7 promoter and smoking status among UK patients 
with schizophrenia160. 
In vivo studies in rodents have demonstrated that reductions in α7 nAChR function promote 
nicotine use, proposing that low expression of α7 nAChRs may act as a potential mechanism 
of a shared vulnerability to tobacco use and schizophrenia161. Furthermore, a study 
performed by Harenza et al., using pharmacological approaches, reported that CHRNA7 
contributes to nicotine conditioned place preference: the gain-of-function α7 mice did not 
show nicotine preference at all dose analyzed, in contrast to α7 knock-out mice that 
displayed nicotine place preference at a lower dose than normally required to show 
preference162. Preclinical studies using rodent intravenous nicotine self-administration also 
suggested that α7 nAChR might be involved in addiction mechanisms by modulating the 
activity of ß2* nAChRs163. In fact, it has been reported that the activation of β2* nAChRs 
facilitates nicotine self-administration, while the stimulation of α7 nAChRs seems to 
negatively modulate both nicotine reinforcement and β2* nAChR function in the VTA. 
Varenicline, a drug approved by US Food and Drug Administration for use as smoking 
cessation aid, is a α4ß2 nAChR partial agonist; although with lower affinity, varenicline is also 
a full agonist of 7 nAChRs164. The same drug has been shown to provide some cognitive 
improvement in people with schizophrenia165,166. It is thus possible that activation of 7 
nAChRs can contribute to the action of varenicline as a treatment for smoking cessation and 
schizophrenia. 
1.4 Treatments for nicotine addiction 
Currently, treatment for smoking cessation includes various methods, from behavioural 
counselling to pharmacotherapy. The quitting success rate for cigarette smoke is higher in 
individuals that receive treatment consisting in behavioural and/ or pharmacotherapy than 
individuals who do not seek help167. Several evidences support that the combination of 
medication and counselling or psychological therapies are more effective than their use 
alone167. It was reported that smoking cessation rates increases of about 8% to 14% in 




individuals that received both behavioural counselling and pharmacotherapy compared to 
individuals that did not received treatments or behavioural counselling only167. 
Given the elevated costs to society for cigarette smoking related diseases, the treatments 
aimed at smoking cessation are certainly among the most cost-effective interventions in 
health care168,169. 
1.4.1 Behavioural counselling 
Behavioural counselling represents an integral component of comprehensive tobacco 
dependence treatment and it is based on advice, discussion, encouragement, and other 
activities aimed to help quit attempts succeed170. Behavioral interventions includes 
individual or group therapy sessions, furthermore it is possible offer support by telephone 
counselling171. 
Counselling usually uses behaviour change techniques addressing some factors, among 
which motivation, that has an important role in smoking abstinence success170. It has been 
demonstrated that behavioural interventions are effective in helping smokers to quit, and 
moreover, it is reported that intensive behavioural counselling (10 minutes for session) are 
more effective on smoking cessation than brief interventions (3 minutes per session)172. 
It was reported that the quitting success rate increases of about 11% to 15% in pregnant 
women that received behavioural counselling compared with controls (no interventions)173.  
1.4.2 Pharmacological therapy 
Treating Tobacco Use and Dependence clinical practice guidelines divided pharmacological 
therapy for treatment nicotine addiction in two categories: first-line medication, including 
nicotine replacement therapy (NRT), bupropion, and varenicline;  and second-line therapies, 
including nortriptyline and clonidine172.  
The latter category of therapies are not approved by US Federal Drug Administration (FDA) 
and, given their side effects, are recommended only when first-line treatments are not 
effective or not tolerated.  
Pharmacotherapy for ND acts through the reduction of craving and withdrawal symptoms 
and, moreover, it decreases the short-term reinforcing effects of tobacco.  
The description of treatments included in the first-line category are listed below: 
 Nicotine replacement therapy (NRT) 




NRT is one of the most common treatment used to help smokers to quit174. The main action 
mechanism is the replacement of nicotine effects obtained by tobacco consumption, and, 
through this, the reduction of the severity of withdrawal symptoms, cravings, and 
reinforcing effects of nicotine obtained from tobacco. Furthermore, it provides an 
alternative source of reinforcing and cognitive effects175. NRT does not entirely eliminate all 
withdrawal symptoms since the delivery systems do not replicate the fast and elevated 
levels of nicotine obtained by inhalation of cigarette smoke176,177. 
Nicotine replacement therapy is available in different formulations, including patch, gum, 
nasal spray, inhaler, lozenge and, among all these formulations, there is no evidence for a 
differences in treatment efficacy178. 
The side effects depend on the formulation used, usually it is contraindicated in individuals 
with uncontrolled hypertension and myocardial infarction within the past 6 weeks. 
 Bupropion 
Bupropion is an antidepressant that it has been found to have a positive effect on smoking 
cessation. Its action mechanism in help smoker to quit is not comprehensively understood, 
however both dopamine and norepinephrine reuptake inhibition and a light nicotinic 
antagonist activity could lead to the reported decrease in the severity of nicotine cravings 
and withdrawal symptoms179,180. Two different studies suggested that bupropion and NRT 
have similar effects on smoking cessation178,181. The most common bupropion side effects 
are insomnia, occurring in 30-40% of individuals, and dry mouth, occurring in about 10% of 
individuals181. 
 Varenicline 
Varenicline, launched in 2006, is a drug approved by The United States Food and Drug (US-
FDA) Administration for use as smoking cessation aid. In the last 10 years, varenicline has 
been the main prescription drug to treat smoking cessation. Among all pharmacologic 
treatments, varenicline is the intervention that provides the highest smoking cessation rate 
(28%). The quit success rate for individuals treated with bupropion is instead 19% and 17% 
for individuals using NRT182. 
Varenicline has a receptor-dependent mechanism of action, acting as a α4β2 neuronal 
nicotinic acetylcholine receptor partial agonist and, although with lower affinity, as a full 




agonist of α7 nAChRs164. Varenicline reduces the cravings and withdrawal symptoms in 
individuals attempting to quit smoking. Moreover, it could reduce the pleasurable effects of 
cigarettes, thereby potentially decreasing the relapse risk183,184. 
Two identically randomized, double-blind, multicentre trials have reported that varenicline is 
much more effective than placebo (odds ratio of 2.5) and it is more effective than bupropion 
(odds ratio of 1.7 )185,186.  
The use of varenicline was approved for up to 12 weeks by US-FDA. However, if individuals 
maintain smoking cessation the use of varenicline can be prolonged for another twelve 
weeks187. 
Varenicline has never been tested in subjects under 18 years old or pregnant women and, 
thus, it is recommended to avoid the use in these two categories182. Furthermore, 
individuals should not have a history of psychiatric disorders before starting varenicline and 
medical staff should advise them to stop varenicline in case of agitation, depressed mood, or 
any other changes in behaviour not characteristic of nicotine withdrawal. The main 
varenicline side effects are nausea, insomnia, gastrointestinal upsets and headache; 
however, the incidence of adverse events leading to drug discontinuation is not different to 
that reported taking the placebo 185,186. 






2.1 Clinical features 
Cluster Headache (CH) is a rare primary headache with a mean prevalence of 0.1% among 
general population and 1% among Third Level Headache Centers. The term “cluster” 
originates from the tendency of attacks to cluster together into bouts that last several weeks 
followed by periods of remission, which can last for several months to years. CH  shows a 
clear male predominance with a male:female ratio between 2.5-3.5:1188.  
The disease is characterized by a well-defined clinical picture and the diagnosis is made 
according to the International Classification of Headache Disorders (2013)189. A patient with 
CH has to experience at least 5 attacks according to the criteria listed below: 
- Unilateral retro-orbital or fronto-temporal pain, lasting from 15 to 180 minutes,  
- Association with either one or both symptoms listed below:  
 at least one of the following signs, ipsilateral to the headache: a) conjunctival 
injection and/or lacrimation b) nasal congestion and/or rhinorrhoea c) eyelid oedema 
d) forehead and facial sweating e) forehead and facial flushing f) sensation of fullness 
in the ear g) miosis and/or ptosis  
 a sense of restlessness or agitation 
-  Attacks have a frequency ranging from 1 every two days to 8 times a day. 
- Exclusion of other disorders. 
CH attacks show a characteristic circadian periodicity (Table 2.1): they tend to occur at 
almost the same time every day especially at night, during the first REM sleep 190and are also 
more frequent in spring and autumn191. Thus, CH displays both a typical circadian and a 
circannual rhythmicity.  
Cluster headache can be distinguished in episodic, affecting 85-90% of patients, and 
chronic189. The main difference between these two forms is in the remission period that in 
the first case must be at least one month while in the second case CH patients show 
continuous attacks and no remission periods. 




During the attacks the patient is restless, unable to remain motionless, tends to isolate, 
refuses to be touched or comforted, walks nervously and writhes192. These behaviours 
highlight how the life quality of subjects with CH is strongly compromised and thus the 
primary need for patients is to suspend the attacks.  
Most of CH attacks are spontaneous, however, in some cases may be triggered by different 
factors including alcohol intake and volatile substances such as solvents, oil-based paints 
NO-donors like nitroglycerin and histamine193,194. 
 
Features Cluster headache 
Pain location  Unilateral retro-orbital or fronto-temporal 
Pain duration 15-180 minutes 
CH periodicity  Circannual 
Attacks periodicity  Circadian 
Attacks frequency  1-8 times a day 
Associated symptoms 
Myosis, palpebral ptosis, conjunctival injections, tearing, nasal 
congestion and rhinorrhea 
Behaviour during the attacks  Agitated, restless 
Sex Males: females = 2.5-3.5:1 
Start age  20-50 years 
Table 2.1 Main features of cluster headache 
 
2.2 Pathophysiology 
Despite its clear clinical presentation, the biology of CH is poorly understood. Because of the 
circadian and seasonal rhythmicity of attacks the involvement of the biological clock has 
been proposed. Furthermore, a possible role has been hypothesised for vasomotor changes, 
inflammation, immune changes, autonomic system imbalance and hypothalamic 
dysfunction. All these processes may also be interrelated, participating together in the 
genesis of CH symptoms195. 
Evidence for activation of the trigeminovascular system and the cranial parasympathetic 
nervous system, which are involved in controlling cranial vascular reactivity, has been 
reported196,197. During the crisis, the concentration of CGRP (calcitonin gene related peptide) 
and VIP (vasoactive intestinal peptide) increases at the external jugular vein, indicating the 




activation of the trigeminovascular and parasympathetic nervous system196,198. This process 
leads to intracranial vasodilatation with consequent pain, sterile neurogenic inflammation, 
oedema and protein discharge at dural level195,198,199.   Neurogenic inflammation can activate 
trigeminal nerve fibres themselves, which transmit pain inputs to the spinal trigeminal 
nucleus (STN) and, via the ventral postero-medial nucleus of thalamus (VPMN), to the 
cortex200. Furthermore, the activation of trigeminal-parasympathetic reflex leads to onset of 
autonomic signs including tearing, nasal congestion, rhinorrhoea and sweating196,199.  
Nitric oxide (NO) has been suggested as a common mediator of vascular headache 
pathophysiology201.  In CH patients, increased levels of NO in the plasma have been found. 
Furthermore, several studies have shown that the administration of nitroglycerin, a NO 
donor, can trigger a headache attack during the active phase of cluster201,202. NO acts as a 
potent vasodilator, but also it plays a role in central and peripheral modulation of 
nociception203, especially in both initiation and maintenance of hyperalgesia204,205. These 
processes are probably associated with activation of the calcium dependent NO synthase 
(NOS) isoforms206.  
NO is also involved in inflammation. It has been supposed that NO induces the release of 
CGRP, however other findings failed to support this suggestion207,208. 
CH patients seem to show alterations in melatonin metabolism compared to control. The 
melatonin production, normally follows a circadian rhythmicity with a minimum level during 
the day and a peak during the night. This hormone is a marker of pineal gland activity and it 
is involved in regulation of sleep-wake rhythmicity194. Melatonin and its rhythmic secretion 
are regulated by the suprachiasmatic nucleus209. 
Neuroimaging studies using PET (positron emission tomography) confirmed a dysfunction  of 
chronobiological rhythms with the involvement of suprachiasmic nucleus of the 
hypothalamus. These investigations, carried out during CH attack, demonstrated the 
activation of the ipsilateral hypothalamic grey matter210.  
Furthermore, functional magnetic resonance (fMR) studies have shown the activation of 
posterior hypothalamus during attacks211. Posterior hypothalamus is connected with the STN 
and its activation can activate both the trigeminal system and the parasympathetic reflex, 
inducing pain and autonomic symptoms212. 
Based on these observations, CH can be considered a central nervous system disorder that is 
manifested by neurovascular mechanisms in which the hypothalamus is involved212. 




The activation of both the trigemino-vascular and cranial parasympathetic systems provides 
the anatomical basis for the expression of the first division trigeminal pain and the ipsilateral 
autonomic symptoms that occur during cluster attacks194. However, the primary trigger of 
the trigemino-vascular system activation remains still unknown.  
2.3 The genetics of cluster headache 
Twin and family studies have indicated the importance of genetic factors in CH188. Twin data 
is scarce given the rarity of the disorder, however, monozygotic twins show a higher 
concordance rate for CH than dizygotic twins. Familial aggregation has been demonstrated 
by several studies: first-degree relatives of CH patients have a 5-to 18-fold increased risk and 
second-degree relatives a 1-to 3-fold increased risk (depending on the estimate of 
prevalence)188. Despite the evidence of genetic factors in CH, the inheritance model is very 
complex. A putative autosomal dominant inheritance with low penetrance has been 
reported in some families, although in the majority of cases the inheritance is likely 
multifactorial, resulting from interactions between various genetic loci and environmental 
factors213. 
Nowadays, the molecular genetic background of CH is still largely unknown214. The complex 
nature of the disorder and its low prevalence have hindered the genetic analysis of CH.  
2.4 Molecular genetic studies of Cluster headache susceptibility 
At the time our project started, only a limited number of small-scale linkage and candidate 
gene association studies have been performed in order to investigate the genetic risk factors 
involved in CH aetiology. These studies are summarized in table 2.2 and described more in 










Study Study design Genes/variants investigated Subjects Results 
Sjostrand et al. 
2001 
Case control association 
An intragenic polymorphic (CA)n-repeat (D19S1150) in CACNA1A 
and a (CAG)n-repeat in the CACNA1A 3'UTR region   
75 CH patients, 108  
controls 
No association 
Sjöstrand et al. 
2002 
Case control association Five polymorphic microsatellite markers  in NOS1, NOS2A, NOS3 
91 CH patients, 111 
controls 
No association 
Aridon et al. 2004 Linkage analysis The 6q23 region including TAR1, TAR3, TAR4, TAR5, PNR, GPR58 
6 CH patients, 10 
healthy subjects 
No significant linkage 
Rainero et al.2004 Case control association 
−3250C>T (rs4796717), −1717C>T (rs8072081) in HCRT; 264T>C 
(rs1056526), 1375C>T (rs2271933) in HCRTR1 and 1246G>A 
(rs2653349), IVS4+12.564A>C (rs1027650) in HCRTR2 
109 CH patients, 211 
controls 
Significant association between CH and the 
rs2653349 variant (1246 G>A) 
Rainero et al.2005 Case control association C282Y and H63D mutations in the HFE gene 
109 CH patients, 211  
controls 
No association 
Baumber et al. 2006 
Genome-wide linkage 
analysis   
400 markers, 9 cM spacing 5 Danish pedigrees 
Suggestive linkage: D2S1353, D2S1363, 
GATA151F02 (Chr 8), D9S2169 
Additional markers around four markers with suggestive linkage 
from 5 Danish pedigrees 
33 Danish and Italian 
pedigrees, 82 
members affected 
No significant linkage 
Case control association 1246G>A (rs2653349), rs3122169 in HCRTR2 
259 CH patients, 267 
controls 
No association 
Schurks et al.2006 Case control association 1246G>A (rs2653349) in HCRTR2 
226 CH patients, 266 
controls  
Individuals with GG getotype had a twofold 
increase in risk for CH (OR 1.97; 95% CI 1.32 to 
2.92; p = 0.0007) 
Fourier et al. 2008 Case control association rs1800759 and rs1126671 mutations in ADH4 
390 CH patients, 389 
controls 
No statistically significant association for 
rs1800759C>A and rs1126671G>A  
Cevoli et al. 2008 Case control association 
T3111C variant (located in the 3’ flanking region of the CLOCK 
gene) 
101 CH patients, 100 
controls 
No association 
Zhang et al. 2010 Case control association PER3 VNTR (variable number tandem repeat) polymorphism  
149 CH patients, 432 
controls 
No association 
Schurks et al. 2011 Case control association rs1801133 in MTHFR 
147 CH patients, 599 
controls 
No association 




Study Study design Genes/variants investigated Subjects Results 
Summ et al. 2010 Case control association common polymorphism in SERPINA1 
55 CH patients, 55 
controls 
No association with CH. 
Among CH patients, those heterozygous for 
M allele had more frequent attacks per day 
(median, 3) than those homozygous for M allele 
(median, 2; P=0.02). 
Weller et al. 2015 
Case control association 
1246G>A (rs2653349) in HCRTR2 
575 patients, 874 
controls 
No association 
Case control association 
(Meta-analysis)  
1167 CH patients, 
1618 controls 
Significant association between CH and the 
rs2653349 variant (p = 0.006) 
Zarrilli et al. in 2015 Case control association 
G1246A mutation in HCRTR2, T3092C mutation in  CLOCK, 
rs1800759 and rs1126671 mutations in ADH4  
54 CH patients, 200 
controls  
rs1800759C>A and rs1126671G>A in ADH4 
showed significant association with CH 









2.4.1 Linkage studies 
A general description of linkage mapping approaches is reported in paragraph 1.3.1. 
In order to identify chromosomal regions containing potentially susceptibility loci for CH, 
some research groups performed parametric linkage studies. The application of this 
methods, however, has been limited by the lack of large family pedigrees with many 
affected individuals.   
In 2004, Aridon et al. studied two small families with CH in order to investigate the presence 
of linkage in the 6q23 region. In total 6 individuals with CH (two males and two females in 
the first family, and two affected first cousins in the second one) and 10 healthy subjects 
were included in this study215. Four microsatellites from the 6q23 region were studied; this 
region encompasses a cluster of genes encoding G-protein-coupled receptors that bind and 
are activated by trace amines (TAR1, TAR3, TAR4, TAR5, PNR e GPR58), including tyramine, 
octopamine and synephrine. These neurotransmitters have been found increased in plasma 
and platelets of patients affected by CH, both in active and remission periods216. Therefore, a 
possible involvement of such molecules in CH etiopathogenesis has been suggested. 
However, this study did not identify a disease segregating haplotype, suggesting that this 
specific region is not associated in the two studied families with CH215. 
A genome-wide genetic screen was carried out on 5 informative Danish CH families using 
approximately 400 microsatellite markers217.  Furthermore, further 111 individuals from 
Danish and Italian kindreds were analysed with additional markers in those loci showing 
suggestive evidence of linkage. Even if potential linkage has been detected at four possible 
disease loci in Danish kindreds, no single chromosome location reached statistical 
significance217.  
2.4.2 Association Studies 
A general description of association studies is reported in paragraph 1.3.2  
A case-control association study was performed in order to evaluate the contribution of 
different polymorphisms in the hypocretin/orexin system genes in 109 Italian patients 
affected by CH and 211 controls218. This study identified a significant association between CH 




and the rs2653349 variant (1246 G>A) in exon 5 of hypocretin receptor type 2 (HCRTR2). The 
hypocretins (orexins) are hypothalamic neuropeptides thought to have an important role in 
the regulation of sleep and arousal states219. In particular, this study reported that 
homozygous individuals for G allele have an increased risk to develop disease (OR: 6.79, 95% 
CI, 2.25 to 22.99). The G allele causes a substitution of amino acid valine with isoleucine at 
position 308 (V308I). This amino acid change, that affect the receptor dimerization, could 
contribute to CH susceptibility218. 
The association between 1246 G>A variant in HCRTR2 gene and CH was also confirmed in 
successive studies217,220,221. In contrast, a more recent genetic association study did not show 
significant association between rs2653349 and CH in a cohort of 575 patients and 874 
controls222 (p = 0.319). However, in the same study, a meta-analysis performed on 1167 
subjects with CH and 1618 controls from six study populations, identified association of the 
variant with CH (p = 0.006)222.  
In the study performed by Zarrilli et al. in 2015221, researchers have also analysed variants in 
other two candidate gene: CLOCK gene, encoding for a transcription factor with a central 
role in the regulation of circadian rhythms, and ADH4 gene, encoding for class II alcohol 
dehydrogenase 4 pi subunit, which is a member of the alcohol dehydrogenase family. This 
study was performed on 54 unrelated sporadic CH patients, in 200 controls in 8 families with 
CH. In ADH4, both variant tested (rs1800759C>A and rs1126671G>A) showed a significant 
association with CH (p= 0.03 in both cases). However, a recent replication study on 
rs1126671 and rs1800759 performed in a Swedish case–control cohort (390 unrelated 
patients with CH and 389 controls) did not support an association of ADH4 variants with 
CH223.  
No statistically significant association was identified for rs1801260 (T3092C) in the CLOCK 
gene and CH.  This finding confirms the result obtained by a previous study in which 
association analysis of T3111C variant (located in the 3’ flanking region of the CLOCK gene) 
among 101 CH patients and 100 healthy subjects did not provide significant results224.  
The PER3 gene, a member of the Period family genes expressed in a circadian pattern in the 
suprachiasmatic nucleus, has also been studied in CH. PER3 transcription level is regulated 
by the CLOCK gene225 and variant in PER3 has been associated to sleep disorders. The 
analysis of a PER3 VNTR (variable number tandem repeat) polymorphism in CH, did not show 
statistically significant results226. 




NO has been suggested as the common mediator in vascular headache pathophysiology227. 
NO is involved in vasodilation and inflammation228 and, thus, it could be a promoting factor 
for CH attacks. Several polymorphisms in genes encoding for NO synthases isoforms (NOS1, 
NOS2A, NOS3) have been studied in association to CH229. However, the case-control 
association study performed by Sjöstrand et al. in a Swedish population including 91 CH 
patients and 111 controls failed to show significant results for all tested variants in genes 
encoding for NOS isoforms229. 
Furthermore, analysis of CACNA1A in CH did not reveal any statistically significant 
differences with regards to phenotype and allele frequencies between patients and 
controls230. CACNA1A, encoding for the alpha 1A subunit of the Cav2.1 calcium channel, has 
been implicated in several episodic neurological disorders, especially it is reported to have a 
critical role in familial hemiplegic migraine (FHM)231. 
Methylenetetrahydrofolate reductase (MTHFR) is an enzyme with a crucial role in the 
remethylation pathway converting homocysteine to methionine. The rs1801133 variant 
(677C>T) in MTHFR, which have an effect on enzyme activity leading to increased 
homocysteine levels, has been involved in vascular oxidative stress response232 and has been 
linked to migraine233,234. The effect of this variant was also tested in CH by a case–control 
association study among 147 CH patients and 599 controls.  No significant difference 
between cases and control was identify for rs1801133 polymorphism235. 
Finally, case-control association studies were also carried out for the HFE and SERPINA1 
genes, however, the polymorphisms tested did not show statistically significant association 
with CH236,237. The HFE gene encodes for a protein that modulates iron absorption, and 
mutations in this gene are responsible for toxic iron overload in several body organs. Recent 
studies suggested that iron metabolism could be involved in the pathophysiology of primary 
headaches238. The SERPINA1 gene encodes the alpha 1-antitrypsin, mutations in this peptide 
could predispose to pulmonary emphysema, a chronic obstructive pulmonary disease 
(COPD) that seems to be correlated with CH239.  
2.5 Nicotine dependence in Cluster Headache  
Smoking is the most consistent lifetime habit reported in CH patients. Over 80% of CH 
patients have a prolonged history of tobacco usage240. A recent study suggested that second 
hand cigarette exposure during childhood is also a risk factor for the development of CH241.  




However, the link between smoking and CH is unclear, and smoking cessation does not seem 
to alter the clinical course of the disorder. Since not all individuals who are smokers or are 
exposed to second hand smoke go on to develop CH, some other underlying factors must be 
involved in CH pathogenesis. Thus, tobacco use could be an environmental trigger for CH in 
genetically predisposed subjects; an alternative hypothesis is that the genetic risk factors 
involved in smoking-related traits might also have a role in CH susceptibility. As described in 
chapter 1, the α5/α3/β4 nicotinic receptor subunit gene cluster on chromosome 15q25 
(CHRNA5, CHRNA3, CHRNB4) is the strongest and highly replicated locus for smoking-related 
traits, and many independent studies demonstrated that rs16969968, a common non-
synonymous variant in CHRNA5, is associated with nicotine dependence, smoking quantity 
(CPD), as well as smoking related diseases such as lung cancer and chronic obstructive 
pulmonary disease98. Rare and low frequency coding variants in CHRNA5 also contribute to 
nicotine dependence126. The α6/β3 nicotinic receptor subunit gene cluster (CHRNA6, 
CHRNB3) on chromosome 8p11, and more recently CHRNA4 (chromosome 20q11) have also 
been correlated to smoking behaviours and its consequences97,242,243. The role of nicotinic 
receptor genes in CH has never been investigated so far. 
2.6 CH treatments 
To date, there is no a specific drug for CH treatment; the drugs used have only the effect of 
reducing the pain associated with the disease. The main treatment for acute management of 
attacks have a vasoconstrictor effect with immediate action, including inhalation of oxygen 
and subcutaneous administration of triptans (serotonin [5-HT1B/1D] receptor agonists)194. 
However, about 20% of patients are non-responders and often prolonged use of these drugs 
causes side effects244. Only a limited number of studies have investigated the 
pharmacogenetics of triptan response in CH. A report has linked a common polymorphism in 
the gene coding for the G-protein ß3 subunit (GNB3) with triptan response245.  
Octreotide, an injectable synthetic analogues of the brain hormone somatostatin, is another 
drug used for the treatment of acute CH attacks. The mechanism of action of these peptides 
is unknown, but it has been shown to inhibit the release of numerous vasoactive peptides, 
including CGRP246. Furthermore, neurons containing somatostatin are located in the regions 
of the central nervous system involved in nociception, including the hypothalamus, which 
have also been involved in CH etiopathogenesis247. The most frequent adverse reactions of 




somatostatin are hyperglycaemia, nausea, abdominal pain and diarrhoea. 
Furthermore, local anaesthetics, such as lidocaine, and the injectable form of 
dihydroergotamine (D.H.E.) have also been suggested to be effective in the acute treatment 
of CH248-251.  
In addition to acute treatments, there are also several preventive therapies for CH. They 
include, calcium antagonists (Verapamil) which interferes with slow calcium channels and it 
is the most widely used drug for preventing CH252. Furthermore, effective preventive 
treatments are also inflammation-suppressing drugs (corticosteroids), lithium carbonate, 
used also to treat bipolar disorder, and melatonin195.  
A recent Japanese study has suggested the role of naratriptan as a preventive medicine for 
CH. In fact, the administration of naratriptan two hours before attacks seems to provide a 
good response in patients with CH253. In contrast to other triptans, naratriptan offers a long 
half-life and improved bioavailability254.  




MATERIALS AND METHODS 
CHAPTER 3 
 Materials and methods: Role of 7 nAChR in nicotine dependence 
3.1 ND Study sample 
3.1.1 Smokers sample 
The collection of treatment seeking smokers was carried out in collaboration with Prof. M. 
Zoli and L.A. Pini at University of Modena and Reggio Emilia. The study sample includes 408 
Italian smokers enrolled at 3 Smoking Cessation Centers (Modena, Parma and Imola) in Italy. 
Phenotypic data collected at baseline included sex, age, number of cigarettes per day (CPD), 
and Fagerström test for nicotine dependence (FTND). Additional information collected on 
each subject included self-reported drug treatment history, physical health or psychiatric 
problems, family history of tobacco use, reasons for starting tobacco use, smoking initiation 
age.   
All participants received group or individual counseling; in addition, 142 subjects also 
received pharmacological treatment with varenicline. All individuals were followed up at 3 
months and 6 months after treatment in order to assess maintenance of smoking cessation. 
The DNA from 380 smokers was extracted from blood with Blood/Cultured Cell Genomic 
DNA Extraction Mini kit (Fisher Molecular Biology). For 28 smokers, instead, the DNA was 
extracted from saliva with ORAcollect-DNA (OCR-100) and prepIT-L2P (DNAGenotek). 
3.1.2 Controls samples 
A healthy population control sample including 139 never smokers and 55 light smokers 
(FTND scores =0) was recruited among medical staff at Modena Policlinico hospital.  
As a further comparison population sample, we used a group of 204 Italian individuals with 
ASD. These subjects were recruited at the Stella Maris Clinical Research Institute for Child 
and Adolescent Neuropsychiatry (Calambrone, Pisa, Italy). For ASD diagnosis, parents 
undertook the Autism Diagnostic Interview-Revised (ADI-R)255 that is a standardised, semi-
structured clinical interview with the aim of obtaining an accurate development history from 




caregivers of children, while probands were administered the Autism Diagnostic Observation 
Schedule (ADOS)256, that is a standardised protocol for direct observation of social 
interaction and communicative behaviours. A clinical evaluation was performed to exclude 
recognizable medical causes associated with autism. Karyotyping, molecular genetic testing 
for Fragile X syndrome, EEG and aCGH were obtained where possible for all probands. 
ASD DNA samples were extracted from blood with the QIAGEN DNA Blood extraction kit. The 
control group DNA (never smokers and light smokers) were extracted from blood with the 
Blood/Cultured Cell Genomic DNA Extraction Mini kit (Fisher Molecular Biology).  
All participants provided a written informed consent to participate. This study was approved 
by the local Ethical Committee and took place in observation of the declaration of Helsinki 
(protocol number 2224/2013). 
3.2 SNP Genotyping and CNVs detection by Illumina Infinium® PsychArray microarrays 
Genotyping was performed on Illumina Infinium® PsychArray microarrays (Illumina, San 
Diego, California, USA), using a standard protocol in two parallel stages, using Illumina 
PsychArray-24 v1.0 and PsychArray-24 v1-1 array, respectively257. We restricted the analysis 
to 566178 variants present on both versions of the array. Content for the Infinium 
PsychArray includes 265,000 validated tag SNPs, 245,000 exonic variants, and 50,000 
additional markers associated with common psychiatric disorders: schizophrenia, bipolar 
disorder, autism-spectrum disorders, attention deficit hyperactivity disorder, major 
depressive disorder, obsessive compulsive disorder, anorexia nervosa, Tourette’s syndrome.  
The genotyping is based on the Illumina Infinium high Throughput Screening (HTS) assay. 
Locus discrimination or copy number variation (CNV) determination results from sequence-
specific hybridization capture and array-based, single-base primer extension. Briefly, the first 
step is whole-genome amplification to uniformly amplify the DNA amount of each sample . A 
controlled enzymatic process fragments the amplified product; after isopropanol 
precipitation, the precipitated DNA is resuspended in hybridization buffer and loaded to the  
BeadChip where it anneals to locus-specific 50-mers. The 3' end of the primer maps adjacent 
to or overlaps with the SNP site (according to Infinium II or  Infinium I probe design). 
Extension occurs only in the presence of a perfect match and it is generated the signal which 
determines the genotype call for the sample. Allele-specific single base extension of the 
primer incorporates a labeled nucleotide (C and G are biotin labeled, while A and T are 




dinitrophenyl labeled). The BeadChip is then scanned by the Illumina iScan, a laser system 
that excites the fluorophore of the single-base extension product on the beads and records 
the fluorescence signals. For each SNP, fluorescence signals specify the two alleles and the 
homozygous/heterozygous genotypes (red/red or green/green for homozygous , red/green 
(yellow) signals for heterozygous)(Figure 3.1). 
 
 
Figure 3.1:  Schematic representation of the Illumina Infinium HTS Assay protocol. 
 
SNP genotyping data can be analyzed and visualized with Illumina GenomeStudio software. 
This software includes algorithms designed for automated clustering and allele-calling. For 
each SNP the software clusters samples by genotype in three possible clusters (Figure 3.2). 
Each cluster can be moved manually so samples can be included or excluded from the 
clusters in each SNP.  





Figure 3.2: SNP genotypes graphical display in GenomeStudio (color code: red=AA; purple=AB; blue=BB). Norm-R 
represents the signal intensity (y-axis) while Norm Theta is the allele frequency (; x-axis).  
 
In GenomeStudio is also possible to visualize SNP data on a genome-wide scale using the 
Illumina Genome Viewer (IGV) tool. Different data plots can be displayed in IGV. In 
particular, to check the presence of a CNV it is very useful to visualize and combine genomic 
data plots of the logR Ratio and the B-allele frequency parameters. 
LogR Ratio is the log2(Rsubject=Rreference), a measure of the observed normalised total signal 
intensity of the subject sample compared to the expected intensity (which in turn is based 
on the observed allelic ratio of the canonical genotype clusters)258 . The B-allele frequency is 
a normalised measure of the relative signal intensity ratio of both alleles. A duplication is 
identified when an upward deflection in the logR Ratio together with a split in the 
heterozygous allele frequencies (corresponding to a 2:1 and 1:2 allelic ratios or to AAB and 
ABB genotypes) in the B-allele frequency plot are detected (Figure 3.3). In turn, a deletion is 
identified when a downward deflection in the logR Ratio and a lack of heterozygous calls in 
the B-allele frequency plot are detected (confirming the reduction in copy number – Figure 
3.3). It is possible to determine if the CNV in question is de novo or inherited, by looking at 
the same region in the respective parents. 
All SNPs LRR and BAF values for each individual can be exported from GenomeStudio to 
identify CNVs using three different CNV detection algorithms: PennCNV259, QuantiSNP260 and 
CNVPartition (Illumina). In particular, CNVs required calling by at least two algorithms with 
one being PennCNV. It was not possible to assess CHRFAM7A copy number using genome-




wide array SNP data as no SNPs uniquely mapping the CHRFAM7A gene are present in most 
commercial arrays. 
 
Figure 3.3: Examples of LRR and BAF plots for a deleted region, region with 2 normal copies and duplicated region.The 
decrease in the LogR Ratio and the the lack of heterozygous calls indicates the presence of a deletion (1 copy, genotype B/- 
or A/-). The increase in the LogR  and the split of the heterozygous cluster into two intermediate clusters indicates the 
presence of a duplication (3 copies, four possible genotypes for each SNP: AAA, AAB, ABB, BBB). 
 
3.3 Validation of CHRNA7 CNVs by Real-Time PCR 
To validate the presence of CHRNA7 duplications detected by SNP array we performed a  
real-time quantitative PCR (qPCR) using SsoAdvanced™ Universal SYBR® Green Supermix 
(Biorad). SYBR Green is a non-specific fluorescence dye that binds to the minor groove double-
stranded DNA. 
The analysis of qPCR data relies on the threshold Cycle (Ct), that is defined as the point at 
which the fluorescence rises appreciably above the background fluorescence. DNA 
quantification, based on fluorescence measure, always occurs during the exponential phase, 
when  the amount of PCR product is taken to be proportional to the amount of input DNA. 
Primers for qPCRs for CNV validation were designed from genomic DNA sequence using 
Primer3, (http://bioinfo.ut.ee/primer3-0.4.0/primer3/). For primers design, we used the 
following conditions: 
 Product Size Range= 90-140bp 
 Number to return = 10 
 Primer Size = Min: 20; Opt: 22; Max: 30 
 Primer GC%= Min: 40; Max: 50 




 Max Self-Complementarity= 5.00 
 Max 3’ Self-Complementarity = 2.00 
 Max Poly X = 3 
 
The primer used to specific CHRNA7 amplification are listed in the follow table: 
 
PCR efficiency was calculated using 4 dilution series of template DNA, and each was run in 
triplicate. For the relative quantification, a region of the FOXP2 gene was amplified as 
internal control, with the following primers: 
FOXP2 forward primer: 5’-TGCTAGAGGAGTGGGACAAGTA-3’,  
FOXP2 reverse primer: 3’-GAAGCAGGACTCTAAGTGCAGA-5’ 
Each reaction was set up in triplicate using the following conditions: 
 
A control subject predicted to have two normal copies of CHRNA7 was included in all qPCR 
experiments. The qPCR reactions were run on the CFX Connect™ Real-Time PCR Detection 
System (Biorad) according to the following qPCR program, which includes three main stages:  
1) Polymerase activation: incubation at 98°C for 3 minutes;  
2) Anneal/extend: 40 cycles of incubation at 98°C for 10 seconds, at 60°C for 30 seconds;  
3) Melting curve: incubation at 95°C for 1 minute, followed by an incubation at 65°C for 3 
seconds, repeated for 61 times with an increase of 0.5°C each cycle. 
qPCR Reaction MIX Amount (μl)
DNA template (5 ng/μl) 5
SsoAdvanced™ Universal SYBR® 
Green Supermix 2X
7.5
Primer F (10 μM) 0.75
Primer R (10 μM) 0.75
H2O 1
Final volume 15




Melting curve analysis of each PCR products were carried out to ensure specific 
amplification, as specificity of amplification is considered to be an important issue with 
intercalating dye assays. 
Melting curve analysis is also called dissociation curve, because it is an assessment of the 
dissociation-characteristics of double-stranded DNA during heating. It consists in a step in 
which the temperature of the sample is incrementally increased, while the instrument 
continues to measure fluorescence. As the temperature rises enough, dsDNA denatures 
becoming single-stranded, and the SYBR Green dye dissociates, resulting in a decrease 
fluorescence.  
Melting curve analysis permits the identification of  primer-dimers or other non-specific PCR 
products that, giving spurious fluorescence signals, may decrease the PCR efficiency.  
Serial DNA dilutions were used to calculate PCR efficiencies for CHRNA7 assay.  
Relative copy number was calculated using the comparative Ct method (2-ΔΔCt method)261:  

Ct sample DNA= Ct fragment of interest - Ct FOXP2 
Ct control DNA= Ct fragment of interest - Ct FOXP2 
Ct = Ct sample DNA - Ct control DNA 
ratio = 2-ΔΔCt 
Copy number = 2*ratio 
 
3.4 Mutation screening of the CHRNA7 proximal promoter  
3.4.1 Primer design 
CHRNA7 genomic sequence was retrieved from the UCSC genome Browser (hg 19). All the 
primers were designed using Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/primer3/). Two 
different PCR amplicons were designed to amplify 740 bp upstream the CHRNA7 start codon:  
 
3.4.2 Polymerase Chain Reaction (PCR) assay 
Optimisation of PCR conditions was carried out by altering the annealing temperatures, 




MgCl2 concentrations or cycle numbers, until achievement of the optimal conditions. 
Magnesium acts as a cofactor to the Taq polymerase and stabilized DNA base pairing,  
therefore variation in magnesium concentration influences the reaction specificity. 
The PCR reactions were set up in a final volume of 15 μl using 30 ng of template DNA and 
with final concentrations of 0.2 mM of each dNTP, 0.05 u/ul AmpliTaq Gold DNA Polymerase 
(Life Technologies), 1.5-2.0 mM MgCl2, 1X AmpliTaq Gold buffer, 0.2 mM of each primer 
(forward and reverse) and 30 ng of template DNA. 
To deal with the GC rich sequences of the CHRNA7 promoter amplicons, 5% dimethyl 
sulfoxide (DMSO) and/or 0.1 mM 7-deaza-2‟-deoxiguanosina-5‟-trifosfato (Deaza GTP) were 
also added to the PCR mix, in order to improve the denaturation of the template DNA. 
A “Touch-Down” PCR program (TD) was used for the amplification of  both fragments262: 
starting with an initial higher temperature (T1) to ensure a specific primer annealing, then 
progressively decreasing the temperature until it reaching a second, lower temperature (T2), 




The PCR products were visualized with a UV transilluminator after electrophoresis on  2% 
agarose gel and GelRed staining (Biotium). The 100 bp and 1kb DNA ladders (NEB) were 
loaded to check the PCR fragment size. 
3.4.3 PCR purification  
After obtaining successful PCR products and confirming them on 2% agarose gels, products 
were purified prior to the sequencing reaction. The EXO/SAP (GE Healthcare) clean 




up protocol was used, in order to digest primers and remove unused nucleotides. The 
reaction was performed adding 0.5 l of SAP, 0.5 l of exonuclease (for unused primer 
digestion) to 6 l  of each PCR product. The reactions were performed in the MJ 
Thermocyclers using caps and heated lids, with the following 
programme: 
37°C x 15 minutes: Treatment step 
80°C x 15 minutes: Enzymatic inactivation step 
 
3.4.4 Sanger Sequencing reaction  
Sequencing was carried out with the Sanger Method, using the BigDye Terminator kit v1.1 (Life 




The primers used for the Sanger sequencing are: 
 
3.4.5 Ethanol-EDTA Precipitation of Sequencing Reactions 
Once the amplification reaction was complete, sequencing products were precipitated using 
a reaction mix containing 1/10 of the volume of Sodium Acetate (3 M, pH 5.2) and 2.5 
volumes of ice-cold 100% ethanol.  
The steps of the precipitation protocol were: 
1. The precipitation reaction mix was added to each sample,  
2. The plate was spun at 3000 g at 4 °C for 30 min. 




3. The seal was removed and the plate inverted on white paper towels (to remove the 
ethanol). 
4. 70 μl of 70% ethanol was added to each well, and the plate was again spun at 1650 
g at 4 °C for 15 min. 
5. The seal was removed and the plate again inverted on white paper towels. The latter 
was spun inverted at 185 g for 10-15 sec (to remove remaining ethanol). 
6. The plate was dried at room temperature. 
7. 15 μl of Injection Solution (DNA Sequencing Reaction Cleanup kit, Millipore) was added to 
each well. 
The sequencing reaction products were run on the ABI PRISM 3730 DNA analyser (Life 
Technologies). The sequences were analysed and compared to the reference sequence using 
the software Sequencher 5.0 (Gene Code Corporation). 
3.5 In vitro functional analysis of rs28531779 variant on CHRNA7 promoter activity  
Two luciferase constructs containing CHRNA7 core promoter were designed to analyse the 
effect of rs28531779 variant on CHRNA7 promoter activity using dual luciferase assays.  
3.5.1 Plasmid construction and cell transfection 
Two different genomic DNA, one carrying G/G genotype (WT) for rs28531779 variants and 
one with C/C genotype (MUT) were used to amplify a region of 269 bp upstream to the 
CHRNA7 start codon by PCR using forward primer 5’-tttggtacc-gtacctcccgctcacacctc-3’ and 
reverse primer 5’-tttaagctt-gttgagtcccggagctgca-3’. The WT and MUT PCR fragments were 
cloned into the luciferase pGL3-basic promoter vector: pGL3 WT or the pGL3 MUT (Promega 
Biosciences, Promega Corp., San Luis Oispo, CA). Both PCR products was ligated into pGL3-
Basic vector by using T4 DNA ligase (NEB) and verified by sanger sequencing. The pGL3 basic 
(empty vector), pGL3 WT or the pGL3 MUT reporter vectors were transiently transfected 
using Lipofectamine LTX reagent (Invitrogen) in two different neuroblastoma cell lines: SK-N-
BE-2(C) and SHSY-5Y. Renilla luciferase vector, TK-RL, was co-transfected as internal control. 
Luciferase assays were evaluated 48h post transfection. The experiments were performed in 
triplicate. 




3.5.2 Dual-Luciferase assay  
The Dual-Luciferase Assay (Promega) was used to measure differences in transcriptional 
activity of the CHRNA7 promoter carrying G/G or C/C genotype. SK-N-BE-2(C) and SHSY-5Y 
transfected cells (see above) were washed twice in PBS and lysed in 100µl of “Passive Lysis 
Buffer” (PLB). Samples were analysed for both Firefly and Renilla luciferase activities by 
sequentially using 100 µl of “Luciferase Assay Reagent II” (Firefly activity) and “Stop and 
Glow” (Renilla activity) reagents. Firefly luciferase values were normalized to the renilla 
luciferase activities (normalized signals).  Relative luciferase activity was calculated by the 
ratio between pGL3 WT (or pGL3 MUT) normalized signals and pGL3 basic empty vector 
normalized signals.  
3.6 CHRFAM7A Genotyping using ABI3730 and Gene-mapper v3.0 software 
Analysis of fluorescent labeled PCR products by ABI3730 and Gene-mapper v3.0 software 
allows to define the fragment size with high precision. Using this approach, it is possible to 
discriminate fragment length differences at single base pair resolution.  
3.6.1 Primer design and PCR assays 
DNA sequences and genomic organization of the CHRFAM7A gene are from the UCSC genome 
Browser (hg 19). The primers for the analysis of CHRFAM7A Δ2bp polymorphism were 
designed using Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/primer3/) and map in intronic 
regions adjacent to exon 6. The primers amplify a region of 238 bases pair encompassing the 
polymorphism; the forward primer is labeled with a fluorophore at 5’ position (forward: 5' 
[6-FAM] gtttccatcacccacacagg; reverse: 5' agcttgcccaggaataggaa). The use of 5’ 
fluorescent labeled primer allows to analyze the PCR product by ABI PRISM 3730  and 
GeneMapper v3.0 software. CHRFAM7A exon 6 belong to the duplicated region deriving 
from CHRNA7. Therefore, primers used for the analysis of CHRFAM7A Δ2bp polymorphism 
amplify also the CHRNA7 exon 6. However the Δ2bp polymorphism is specific for CHRFAM7A 
and it is never observed in CHRNA7. 
Then the PCR assays were performed as previously described (3.4.2), using 2.5 mM MgCl2. 
3.6.2 PCR product analysis by  ABI PRISM 3730 automatic sequencer 
The PCR products were diluted 1:20 with water. 




For each PCR product a mix containing  0.2 µL of Size standard (LIZ 600) and 8.8 ul of 
formamide was prepared. The LIZ 600 is a five dye-labelled high density size standard that 
allows to define the length of analysis fragment.  
Nine µL of the mix have loaded to a 96-well plate and, in each well, were added 1 µL of 
diluted PCR product. Then the plate is loaded to ABI PRISM 3730 automatic sequencer to the 
electrophoretic run.  
The capillary electrophoresis allows to separate fragments of different sizes. During the 
electrophoresis a laser excites the dye labelled PCR product and the fluorescence signal is 
detected. The analysis were then performed by Genemapper v3.0 software.  
3.6.3 Analysis of CHRFAM7A 2bp polymorphism and CNV by Genemapper v3.0 
software  
In Genemapper v3.0 software the fluorescent signal is represented by a peak in the graph: 
the Y axis reports the fluorescent intensity (RFU) and the X axis indicate the length of the 
product.  The fragment length is calculated based on the size standard with which it co‐
migrates. The CHRFAM7A PCR product is 238 bp long for the wt allele and 236 for the Δ2bp 
allele, thus, when both alleles are present we can observe the presence of two separated 
peaks representing fragments with 2 different sizes in Genemapper v3.0 (Figure 3.4).   
 
 
Figure 3.4: Fluorescence peak representation in Gene Mapper software, the Y axis reports the fluorescent intensity (RFU) 
and the X axis indicate the length of the product (base pair).   (a) Graph with only one peaks indicating the 238 bp fragment;  
(b) Graph with two peaks indicating the 236 bp e 238 bp fragments 
 




The peak height (fluorescence intensity)  is proportional to the amount of DNA template, 
therefore, since the CHRNA7 copy number is known (see paragraph 3.2 and 3.3) the ratio 
between the peak height of the 236 bp fragment and the 238 bp fragment allows to 
determine also the CHRFAM7A copy number (Table 3.1)  
 
236 bp  /238 bp 
(ratio) 
Copy number  
CHRFAM7A∆2bp CHRFAM7A CHRNA7 
1/4(0.25) 
1 2 2 
or 
1 1 3 
1/3 (0.33) 
1 1 2 
or 
1 0 3 
1/2 (0.50) 1 0 2 
2/3 (0.66) 
2 1 2 
or 
2 0 3 
2/2 (1.00) 2 0 2 
3/2 (1.50) 3 0 2 
 
Table 3.1: Evaluation of CHRFAM7A copy number by the peak height ratio between 236 bp fragment and 238 bp 
fragment  (236/238) 
 
The alleles were defined as follows: 0 = absence of the CHRFAM7A gene; 1 = wild type (TG) 
allele of rs67158670; 2 = bp allele of rs67158670 .Each assay was performed twice.  
For all samples without the 2bp deletion in exon 6 of CHRFAM7A it is not possible establish 
the copy number with this method, therefore it was used a quantitative Real Time PCR 
(qPCR).  
3.6.4 Analysis of CHRFAM7A copy number by real time PCR  
To assess CHRFAM7A copy number in individual without the bp allele we performed a  
real-time quantitative PCR (qPCR) using SsoAdvanced™ Universal SYBR® Green Supermix 
(Biorad).  
The selective amplification of CHRFAM7A is not easy since it derives from the fusion of 
CHRNA7 partial duplication with a copy of FAM7A. Therefore to exclusively amplify 




CHRFAM7A we designed a primer pair to amplify a region of 217 bp spanning the breakpoint 
between FAM7A exons D-A and CHRNA7 exons 5–10 (Primer forward: 5’ - 
tccttgccaatcaactttatga-3’ and primer reverse: 5’- cacaccaccacacctggttaat-3’) (Figure 3.5) 
 
 
Figure 3.5: A) schematic representation of CHRFAM7A exonic organization, the blue genomic region derives from FAM7A 
duplication and the red genomic region derives from a partial duplication of CHRNA7. B) CHRFAM7A region amplified by 
qPCR primers: the forward primer (underlined in blue)  maps in the homology region with FAM7A (blue), the forward 
primer (underlined in red) maps in the homology region with CHRNA7 (red). 
 
The Real time protocol used for the validation of CHRNA7 duplication is described in 
paragraph 3.3. 
3.7 Statistical analysis 
All the analyses statistical analysis were performed using PLINK 1.9263 and STATA statistical 
software version 9.0. 
3.7.1 Study sample analysis 
Chi-square test and t-test were used to perform explorative analysis in the study sample. 
Specifically, possible gender difference among the pharmacological treatment group and the 
no pharmacological treatment group and between abstinent individuals and not-abstinent 
individuals were analyzed by Chi-square test. Difference in FNTD score between male and 
female and between abstinent subjects and not-abstinent subjects were tested using a t-
test. T-test was also used to compare age and FNTD means among pharmacological and no 




pharmacological treatment  groups. To check if FTND score and CPD satisfied the assumption 
of normality we used Shapiro-Wilk test.  
3.7.2 Quantitative analysis 
We used linear regression to test the association of CHRFAM7A copy number, the 
CHRFAM7A bp variant, and CHRNA7 promoter variants with FTND score and CPD, 
including gender as covariate. Age was not included as a covariate in regression models as it 
did not show any influence on any of the smoking phenotypes in our sample. To test for the 
influence of the bp polymorphism independently of CHRFAM7A copy number, regression 
analysis was conducted in the stratified sample of individuals with 1 or 2 copies of 
CHRFAM7A.  
T-test and Mann-Whitney test were used to compare FTND and CPD means between 
subjects carrying different genotypes of the rs28531779 variant. Because only a single 
individual was homozygous for the minor allele, the heterozygous and minor allele 
homozygous individuals were collapsed into a single group and compared with the 
homozygous individuals for the major allele. 
3.7.3 Categorical association analysis 
Analysis of CHRFAM7A/CHRNA7 copy number and CHRFAM7A genotypes in the sample of 
smokers and in the population control samples was performed by Fisher exact test. 
Logistic regression analysis was conducted to investigate for an effect on quit success for 
CHRFAM7A and CHRNA7 genetic variants, using nicotine dependence level (FTND score) and 
gender as covariates. As above, the additive effect of the bp allele was tested by logistic 
regression analysis of abstinent/non-abstinent status by stratification of the sample 
according to CHRFAM7A copy number. 
3.7.4 Rare variants analysis 
Rare CHRNA7 promoter variants were analyzed using the Sequence Kernel Association Test 
(SKAT)264, which aggregates individual score test statistics of a set of SNPs, as individually 
these SNPs are too rare for statistical analysis. 
3.7.5 Luciferase assay 
T-test was used to test differences in luciferase activity between cells transfected with the 
pGL3 MUT vector and cells transfected with the pGL3 wt vector.




CHAPTER 4  
Materials and methods:  Genetic analysis of cluster headache 
4.1 CH study sample  
4.1.1 Cluster headache sample 
One hundred patients suffering from cluster headache (CH) were recruited at the Headache 
and Drug Abuse Research Centre, Policlinico Hospital, University of Modena e Reggio Emilia. 
CH diagnosis was made according the ICHD-III beta criteria (Headache Classification 
Committee of the International Headache Society 2013)189. For each CH subject the following 
clinical data was collected: gender, age, headache history (age of onset, duration of the 
active phase, number of clusters per day and per month, triggering factors, exacerbating 
factors, autonomic symptoms associated, correlation with cigarette smoking in the active 
phase), drug treatment history and smoking status, including number of cigarettes per day 
(CPD), and Fagerström test. DNA was extracted from blood with the Blood/Cultured Cell 
Genomic DNA Extraction Mini kit (Fisher Molecular Biology). 
4.1.2 Control sample 
The control sample consisted of 360 age-matched healthy subjects who are cigarette 
smokers, with no history of CH and/or migraine, recruited at University of Modena as part of 
the study on the genetics of nicotine dependence (see paragraph 3.1.1). Control individuals 
were examined for tobacco dependence measures (CPD, Fagerström test) and to exclude a 
history of CH or migraine. Furthermore, all other information collected for these subjects are 
described in paragraph 3.1.1. 
All participants are of self-reported European ancestry (Italian). DNA was extracted from 
blood with the Blood/Cultured Cell Genomic DNA Extraction Mini kit (Fisher Molecular 
Biology) and from saliva with ORAcollect-DNA (OCR-100) and prepIT-L2P (DNAGenotek). 
4.2 SNP Genotyping and quality control procedures 
The SNP genotyping was performed by Illumina Infinium® PsychArray microarrays (see 
paragraph 3.2). 




The clustering algorithm implemented in GenomeStudio was used to cluster the data. 
GenomeStudio was also used to evaluate all genotypes using a quantitative genotype quality 
score called GenCall (GC) score ranging from 0 to 1 with 1 being the best. The GenCall scores 
generally decrease in the value the further a sample is from the centre of the cluster to 
which the data point is associated. The no-called threshold is the lower bound for calling 
genotypes relative to its associated cluster. The GC cutoff was set at 0.15, and the cutoff  for 
sample genotyping success rate was 95%.  
GenomeStudio allowed also to analyse the Log R Ratio (LRR) and B Allele Frequency (BAF) 
(See paragraph 3.2). Samples with standard deviation of Log R Ratio > 0.20 and standard 
deviation of the B Allele Frequency values > 0.13 were marked not suitable for CNV analysis.  
SNPs quality control (QC) was performed according to recommended guidelines265. Briefly, 
we manually edited or zeroed, all SNPs according to several GenomeStudio QC parameters:  
GenTrain scores (genotype clustering quality score <0.6), low Custer Separation values, low 
Call Frequency, low or high AB R Mean values (mean normalized intensity of the 
heterozygote cluster), low or high AB T Mean values (mean of the theta values of the 
heterozygote cluster), low or high Het Excess (indicator of the quantity of excess 
heterozygote calls relative to expectations based on Hardy-Weinberg Equilibrium) and very 
low minor allele frequency (MAF), given that very rare SNPs could be mis-called by the 
GenCall algorithm. Probes mapping as “0” (no position), “Y” (Y chromosome) and MT 
(mtDNA) were excluded. The overall data quality was high: only one sample failed QC 
thresholds (one additional sample was subsequently removed because of not European 
ethnicity). The reproducibility of the assay was evaluated using  10 replicate samples: 
agreement of genotyping calls was 99.99% over all genotypes across these pairs.  
After manual editing genotypes were exported to the PLINK 1.9 software263,266 for additional 
data cleaning, to remove SNPs deviating from Hardy–Weinberg equilibrium (p<0.001), and 
markers with heterozygous haploid genotypes on the X. Principal component analysis (PCA) 
was performed using PLINK 1.9 on SNPs with MAF > 0.05, pruned for linkage disequilibrium 
(200 kb widnow size, r2>0.5). PCA is currently the most used method for the assessment of 
population substructure in a GWAS. The advantage of PCA is that the resulting correction is 
specific to the SNP variation in frequency across ancestral populations.   
PCA plots were generated using the Genesis tool267. One outlying sample was identified and 
excluded from subsequent association analysis (Figure 4.1). We ruled out relatedness across 




subjects (cases and controls) through identity-by-descent analysis, as implemented in PLINK, 
for all possible pairs of individuals. 556485 variants pass filters and QC, of these 211927 are 
monomorphic and were excluded from association analysis. 
 
Figure 4.1: Principal component analysis (PCA) plot. The red arrow indicates the outlying sample excluded from genetic 
analysis. 
 
4.3 Association analysis 
Single SNP association analysis was perfomed using the PLINK v 1.9 software263.  On 290505 
SNPs that passed QC and MAF > 0.01 a basic case-control analysis was performed using 
Fisher’s exact test. 
In order to aggregate all SNPs in LD with each others, results from the association analysis 
were clumped according to P-value using PLINK. Each clump is represented by an index 
variant (that with the lowest P-value in the clump), and contains all SNPs with P-value<0.01 
in linkage disequilibrium with it (R2>0.5, within 250 kb of the index SNP).  
Plink was also used to carry out logistic regression analysis. Bonferroni correction was 
applied to correct for multiple tests (P < 1.7x10-7, corresponding to 0.05/number of analysed 
SNPs). 
Quantile-quantile (Q-Q) plot for test statistics was performed using the R package. Q–Q plot 
is a probability plot, in which the observed and the null distributions under the assumption 
of no association, are compared by plotting their quantiles against each other. 
LocusZoom268 was used to create the regional association plot, in which for each SNP is 
represented the p-value (in the Y axis) and the localization in the genome (in the X axis) .  




4.4 Gene-based association analysis 
The Sequence Kernel Association Test (SKAT)264 was used to perform gene-based association 
analysis. It is an efficient regression method to test for association between rare genetic 
variants in a region and a continuous or dichotomous trait while adjusting for 
covariates. SKAT aggregates individual score test statistics of a set of SNPs and easily 
computes gene-level p-values. After quality control, all non-monomorphic SNPs were 
mapped to RefSeq genes (downloaded from the UCSC Table Browser, GTCh37/hg19). A 
collection of 1038 candidate genes with a putative role in cluster headache pathogenesis 
was selected according to Gene Ontology (GO) biological process annotations 
(http://geneontology.org/page/download-annotations), including 66 GO terms. These 1038 
genes are implicated in circadian rhythm, pain perception and response, blood pressure 
regulation and vasodilation/vasoconstriction, alcohol metabolism, neuropeptide signaling, 
ion channels, tumor necrosis factor (TNF) signalling, nicotinic acetylcholine receptors 
(Appendix: Table S1 and Table S2).  
Gene-based analysis was performed only on protein altering variants (nonsynonymous and 
splicing variants) with MAF <0.05 within these candidate genes.  In total, 2568 variants in 
745 candidate genes were analysed.  These included 2497 missense, 11 frameshift, 40 
stopgain, 3 stoploss, and 17 splicing variants. A Bonferroni correction which considers the 
number of the evaluated genes was used to define the significance threshold of the gene-
based test results (p < 6.7x10-5).  
We used two freely available bioinformatic tools to functional annotation of variants: 
Polymorphism Phenotyping, (PolyPhen -  http://genetics.bwh.harvard.edu/pph2/)269 and the 
Combined Annotation–Dependent Depletion method (CADD)270.  Polyphen-2 is an algorithm 
that predicts the impact of the non-synonymous change, combining sequence conservation 
data and protein structure annotations; the output is a score ranging from 0 (neutral) to 1 
(damaging).  CADD is a scoring algorithm that predicts the deleteriousness of variants in the 
human genome by integrating multiple annotation algorithms a variety into one metric score 
(C score).  
4.5 MME mutation screening 
4.5.1 Primer design and PCR assay 
DNA sequences and genomic organization of the MME genes are from the UCSC genome 




Browser (hg 19). All coding exons, intron-exon boundaries were sequenced by Sanger 
method. All the primers were designed using Primer3 (http://bioinfo.ut.ee/primer3-
0.4.0/primer3/). 
Region  Foreward primer (5’-3’) Reverse primer (5’-3’) lenght  
Exon 2  
(first coding exon) 
cagccacattaagcatttgg cgttggatagatggtaaaagca  326 
Exon 3 ggggcttcgttggtagaga caactacatggcaagctcca 559 
Exon 4 atgcaatcaaaagggagcaa tggtggtggtacacaaatcct 399 
Exon 5-6-7 tgtacctccagaaaagcaagg ccaggtattagggacagagca 797 
Exon 8 atggtcaccccataaacagc gaatgaaaaacatcagagggcta 300  
Exon 9 gaatctgtgcaggtcatttcttta aaaagcggttgacattattcagt 344 
Exon 10 cccacagccaaatctcaataa cggcacaataagagagcaca 351 
Exon 11-12 tgaggaagaatcccaagtgaa tgcaaagttcaccatgtcct 556 
Exon 13 gccttgtgaggagaagtgatg ttagccaaatgatggagaactg 347 
Exon 14 tttaatcaagagtgtcgataatagcaa acatattgaaggagcttacaagttttt 430 
Exon 15 aattgctagtcatgggcagatt atttcaggcaccccatagc 246 
Exon 16 tgctctcttttaactttattgactga ggagggaaagacctgcttct 271 
Exon 17 ttcatctaggaatggtaataatgctt tgcttgtttagaggtattgtaattgg 247 
Exon 18 aagcctgccatcactgaataa aattgaaagtgtggtgaaaattagag 400 
Exon 19-20 gacagtctctctcatcgtctgc gaaacactctaaatcactaaaatggaa 489 
Exon 21-22 tggcatgatcttttacataggttt agcaccttgattgctgttca 605 
Exon 23 ggctccagtgtggtatgga tgatggtgccctctctgtta 300 
 
Then the PCR assays were performed as previously described (3.4.2), using 2.5 mM MgCl2. 
For the PCR products purification protocol see the paragraph 3.4.3. 
4.5.2 Sanger Sequencing reaction and sequences precipitation 
The primes used for Sanger sequencing are the same used for PCR amplification. Moreover, 
for PCR fragment including MME exons 5-6-7 an addiction sequence primer was designed, as 
well as for the sequencing of PCR fragment including MME exons 21-22. Primers sequencing 
are shown un the following table: 
 




Additional Sequence primers 
Exons 5-6-7 tccaagaagcacctaaagcaa 
Exons 21-22 atgttcctggttgcctttca 
 
For the Sanger Sequencing reaction and sequences precipitation protocols see the paragraph 
3.4.4 and paragraph 3.4.5.  




AIM AND RATIONALE OF THE PROJECT 
CHAPTER 5 
 
In recent years, multiple studies highlighted the importance of genetic factors in several 
smoking related phenotypes, including nicotine dependence, cigarette consumption 
quantity and smoking cessation.  Despite the clear heritability of smoking behaviours 
(estimated to be >50%), their genetic determinants still remain not completely understood, 
due to the complex architecture of these traits, in which several genes and environmental 
factors interact which each other.   
The work presented in this thesis, was carried out within Prof. Elena Maestrini’s research 
team, and was part of a project aimed at investigating genetic factors involved in nicotine 
dependence and smoking cessation. To this purpose, we recruited 408 nicotine dependent 
smokers from 3 different Smoking Cessation Centres of the Emilia Romagna region in Italy, 
who were enrolled on a smoking cessation program, and were followed up for a period of at 
least six-months to collect data on smoking abstinence after treatment. 
During the recruitment of smokers for this project, we identified a group of strong smokers 
who were also affected by cluster headache (CH), a form of headache that is clinically well 
distinguished from other forms of migraine. Previous epidemiological studies indicated the 
importance of complex genetic factors in CH susceptibility, but existing genetic studies were 
extremely limited and inconclusive; therefore, we decided to perform a genetic study to 
investigate genetic factors involved in this disorder, and their possible relationship to 
nicotine dependence. Therefore, alongside the recruitment of treatment seeking smokers, a 
clinically homogeneous sample of 100 patients with CH, regardless of their smoking status, 
was collected at the Division of Toxicology and from Clinical Pharmacology, Headache 
Centre, University of Modena and Reggio Emilia; this sample was studied independently 
from the rest of the smokers. 
The specific aims of these two related projects are outlined below (paragraphs 5.1 and 5.2). 




5.1 Role of α7 nAChR in nicotine dependence 
The aim of this study was to investigate the contribution of genetic variation in the CHRNA7 
and CHRFAM7A genes to nicotine dependence and smoking cessation in a sample of 408 
smokers recruited at smoking cessation centers.  
In recent years, multiple genome-wide association studies (GWAS) for smoking behaviors 
and ND have been performed on thousands of smokers; these studies have implicated genes 
encoding for different nicotinic acetylcholine receptor (nAChR) subunits, including the gene 
clusters on chromosomes 15q25 (CHRNA5-CHRNA3-CHRNB4) and 8p11 (CHRNB3- 
CHRNA6)5,98, as well as the CHRNA4 gene243.  
CHRNA7, the gene encoding the α7 subunit of homopentameric nAChR, has a still uncertain 
role in nicotine dependence, although it is implicated in a wide range of phenotypes and 
neuropsychiatric conditions131,139. CHRNA7 is partially duplicated in a chimeric gene called 
CHRFAM7A, including CHRNA7 exons 5-10 and exons A–E of the FAM7A gene.  CHRFAM7A is 
present in a variable number of copies and it harbours a polymorphic 2bp deletion within 
exon 6, rs67158670 -/TG (2bp), never observed in the CHRNA7 sequence.  The CHRFAM7A 
2bp allele, as well as SNPs in the proximal promoter of CHRNA7, have been associated to 
schizophrenia, and to the P50 sensory gating deficit142,143,150,151. Interestingly, individuals 
with schizophrenia have a very high risk of tobacco dependence158, suggesting that 
α7nAChRs abnormal function may act as a shared vulnerability mechanism to smoking and 
schizophrenia. 
GWAS studies for smoking related traits have not identified significant association in 
CHRNA7, but this lack of association could be due to the complex genetic architecture of this 
genetic region. Indeed, the presence of a duplication giving rise to the CHRFAM7A chimeric 
gene, together with the very high C+G content of the CHRNA7 promoter region, has 
hampered genetic analysis of this region by standard genotyping arrays or next generation 
sequencing. In particular, the most commonly used commercial SNPs arrays (including 
Illumina 1M, Illumina Omni1-Quad and Affymetrix 6.0 array), do not contain SNP probes in 
CHRNA7 exon1 and in the 1200 bp 5’ to exon 1. This genomic region is predicted to harbor 
CHRNA7 core promoter, a region of 231 bp immediately 5’ to start site, reported to be 
sufficient to regulate transcription levels in vitro150 (Figure 5.1). Likewise, the 2bp 
CHRFAM7A variant (rs67158670) is not represented in commercial SNPs arrays. Moreover 




SNPs located in the duplicated portion of CHRNA7 and CHRFAM7A cannot be univocally 
mapped to a gene or the other, and thus they are not reliable. 
 
 
Figure 5.1: 3 kb region on chromosome 15q13.3  spanning CHRNA7 promoter region (UCSC, hg19). The CHRNA7 core 
promoter, as defined in Leonard et al. 2002
150
 is indicated as red bar. The SNPs located on CHRNA7 core promoter, reported 
to reduce CHRNA7 promoter activity in vitro
150
,  are written in blue. Encode regulator tracks are indicated: H3K4Me3 track 
shows a histone mark associated with promoters, H3K27Ac tracks show where modification of histone proteins is 
suggestive of enhancer and other regulatory activity. SNP probes present in  Illumina 1M, Illumina Omni1-Quad and 
Affymetrix 6.0 array are indicated.  
 
SNPs in CHRNA7 proximal promoter, described to reduce CHRNA7 promoter activity in vitro, 
have been significantly associated to schizophrenia150, and to a specific schizophrenia 
endophenotype, the P50 sensory gating deficit151.  Interestingly, no genome-wide significant 
association was reported for the CHRNA7 locus in the recent GWAS for schizophrenia 
performed on tens of thousands of cases and controls271. These contrasting results may 
suggest that commercial SNPs arrays used in GWAS do not comprehensively assess genetic 
variation in this gene, pointing out the importance of a specific analysis of the CHRNA7 
promoter and the CHRFAM7A region.  
Even if genetic association studies have not yet reported significant associations for CHRNA7 
variants and nicotine dependence, recent functional studies have suggested that α7 nAChRs 
may be involved in addiction mechanisms161,162, possibly by modulating the activity of ß2∗ 
nAChRs in the VTA163. The α7 subunit is widely expressed in the brain with the highest 
expression level in the cortex and hippocampus34.  




Based on these lines of evidence, 7 nAChRs has been considered a promising therapeutic 
target for the treatment of tobacco addiction, as well as for improving cognition in complex 
disorders such as schizophrenia. 
Over the last few years, varenicline has become the most widely used drug for treating 
nicotine dependence. It is an α4ß2 nAChR partial-agonist and, although with lower affinity, it 
is an α7 nAChR full-agonist164. Varenicline has also been shown to provide some cognitive 
improvement in people with schizophrenia165,166. It is thus possible that activation of α7 
nAChRs can contribute to the action of varenicline as a treatment for smoking cessation and 
schizophrenia. 
We conducted a genetic study in order to investigate the possible role of α7 nAChR genetic 
variation in smoking phenotypes, as well as to test the hypothesis that α7 nAChR variation 
may modulate the efficacy of varenicline in smoking cessation. The study was conducted on 
the collection of 408 treatment seeking smokers, which included a subgroup of 142 
individuals who were treated with varenicline. More specifically, the aims of this study were: 
i) to investigate the association of genetic variants in the CHRNA7 and CHRFAM7A genes 
with smoking quantity and ND in the whole sample of 408 smokers; and ii) to test the effect 
of CHRFAM7A and CHRNA7 genetic variants on smoking cessation in varenicline treated 
smokers, by contrasting individuals who successfully maintained smoking cessation at six 
months after treatment versus those who did not quit smoking. 
5.2 Genetic analysis of cluster headache 
The aim of this project was to investigate the genetic background of CH by performing a 
genome-wide association study (GWAS) in a cohort of 100 Italian patients with CH and 360 
matched controls. 
Cluster headache (CH) is the most severe primary headache displaying a very typical clinical 
picture with severe, unilateral attacks pain, often accompanied by ipsilateral autonomic 
symptoms, showing a typical circadian and circannual rhythmicity190,191. These specific 
symptoms  allow to discriminate CH from other forms of migraine.  Over 80% of CH patients 
have prolonged history of tobacco usage, making smoking the most consistent lifetime habit 
reported in CH patients240. However, it is still an unsolved issue if tobacco use could be an 
environmental trigger for CH in genetically predisposed subjects, or specific genetic risk 
factors for CH may also predispose individuals to tobacco smoking. Family and twin studies 




have indicated a genetic component for CH188, but at present, its genetic background is 
largely unexplored. Prior to our study, only small-scale genetic studies have been completed, 
which investigated the involvement of variants in single candidate genes thought to be 
involved in the pathophysiology of CH217,218,220,222,226,229,230,235,239. Among these, the only 
evidence of association has been reported for a common variant in the HCRTR2 gene239. 
Hence, as for most complex disorders, the candidate gene approach has not been successful 
in the identification of risk genes. By contrast, GWAS have now yielded hundreds of 
significant results for numerous complex disorders, including migraine, providing a 
substantial contribution to our understanding of the genetic determinants of many 
disorders. For example, genome wide significant risk loci have been identified for migraine, 
implicating genes expressed in vascular and/or smooth muscle tissue into migraine 
pathophysiology272. 
So far, most GWAS have been performed to identify association with common variants in the 
general population (> 5%), each having a modest effect on risk, hence requiring very large 
numbers of cases and controls. However, low frequency and rare variants have been shown 
to play a significant role in the aetiology of several complex diseases; in particular, exonic 
functional variants, such as nonsynonymous SNPs lying in the coding regions of genes, are 
expected to have a greater impact on the disease phenotype. These variants are not typically 
interrogated by the widely-used SNP genotyping platforms. Exome sequencing technology 
has provided the means to comprehensively assess coding variation, including the discovery 
of very rare and private variants. Recently, “exome” genotyping arrays have been developed 
as a cost-effective alternative to exome sequencing, in order to allow genotyping of rare 
coding variants identified by exome sequencing studies in samples of thousands of 
individuals. 
Given this framework, we decided to carry out an hypothesis-free GWAS in a sample of 100 
CH cases and 360 controls, using the Infinium PsychArray (Illumina)257, which combines both 
common highly-informative genome-wide tag SNPs and SNPs in coding regions of genes, 
with an enrichment in genetic variants associated with common psychiatric conditions. 
Given the unknown genetic architecture of CH, this approach represents the most powerful 
and cost-effective design to simultaneously investigate the contribution of both rare and 
common variants to CH susceptibility. Moreover, this approach allows to test the association 
of genetic variants previously implicated in migraine and in ND. 




Specifically, the aims of this study were: i) to test genome-wide association for common SNP; 
ii) to investigate the possible genetic overlap between CH and migraine,; iii) to test the 
hypothesis that genetic factors involved in smoking dependence might also predispose to 
CH, in order to clarify the observed link between smoking and CH; iv) to perform a gene-
based analysis, limited to rare protein-altering variants (PAVs) in a subset of 745 candidate 
genes involved in molecular pathways with a plausible role in CH pathogenesis. 
Finally, it should be noted upfront that our sample is very small and lacks power to detect 
significant associations for variants conferring low or moderate risk. Our results therefore 
should be considered as preliminary and warrant replication in much larger and independent 
samples in order to achieve an adequate statistical power. However, we think that this  
study is worthy of note as it represents the first attempt at a comprehensive genome wide 
analysis in CH, for which genetic studies are still very limited. 






Analysis of CHRNA7 and CHRFAM7A in nicotine dependence 
 
6.1 Sample characteristics 
The study sample consisted of 408 Italian regular smokers enrolled at three Smoking 
Cessation Centers (Modena, Parma and Imola) in Italy. Baseline phenotypic data was 
collected on all participants recruited in the smoking cessation program, including sex, age, 
number of cigarettes per day (CPD), and Fagerström test for nicotine dependence (FTND). All 
participants received group or individual counseling; in addition, a subgroup of 142 
treatment seeking smokers also received a pharmacological treatment with varenicline. All 
individuals were followed up at six months after treatment in order to assess maintenance 
of smoking cessation.  
The demographic and phenotypic characteristics of the total cohort of smokers are shown in  
Table 6.1, and the distribution of smoking measures (CPD, FTND) are shown in Figure 6.1. 







N 408 142  266 
Sex M/F 235/173 (1.36) 94/48 (1.96) 141/125 (1.13) 
Age (ys) mean ± sd  49.13 ± 11.59 48.87 ± 11.33 49.27 ± 11.74 
CPD (mean ± sd; 
median) 
21.79 ± 9.74; 20 22.69 ± 7.14; 20 21.30 ± 9.78; 20 
FTND (mean ± sd) 5.8 ± 2.15 6.38 ± 1.99 5.50 ± 2.17 
Abstinence rate 129/408 (31.62%) 53/142 (37.32%) 76/266 (28.57%) 
Table 6.1: Sample characteristics 
The FTND score is an ordinal variable ranging from 0 to 10, which satisfied the assumption of 
normality (Shapiro-Wilk test; p= 0.11); thus, we modeled the FTND score as a normal 
continuous variable in subsequent statistical analysis. The distribution of CPD did not satisfy 
the assumption of normality (Shapiro-Wilk test p< 0.0001), possibly because most smokers 




tend to round off the number of daily cigarettes to multiples of 10, thus introducing some 
bias (Figure 6.1). Nevertheless, the FNTD score and CPD are significantly correlated in our 
sample (r= 0.60; P < 10-5). 
We identified an association of gender with FTND (T-test p= 0.02) and CPD (T-test p< 
0.0001), with males having a higher mean FTND (6.02, sd 2.27) and mean CPD (23.6, sd 
10.78) compared to females (mean FTND: 5.52, sd 1.95; mean CPD: 19.37, sd 7.51). Age did 
not show any association with either CDP or FNTD, therefore this variable was not included 
as covariate in subsequent regression analysis.  
 
Figure 6.1: CPD and FTND distribution in the entire sample of smokers (N=408). The mean CPD is 21.80 ± 9.74, the mean 
FTND score is 5.8 ± 2.15. 




Maintenance of abstinence at six months after treatment was investigated in the whole 
sample and in the subgroup of varenicline-treated subjects (Table 6.1). The abstinence rate 
was 31.6% in the whole sample and 37% in the varenicline-treated group. This result is in 
agreement with the current literature167 showing the highest cessation rates with varenicline 
treatment, compared to other pharmacological and behavioural interventions; however, our 
study design did not involve a randomized controlled trial and testing the efficacy of 
pharmacological treatment was beyond the scope of the study.  
By comparing the group of successful quitters to unsuccessful quitters, we observed a 
significant difference in nicotine dependence (FNTD) (p< 0.0001) and CPD (p= 0.002), while 
there was no difference for gender and age (Table 6.2). Thus, the FNTD  score was included 
as a covariate in our regression model to test the effect of genetic variants on smoking 
cessation (paragraph 6.8).   




N 129 279  
CPD (mean ± sd;median) ** 19.64 ± 8.77; 20 22.78 ± 10; 20 
FTND (mean ± sd)*** 5.12 ± 2.05 6.12 ± 2.13 
Sex M/F 76/53 (1.43) 159/120 (1.325) 
Age, ys (mean ± sd, range) 50.23 ± 11.57 48.63 ± 11.58 
Table 6.2: Analysis of abstinence in the sample 
** T-test p= 0.002;  Mann Whitney test p=0.0015 
*** T-test p< 0.0001 
 
6.2 CHRNA7 copy number assessment by Illumina Infinium® PsychArray microarrays 
CHRNA7 copy number was established in the entire sample of smokers, in a control group 
including 194 light smokers (FTND= 0) or never smokers and in a cohort of 204 ASD 
individuals, using SNP array data from the Illumina Infinium® PsychArray microarrays 
(Illumina, San Diego, California, USA). Three CNV prediction algorithms, namely, 
QuantiSNP260, PennCNV259 and CNVPartition (Illumina), were used to obtain high-confidence 
CNV call and to minimize the number of potential false discoveries. Array data of each 
individual were exploited by manual inspection of Log R ratio and B allele frequency in 
Illumina's GenomeStudio software, as described in Materials and Methods.  
Five CHRNA7 microduplications were identified in the sample of smokers, one in the control 
sample and one in the ASD sample (Figure 6.2A). Although the frequency of CHRNA7 




microduplications is slightly higher in the smokers sample compared to controls and to 
individuals with autism, this difference is not significant. 
This CNV includes exon 1 of the longer isoform of OTUD7A and the entire CHRNA7 gene 
(chr15:32049125-32514341 NCBI build 37 coordinates). The duplication was also validated 
by quantitative PCR in all 7 individuals. As shown in Figure 6.2B, five smokers (20150; 10116; 
10061; 10471; 10058), one ASD individual (SM_60.3) and 1 control subject (10315) have 3 
copies of CHRNA7 gene. In the graph is also represented a subject (CTR) with 2 copies of 
CHRNA7 gene, including in the qPCR experiment as control DNA. 
No CHRNA7 deletions were found in our sample, and this is not surprising given the rarity 
and highly penetrant association of this microdeletion with different neuropsychiatric 
disorders132-134. 
 





Figure 6.2: A) GenomeStudio screenshot showing B-allele frequency and log R ratio for an individual without CNVs (10059) 
and an individual carrying the microduplication involving CHRNA7 (10116). The duplication results in an increase of the Log 
R ratio and a deviation of the allelic ratio. The SNPs included in the duplication are boxed. B) qPCR results for the CHRNA7 









6.3 Genotyping of  CHRFAM7A 
The genotypes of the CHRFAM7A 2bp polymorphism (rs67158670) was determined by 
analysis of exon 6 labeled PCR-product using Genemapper v3.0 software. This polymorphism 
is specific of CHRFAM7A and it has not been observed in CHRNA7 exon 6.   
Briefly, to assess rs67158670 genotype, a fragment of 238-236 bp encompassing CHRFAM7A 
and CHRNA7 exon 6 was amplified by 5’ fluorescent labelled PCR primers and PCR products 
were resolved by capillary electrophoresis on the ABI PRISM 3730 automatic sequencer. In 
Genemapper v3.0 software the PCR product fluorescent signal is represented as a peak in 
the graph: the Y axis reports the fluorescent intensity (RFU) and the X axis indicate the 
length of the product in bp (see materials and methods, paragraph 3.6.3). The presence of a 
2bp deletion allele in CHRFAM7A gives rise to a PCR product which is 2 bp shorter than the 
wt allele in CHRNA7 and/or CHRFAM7A, leading to two separated peaks representing 
fragments of 236 bp and 238 bp. In this case, considering that peak height (fluorescence 
intensity) is proportional to the amount of DNA template, the ratio of the two peak heights 
allows to determine the relative copy number of wt alleles compared to 2bp alleles; given 
that the 2bp  allele is specific for CHRFAM7A, and that CHRNA7 copy number has already 
been determined for each sample (see paragraph 6.2), from this analysis we can infer the 
number of copies of the CHRFAM7A gene.  
The allelic status of CHRFAM7A was defined according to the deletion of the whole gene 
(“allele 0”), or presence of a copy of CHRFAM7A with the wt (TG) allele for rs67158670 
(“allele1”), or the 2bp allele (“allele2”). 
In total, 553 individuals were found with at least one copy of CHRFAM7A allele 2 and for 
these individuals it was possible to establish also the gene copy number of CHRFAM7A. The 
ratio between the fluorescence peak height representing CHRFAM7A allele 2 and the 
fluorescence peak height representing CHRNA7 and/or CHRFAM7A allele 1 allowed to define 
six different genotype states for CHRFAM7A in our sample (Figure 6.3).  
 





Figure 6.3: Graphical representation by scatter plot of CHRFAM7A genotype states (according to rs67158670) for 553 
subjects  with at least one copy of CHRFAM7A allele 2. The Y axis represents the ratio between peak heights of CHRFAM7A 
allele 2 and CHRFAM7A allele 1 obtained by analysis with Gene Mapper software. In the X axis are reported the copy 
number of both CHRNA7 and CHRFAM7A, and the different CHRFAMA7A genotypes inferred by the ratio of fluorescence 
peaks heights, taking into account the CHRNA7 copy number (for example a ratio=0.25 indicates 1 copy of CHRFAM7A allele 
2, 2 copies of CHRFAM7A allele 1 and two copies of CHRNA7: ¼=0.25, grey dots). The number of individuals found for each 
genotype state is reported. 
 
Instead, for 253 individuals carrying only the wild type allele, the CHRFAM7A copy number 
was established by real time PCR using CHRFAM7A specific primers (see material and 
methods paragraph 3.6.4). We detected 4 additional possible genotype states at CHRFAM7A 
according to the copy number of allele 1 (Figure 6.4). 





Figure 6.4: Graphical representation by scatter plot of CHRFAM7A copy number for 253 subjects found without the 
CHRFAM7A allele 2. The Y axis represents the 2
-ΔΔCt
 value obtained from real time PCR analysis. The X axis shows 
CHRFAMA7A copy number, the rs67158670 genotypes according to CHRFAM7A copy number  and the number of subjects 
found in each category. All these subjects have 2 copy of CHRNA7.  
 
6.4 Case-control analysis of genetic variation in CHRNA7 and CHRFAM7A 
We performed a case control analysis (Fisher test) to test if CHRNA7 and CHRFAM7A copy 
number genotypes differ between smokers, controls and ASD subjects. No statistically 
significant difference was detected in this analysis (p= 0.651). Furthermore, the copy number 




genotypes distribution observed in our sample is comparable to previously reported data in 
other European populations139. (Table 6.3).  














Smokers 3 (0.74) 58 (14.22) 333 (81.62) 9 (2.21) 4 (0.98) 1 (0.25) 408 
Controls  1 (0.52) 34 (17.53) 148 (76.29) 10 (5.15) 1 (0.52) 0 (0) 194 
Autism 2 (0.98) 31 (15.20) 166 (81.37) 4 (1.96) 1 (0.49) 0 (0) 204 
Total 6 (0.74) 123 (15.26) 647 (80.27) 23 (2.85) 6 (0.74) 1 (0.12) 806 
 
Table 6.3: . CHRNA7/ CHRFAM7A copy number in smokers, controls and individuals with autism 
The majority of individuals carry two copies of each gene (80%), while approximately 16% of 
individuals have only one copy of CHRFAM7A, and only 0.74 % has no copies. A minority of 
subjects have three copies of CHRNA7 (0.86%) or CHRFAM7A (2.85%).  
Next, we analyzed the allelic status of CHRFAM7A according to presence of either the wt 
(TG) allele for the exon 6 polymorphism (“allele1”), or the Δ2bp allele (“allele2”), or deletion 
of the whole gene (“allele 0”), (Table 6.4). There was no significant difference in allele 
frequency between the three samples of smokers, controls, and ASD (Chi2, p-value=0.72). 
 
 Allele1 (%)  
 
0 1 2 Total 
Smokers 68 (8.24) 404 (48.97) 353 (42.79) 825 
Controls 37 (9.30) 185 (46.48) 176 (44.22) 398 
Autism 35 (8.5) 186 (45.14) 191 (46.36) 412 
Total 140 (8.56) 775 (47.4) 720 (44.04) 1635 
                Table 6.4: CHRFAM7A Δ2bp allele frequency distribution in smokers,  controls and autistic individuals              
                
1
“0” = absence of CHRFAM7A; “1” = wild type (TG) allele; “2” = Δ2bp allele 
6.5 Quantitative analysis of CHRFAM7A variants 
Given the availability of quantitative smoking measures on the sample of smokers, we 
performed linear regression analysis to investigate the effect of genetic variants on smoking 




quantity (CPD) or nicotine dependence (FTND). Linear regression analysis with adjustment 
for sex as covariate, did not identify a significant effect for CHRFAM7A copy number on 
either smoking measures (Table 6.5).  
Furthermore, we tested the effect of bp polymorphism on CPD or FTND. In order to test 
for the influence of the bp polymorphism independently of CHRFAM7A copy number, 
regression analysis was conducted in the stratified sample of individuals with 1 or 2 copies of 
CHRFAM7A (Table 6.5). In individuals carrying 2 copies of CHRFAM7A we observed a mild 
association of bp allele with CPD, but this result was not confirmed in regression analysis 
with FTND (Table 6.5). 
FTND         
Variants Coef. Std. Err. 95% C.I. P (FTND) 
CHRFAM7A copy number  -0.09 0.25  -0.57  - 0.39 0.715 
bp allele 
(CHRFAM7A copy number=1)
0.32 0.56  -0.80 - 1.46 0.562 
bp allele 
(CHRFAM7A copy number=2)
0.16 0.16  -0.16 - 0.48 0.333 
CPD         
Variants Coef. Std. Err. 95% C.I. P (CPD) 
CHRFAM7A copy number  -1.16 1.10 -3.34 - 1.00 0.29 
bp allele 
(CHRFAM7A copy number=1)
0.37 2.31 -4.25 - 5.00 0.87 
bp allele 
(CHRFAM7A copy number=2)
1.86 0.73 0.41 - 3.31 0.012 
Table 6.5: Linear regression analysis of CHRFAM7A copy number and bp polymorphism stratified by copy 
number, with adjustment for sex 
 
6.6 Quantitative analysis of CHRNA7 variants 
The region encompassing 740 bp upstream the CHRNA7 start codon, containing the CHRNA7 
core promoter region150 was sequenced in the sample of smokers by Sanger sequencing. We 
identified a total of thirteen polymorphism listed in Table 6.6, of which 2 are common 
variants (MAF> 0.01) and 11 are rare variants (Table 6.6). 
 
 




POSITION (hg19) SNP ID 
Nr het/Nr hom  
N=408 smokers 
(MAF) 
Nr het/Nr hom  
N=129 abstinent 
smokers  (MAF) 




chr15:32322094 -704 T/C rs576919947 1/- (0.001) 
  
1/- (0.002) 
chr15:32322464 -334 C/T rs182726713 4/- (0.005) 
  
4/- (0.007) 
chr15:32322476 -322 C/T rs377300328      1/- (0.001)   1/- (0.002) 
chr15:32322482 -316 C/A rs139231762 3/- (0.004)   3/- (0.005) 
chr15:32322557 -241 A/G rs188889623 6/- (0.007) 1/- (0.004) 5/- (0.009) 
chr15:32322604 -194 G/C rs28531779 27/1 (0.036) 9/1 (0.043) 18/- (0.032) 
chr15:32322607 -191 G/A rs553179500 2/- (0.002) 1/- (0.004)  1/- (0.002) 
chr15:32322632 -166 C/T  - 1/- (0.001)   1/- (0.002) 
chr15:32322643 -155 G/A  - 1/- (0.001)   1/- (0.002) 
chr15:32322706 -92 G/A rs111910242 5/- (0.006) 2/- (0.008) 3/- (0.005) 
chr15:32322712 -86 C/T rs149637464 43/2 (0.055) 15/-(0.058) 28/2 (0.058) 
chr15:32322750 -48 C/G rs201089931 1/- (0.001)   1/- (0.002) 
chr15:32322752 -46 G/T rs145180415 4/- (0.005) 2/- (0.008) 2/- (0.004) 
Table 6.6: CHRNA7 promoter variants. Common variants (MAF> 0.01) are indicated in bold. 
Focusing only on the two common variants rs28531779 and rs149637464 (MAF >0.01), we 
carried out a linear regression analysis, to test for association of these SNPs with smoking 
measures. As above, sex was included as covariate in our regression model. This analysis 
revealed a statistically significant association for the rs28531779 SNP with both FTND (p= 









FTND             
Index SNP CHR BP Coef. Std. Err. 95% C.I. P value 
rs28531779 15 32030401  -4.82 1.73  -1.67   -0.11 0.02639 
CPD             
Index SNP CHR BP Coef. Std. Err. 95% C.I. P  
rs28531779 15 32030401  -0.89 0.4  -8.22  -1.42 0.006 
Table 6.7: Linear regression analysis of CHRFAM7A copy number with adjustment for sex  
Specifically, individuals carrying the minor allele for rs28531779 have a higher FTND score 
and CPD than homozygotes individuals for the G allele (Figure 6.5). Mean CPD for 
rs28531779 GG genotype were 21.37  9.13, and 26.50  13.10 for the GC and CC genotypes 
(Ttest; p-value= 0.003); while mean FTND score for GG genotype was  5.73  2.13, and for 




Figure 6.5 The boxplots display the distribution of CPD (A) and FTND (B) among individuals homozygous for rs28531779 G 
allele and carrying the C allele.   
Then, we also evaluated the cumulative effect of 11 rare (MAF < 0.01) promoter variants on 
smoking measures (FTND, CPD). Using the SKAT method, we performed a burden analysis 
that allows to increase the power to identify variants effect on phenotype than testing each 
variant individually. The SKAT analysis provides a cumulative p-value indicating the degree of 




enrichment of rare variant associations within a genetic region. This analysis did not detect a 
statistically significant result.  
6.7 Analysis of rs28531779 effect  on CHRNA7 promoter activity by dual luciferase assay   
A previous functional study using luciferase assay, suggested that several common variants 
in the CHRNA7 core promoter region, including rs28531779, decrease CHRNA7 promoter 
activity in vitro.  In order to confirm this result, we replicated in vitro functional analysis for 
rs28531779 by dual luciferase assay in two neuroblastoma derived cell lines, BE-2(C) and 
SHSY-5Y. A region of 269 bp including the CHRNA7 core promoter was amplified by PCR from 
two different genomic DNA samples: one carrying the G/G genotype (WT) for rs28531779 
and one carrying the C/C genotype (MUT).  The fragments were cloned into pGL3 Basic 
vector (pGL3 WT or the pGL3 MUT), and analyzed for luciferase reporter gene activity as 
described in material and methods (see paragraph 3.5). In both cell lines tested, reporter 
assays showed a slightly lower luciferase activity in cells transfected with the pGL3 MUT 








Figure 6.6: A) Schematic representation of the “pGL3_wt” and “pGL3_MUT” recombinant plasmids, used in dual luciferase 
assays to verify the effect of rs28531779 on CHRNA7 promoter activity. B) Luciferase activity of CHRNA7 promoter 
constructs measured in Dual luciferase assays using two different cells lines.  Firefly luciferase data are normalized to renilla 
luciferase activity.  Relative luciferase activity was calculated by the ratio between pGL3 WT or pGL3 MUT signals 
normalized to renilla and pGL3 basic empty vector (normalized to renilla). The experiment was set up in triplicate; error 
bars represent SD.  
6.8 Association analysis for smoking abstinence in the varenicline treated sample 
We performed a logistic regression analysis, with adjustment for sex and FTND score as 
covariates, in order to test for an effect of CHRFAM7A copy number, the Δ2bp allele 
(rs67158670) and CHRNA7 promoter variants on smoking abstinence in the group of 142 
subjects treated with varenicline. This analysis identified a possible effect of 
CHRFAM7A copy number on abstinence (OR= 3.18, 95% CI= 1.09 – 9.30, p= 0.035); while no 
statistically significant results were observed for rs67158670 and CHRNA7 promoter variants 










Abstinence (varenicline treated group N=142)     
Variants Coef. Std. Err. 95% C.I. P value  
rs28531779 -1.21 0.69 -2.57   -0.14 0.079 
rs149637464 -0.41 0.60 -1.59   0.76 0.49 
CHRFAM7A copy number 3.17 1.74 1.09 - 9.30 0.035 
Δ2bp allele                    
(CHRFAM7A copy number=1) 
1.09 1.27 -1.40 - 3.59 0.39 
Δ2bp allele                      
(CHRFAM7A copy number=2) 
0.45 1.45 -0.16 - 1.06 0.146 
Table 6.8: Logistic regression analysis to test the effect of CHRNA7 common promoter variants  and CHRFAM7A variant 
(Δ2bp allele  and copy number),  on abstinence with adjustment for sex and FTND. Δ2bp polymorphism was stratified by 
copy number.  
The significant result from logistic regression analysis is also supported by a higher quit 
success rate in smokers carrying 2 or 3 copies of the CHRFAM7A gene compared to smokers 
carrying 0 or 1 copies (1 sided Fisher exact test p= 0.048) (Figure 6.7 A).  
 
 
Figure 6.7: The mosaic plot displays the CHRFAM7A copy number among abstinent and not abstinent subjects in: A) the 
varenicline treated group (N=142), 1 sided Fisher exact test: p= 0.048, B) in the No-pharmacological treatment group 
(N=266), 1 sided Fisher exact test p= 0.23. The blocks width indicates the sample size in the two categories (Copy number 0-
1 and 2-3), while the blocks heights indicate the percentage of subjects (abstinent individuals or not abstinent individuals) 
in each categories.  
 
The logistic regression analysis was repeated on the remaining sample of 266 smokers who 
did not receive varenicline treatment to detect a possible effect of CHRFAM7A copy number 
on abstinence. This analysis did not reveal a statistically significant effect (Table 6.9).  
To support the hypothesis that CHRFAM7A copy number may interact with varenicline in 
modulating the effectiveness of varenicline treatment as a smoking cessation aid, a logistic 




regression analysis was performed in the entire sample of smokers including the “varenicline 
treatment X CHRFAM7A copy number” interaction term in the model. As expected, the 
interaction term yields a mild statistically significant p-vale (p= 0.044). 
 
CHRFAM7A Copy Number Odds ratio 95% C.I. P value 
Varenicline treatment N=142 3.18 1.09 - 9.30 0.035 
No pharmacological  
treatment N= 266 
0.88 0.47 - 1.66 0.705 
Table 6.9: Logistic regression analysis to test the effect of CHRFAM7A copy number variants on abstinence with adjustment 
for sex and FTND in the varenicline treatment group and in the no pharmacological treatment group.  





Genome-wide analysis of common and rare variants influencing risk 
for Cluster Headache 
 
7.1 Sample characteristics 
The genome wide analysis was performed on 99 subjects with cluster headache (CH) and 
359 controls.  All phenotypic and demographic information collected for these 458 
individuals is described in Table 7.1. 
 CH patients Controls 
N 99 359 
Gender (N,%)   
Male 85, 83.84% 204, 56.82% 
Female 16, 16.16% 155, 43.18% 
Age, ys (mean ± sd, range) 47.39 ± 13.12, 23-81 48.96 ± 11.91, 18-70 
CH attacks   
Age at onset, ys  (mean ± sd, range) 30.04±12.65, 6-80  
Chronic (N, %) 14, 14.14%  
N attacks/year (mean ± sd, range);  1.29 ± 0.77, 0.17-4   
N attacks/day (mean ± sd, range);  2.85 ± 1.68, 1-9   
Smoking   
Ever smoking (N,%) 88, 89.11% 359, 100% 
N. cigarette/day (mean ± sd) 19.17 ± 10.83 21.77 ± 9.13 
Fagerström test (mean ± sd); N 4.60 ± 2.54 (N=72) 5.95 ± 2.21 
Table 7.1: Sample characteristics 
 
7.2 SNP genotyping by Illumina Infinium® PsychArray microarrays 
Genotyping was performed on Illumina Infinium® PsychArray microarrays (Illumina, San 
Diego, California, USA), in two batches, the first using Illumina PsychArray-24 v1.0, the 
second using PsychArray-24 v1-1 array257. The Infinium PsychArray combines common 
highly-informative genome-wide tag SNPs (265000 variants), exome-focused markers 
(245000 variants) and 50000 additional polymorphism associated with common psychiatric 
disorders. For the analysis, only SNPs present on both versions of the array (566178 variants) 
were used.  




After quality control filtering (as described in paragraph 4.2), 211927 monomorphic SNPs 
were excluded from the analysis. A total of 344558 SNPs passed the filters and they were 
used for genetic associations analysis for CH disease susceptibility.  
In particular, common SNPs with minor allele frequency (MAF) > 0.01 were used in the 
genome wide association analysis  (paragraph 7.3), while rare (MAF < 0.05) protein altering 
variants (PAVs) were used to perform a gene-based association analysis (paragraph 7.7).  
7.3 Genome wide association analysis  
We performed a single marker case-control association analysis on high quality SNPs with 
minor allele frequency (MAF) > 0.01 (290505 variants) in the study population, using the 
Fisher exact test. In order to exclude the hypothesis that in our sample the statistics results 
could be inflated by artificial differences in allele frequencies caused by population 
stratification or cryptic relatedness and genotyping errors, we calculated the genomic 
inflation factor (λ), defined as the ratio of the observed and expected medians of the test 
statistic distribution, and we carried out a Q-Q plot, showing the expected distribution of 
association test statistics compared to the observed values. In our sample the λ score is 1, 
indicating that no overall inflation of the genome-wide  statistical  results exists. In addition, 
the Q–Q plot showed no global deviation of the observed distribution from the expected null 
distribution (Figure 7.1) indicating that the inflation of the genome-wide association results 
due to population stratification is negligible.   





Figure 7.1: Quantile-quantile (Q-Q) plot of Fisher’s exact test P-values for association with CH. X-axis shows P-values 
expected under the null distribution; Y-axis shows observed data. Grey region shows 95% confidence interval. 
 
The genome wide association results are represented in the Manhattan plot (Figure 7.2). 
This scatter plot displays the SNPs genomic localization along the X-axis with different 
colours for each of the 23 chromosomes and the –log10 of the association P-value for each 
SNP on the Y axis.  





Figure 7.2: Manhattan plot of genome-wide association P-values. The y axis represents the -log10 Fisher’s test P-values; the 




In this study, the genome-wide threshold for statistically significant association, calculated 
by the Bonferroni correction for multiple testing, is P<1.7 x10-7. No variant reached this 
genome-wide significance level; however some SNPs showed suggestive associations (p 
value <10-5 , the threshold is indicated with a grey line in the Manhattan plot).  
7.3.1 Suggestive results from GWAS 
The SNPs with the most significant p-values identified in our study and their chromosomal 
localization are listed in table 7.2. Furthermore, all variants included in the study in LD with 
the index SNPs are also reported. 
Suggestive results (p value <10-5) have been identified for the 2 polymorphisms listed at the 
top of the table. Genotypes for these 2 variants are represented in the Genoplots in Figure 
7.3. For each variant, the genotypes are grouped in two different Geneplots based on 





















 G A 0.11/0.26 0.19 (0.19; 0.22) 1.40 x 10
-6
 0.34 (0.21-0.55) 
rs12668955 7:31116168  ADCYAP1R1 G A 0.34/0.52 0.55 (0.50; 0.47) 9.10 x 10
-6
 0.48 (0.34-0.66) 
rs1495452 3:65834076  MAGI1 A G 0.55/0.38 0.39 (0.45; 0.49) 1.43 x 10
-5
 2.03 (1.48-2.79) 
rs2182605 1:117463537  PTGFRN G A 0.32/0.50 0.51 (0.48; 0.45) 1.80 x 10
-5
 0.49 (0.35-0.68) 
rs16895584 8:122518935   A G 0.24/0.04 0.070 (0.054; 0.051) 1.85 x 10
-5
 3.50 (2.03-6.02) 
rs6469999 8:122415207 rs13255877, rs7833779  A G 0.31/0.17 0.46 (0.16; 0.17) 2.16 x 10
-5
 2.23 (1.56-3.19) 
rs1509957 10:64610718 rs224308, rs10822065  G A 0.60/0.43 0.43 (0.49; 0.42) 2.66 x 10
-5
 1.99 (1.44-2.74) 
Table 7.2: Genome wide association analysis results of SNPs with the most significant p-values.  
Abbreviations: A1 = minor allele in study sample; A2 = major allele; A1-F = A1 frequency; OR = odds ratio for minor allele; CI = confidence interval 
a










Figure 7.3: Plots for variants rs1006417 and rs12668955  in CH and control samples genotyped by  PsychArray-24 v1.0.(A) 
and by  PsychArray-24 v1.1 (B). The colours indicate the genotype: red= CC, purple= GC and blue= GG. 
 
 




The most significant hit is a SNP cluster tagged by rs1006417 located on chromosome 14 (p= 
1.4x10-6). This SNP maps in a chromosomal region with no known genes. The second 
suggestive results is for SNP rs12668955 located on chromosome 7, in an intronic region of 
the ADCYAP1R1 gene encoding for the pituitary adenylate cyclase-activating polypeptide 
(PACAP) receptor (p= 9.10x10-6). Figure 7.4 displays the local association plots for both the 
suggestive results loci.   
 
 
Figure 7.4: Local association plots for chromosome 14 locus (A) and the chromosome 7 locus (B). Association results are 
shown for genotyped SNPs, colored according to their level of linkage disequilibrium of the each SNP with the index SNP 
(purple diamond). The blue line shows the estimated recombination rates from the 1000 Genomes Project November 2014 
release. The genomic locations of genes are shown below the plot based on GRCh37/hg19 assembly. 
 




Given the high prevalence of males suffering from CH, the ratio between males and females 
is very different among CH patients and controls individuals. In order  to take into account 
this gender distribution difference, we performed a logistic regression analysis for the most 
significant SNPs from GWAS, adding sex as covariate. In this analysis, rs1006417 was 
confirmed to be the most significant result (P = 4.18x10-6).  However, for rs12668955, linear 
regression analysis identified a reduction of significance (p= 0.000138), suggesting a possible 
sex effect at this locus. In the logistic regression analysis we have also included CPD and age 
as covariates, but we did not find a significant effect of these variable at each locus tested. 
The logistic regression results are listed in table 7.3. 
Index SNP CHR BP P value 
rs1006417 14 41803291 4.18E-06 
rs12668955 7 31116168 1.38E-04 
rs1495452 3 65834076 7.25E-06 
rs2182605 1 117463537 2.87E-04 
rs16895584 8 122518935 9.95E-05 
rs6469999 8 122415207 3.22E-04 
rs1509957 10 64610718 1.05E-04 
rs117202318 18 10613697 6.15E-06 
rs1324523 6 50080330 2.19E-04 
Table 7.3: logistic regression analysis. P-values for additive effect of SNPs controlling for sex as a covariate.  
 
7.4 Analysis of loci previously implicated in CH  
We investigated if our dataset could provide some support to previously reported putative 
association signals for CH in the HCRTR2 and ADH4 genes. 21 polymorphic SNPs genotyped 
on the PsychArray (18 common variants and 3 rare variants) map in HCRTR2: no common 
SNP provided a significant single marker P-value (Fisher test), including the previously 
implicated variant rs2653349 (G1246A) (Table 7.4). Only a very rare missense variant 
(rs41271312) reached a nominally significant P-value (P = 0.03) (Table 7.4). 
 ADH4 contained 13 polymorphic SNPs (12 common variants including the reported SNPs 









SNP rsID Position (hg19) Locus F_A F_U P OR 
rs7766546 chr6:55006253 HCRTR2 0.4192 0.3841 0.4108 1.157 
rs9475176 chr6:55014872 HCRTR2 0.383 0.3641 0.671 1.084 
rs13200042 chr6:55033223 HCRTR2 0.2424 0.2019 0.2375 1.265 
rs9382460 chr6:55037484 HCRTR2 0.1919 0.1894 0.9188 1.016 
rs41271312 chr6:55039416 HCRTR2 0.0151 0.0014 0.0335 11,03 
rs10456181 chr6:55040696 HCRTR2 0.3889 0.4248 0.372 0.8617 
rs6927478 chr6:55044386 HCRTR2 0.3698 0.4286 0.1609 0.7824 
rs9370399 chr6:55045025 HCRTR2 0.4343 0.3942 0.3264 1.18 
rs3122148 chr6:55065989 HCRTR2 0.2062 0.2207 0.6959 0.9173 
rs6937878 chr6:55067627 HCRTR2 0.1566 0.1894 0.3493 0.7944 
rs9396060 chr6:55079046 HCRTR2 0.1263 0.1685 0.1877 0.713 
rs3122156 chr6:55082807 HCRTR2 0.2626 0.2947 0.4249 0.8524 
rs9357849 chr6:55092069 HCRTR2 0.3081 0.3259 0.6681 0.921 
rs7771240 chr6:55093831 HCRTR2 0.3081 0.3245 0.731 0.9268 
rs9357851 chr6:55097163 HCRTR2 0.2424 0.273 0.4148 0.8522 
rs9382471 chr6:55107267 HCRTR2 0.2677 0.2911 0.5356 0.8902 
rs77680302 chr6:55110524 HCRTR2 0.1162 0.07521 0.08148 1.616 
rs41381449 chr6:55120108 HCRTR2 0 0.00696 0.591 0 
rs2653349 chr6:55142337 HCRTR2 0.1616 0.1453 0.5734 1.134 
rs146899452 chr6:55147138 HCRTR2 0 0.00139 1 0 
rs2653350 chr6:55144102 HCRTR2 0.404 0.4513 0.258 0.8244 
rs3828541 chr4:100042262 ADH4 0.3776 0.3855 0.8686 0.967 
rs1139490 chr4:100045141 ADH4 0.3131 0.3482 0.3972 0.8534 
rs1042365 chr4:100045500 ADH4 0.2879 0.3273 0.3027 0.8309 
rs1139490 chr4:100045141 ADH4 0.3131 0.3482 0.3972 0.8534 
rs1042365 chr4:100045500 ADH4 0.2879 0.3273 0.3027 0.8309 
rs1126673 chr4:100045616 ADH4 0.2929 0.344 0.2014 0.79 
rs1126672 chr4:100047812 ADH4 0.2879 0.3273 0.3027 0.8309 
rs1126671 chr4:100048414 ADH4 0.2929 0.344 0.2014 0.79 
rs1126670 chr4:100052733 ADH4 0.2929 0.344 0.2014 0.79 
rs6532798 chr4:100054827 ADH4 0.2929 0.344 0.2014 0.79 
rs13110764 chr4:100062466 ADH4 0.2879 0.3273 0.3027 0.8309 
rs61734620 chr4:100062814 ADH4 0 0.0029 1 0 
rs2032349 chr4:100062819 ADH4 0.005051 0.01671 0.319 0.2986 
         Table 7.4: Fisher's exact test P-values for all tested SNPs mapping on the HCRTR2 and ADH4 genes 
 
7.5 Analysis of loci previously implicated in migraine  
To explore a possible genetic overlap between migraine and CH, we also inspected 
association results in our dataset for confirmed hits which have emerged from recent large 
scale GWAS for migraine272. A recent meta-analysis reported association for 45 independent 




confirmed SNPs located on 38 different loci272. In our study, 29 of these SNP have been 
directly genotyped or detected by a tag SNP. The Fisher test was used to investigate 
difference between cases and controls for these variants. Only rs9349379 located in 
PHACTR1, encoding  for phosphatase and actin regulator 1 showed a nominally significant P 
value (P = 0.034) (Table 7.5) 
 
SNP POSITION (hg19) locus Tag SNP Tag SNP bp r2 P-value 
rs11172113 chr12:57527283 LRP1 rs11172113 57527283 1.00 0.1979 
rs10218452 chr1:3075597 PRDM16 rs7518255 3086464 0.90 1 
rs12135062 chr1:3103312 PRDM16 rs2651927 3101762 0.87 0.7834 
rs67338227 chr6:97042147 FHL5 rs11153058 97012746 0.73 0.6399 
rs2223239 chr6:96767685 FHL5 rs2205760 96786690 0.74 0.6747 
rs7775721 chr6:97056979 FHL5 (MO) rs2273621 97058553 0.96 0.4564 
rs10166942 chr2:234825093 TRPM8 rs10166942 234825093 1.00 0.3681 
rs566529 chr2:234756811 TRPM8 rs13384669 234759800 0.76 0.5703 
rs6724624 chr2:234820578 TRPM8 (MO) rs10166942 234825093 1.00 0.3681 
rs9349379 chr6:12903957 PHACTR1 rs9349379 12903957 1.00 0.03442 
rs1925950 chr1:156450740 MEF2D rs3790455 156456301 1.00 0.3186 
rs4814864 chr20:19469817 SLC24A3 rs6081613 19465907 0.92 0.3828 
rs1024905 chr12:4518140 FGF6 rs10849061 4523456 0.88 0.688 
rs186166891 chr7:40406876 C7orf10 rs12533531 40418721 0.71 0.6179 
rs10786156 chr10:96014622 PLCE1 rs2274224 96039597 0.99 0.1271 
rs7961602 chr12:57273481 PLCE1 rs4237805 57249600 0.65 0.7452 
rs4910165 chr11:10674044 MRVI1 rs4909945 10673739 0.99 0.865 
rs10456100 chr6:39183470 KCNNK5 rs10456100 39183470 1.00 0.0714 
rs6478241 chr9:119252629 ASTN2 rs6478241 119252629 1.00 0.7441 
rs12260159 chr10:100702737 HPSE2 rs7073636 100665866 0.78 0.05476 
rs17857135 chr17:78262161 RNF213 rs17857135 78262161 1.00 0.1802 
rs2506142 chr10:33468124 NRP1 rs2506144 33468456 0.93 0.9197 
rs1268083 chr6:126049040 HEY2 rs1343116 126069702 0.66 0.4185 
rs6791480 chr3:30480559 TGFBR2 rs4075748 30478985 0.99 0.6563 
rs10895275 chr11:102083608 YAP1 rs8504 102103600 0.97 0.6107 
rs12845494 chrX:40764757 MED14 rs10127045 40745226 0.80 0.5121 
rs10155855 chr7:111328397 DOCK4 rs17158733 111332403 0.53 0.05003 
rs1572668 chr1:73899742 LRRIQ3 rs4113050 73910055 0.98 0.4174 
rs11031122 chr11:30547438 MPPED2 rs11031122 30547438 1.00 0.6469 
Table 7.5: Fisher's exact test P-values for all tested SNPs mapping on loci previously implicated in  migraine
272
. MO: 
migraine without aura. 
 




7.6 Analysis of loci previously implicated in smoking dependence 
 
The relationship between smoking and CH is not clear; tobacco use could be an 
environmental trigger for CH in genetically predisposed subjects, or, conversely, specific 
genetic risk factors involved in smoking behaviors could also predispose individuals to CH. 
Therefore, in order to investigate the latter hypothesis, we inspected different genes 
encoding for nicotinic acetylcholine receptor (nAChR) subunits, which represent confirmed 
associated loci to tobacco addiction and smoking-related traits. In particular we focused our 
analysis on the CHRNA5-CHRNA3-CHRNB4 cluster, the CHRNA6-CHRNB3 cluster and 
CHRNA4. We observed that the allele frequency for each variant tested in these genes did 
not significantly differs between CH patients and control smokers (including the functional 
SNP rs16969968). Given the availability of smoking measures (FTND score and CPD) for CH 
patients and controls smokers included in our study, we also performed a linear regression 
analysis to test for association of the variants with FTND score and CPD, adding age, sex and 
CH status as covariates.  This analysis did not reveal an effect of SNPs tested in nAChR genes 
on both smoking measures.   
7.7 Gene based analysis 
In order to increase power to detect variants directly involved in the disorder, we restricted 
our analysis only to rare (MAF < 0.05) protein altering variants (PAV) located on several 
candidate genes for CH. The comprehensive collection of candidate genes was made 
according to Gene Ontology (GO) biological process annotations 
(http://geneontology.org/page/download-annotations). We selected those genes related to 
cellular processes with a plausible role in CH, including circadian rhythm, pain perception 
and response, neuropeptide signalling, vasodilation and vasoconstriction, ion channels, 
nicotinic acetylcholine receptors, alcohol metabolism, TNF signalling. The list of selected 
genes and GO terms is shown in the appendix (Table s1 and Table s2). In total 2568 rare 
protein altering variants located in 745 candidate genes have been used to carry out the 
gene based analysis by SNP-set Kernel Association Test (SKAT)264. Using this approach all the 
rare variants within a candidate gene are considered jointly and the analysis provide a gene-
level P value that indicates the enrichment level of rare variants associations in a gene. The 
gene based association analysis results with a nominal P-value < 0.01 are listed in table 7.6.  
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Gene MME 2.55x10-5         
rs61762319  0.42 G 0.030/0.021 0.0072(0.023; 0.019) 0.0164(0.0226) Missense p.M8V 0.524(P) 15.63 
rs147564881  2.03x10-5 C 0.035/0 0.001(0.002; 0.009) 0.0022(0.0033) Missense p.G225A 1 (D) 21 
rs61758194  1 A 0/0.0014 0.0002(0; 0) 0.0021(0.0035) Missense p.V345I 0.001(B) 11.65 
Gene NPY1R 1.18x10-3         
rs5578  3.80x10-3 C 0.040/0.0084 0.003(0.007; 0.019) 0.0047(0.0067) Missense p.K374T 0.421(B) 12.96 
rs78156188  1 A 0/0.0028 0.0004(0.002; 0) 0.0006(0.001) Missense p.A111V 0.023(B) 3.073 
Gene BDKRB1 3.30x10-3         
rs143823168  1 C 0/0.0028 0.0018(0.003; 0) 0.0024(0.0036) Missense p.L191V 0.999(D) 9.214 
rs45528332  9.23x10-3 A 0.030/0.0056 0.0036(0.004; 0.005) 0.0062(0.0052) Missense p.G241R 0.926(P) 9.661 
Gene SLC5A3 4.94x10-3         
rs35707420  0.014 A 0.025/0.0042 0.0026(0.006; 0.009) 0.0062(0.0087) Missense V370M 1(D) 18.46 
rs199948762  0.39 G 0.0051/0.0014 . 0.000099(0.0001) Missense N557K 0.001(B) 8.533 
Gene CCL26 7.02x10-3         
rs41463245  0.022 A 0.020/0.0028 0.0036(0.016; 0.023) 0.0086(0.0131) Nonsense W44X . 23.1 
Gene GRM1 9.45x10-3         
rs41305288  0.017 A 0.035/0.0098 0.01(0.017; 0.023) 0.0172(0.0185) Missense p.P729T 1(D) 19.24 
rs362936  1 A 0.0051/0.0097 0.004(0.017; 0.009) 0.0212(0.031) Missense p.G884E 0.998(D) 13.22 
rs138759146  1 C 0/0.0014 . 0.0001(0.0002) Missense p.M909L 0.017(B) 1.328 
rs2941  0.14 A 0.0051/0.022 0.0092(0.025; 0.019) 0.0132(0.0182) Missense p.V929I 0.111(B) 18.3 
rs79336287  0.071 A 0.015/0.0023 0.005(0.004; 0) 0.0017(0.0013) Missense p.P1069L 0(B) 11.39 
Table 7.6: results of SKAT gene-based tests in CH 
Abbreviations:  RA = rare allele; RAF =rare allele frequency; 
a 
single SNP Fisher's exact test P-value; 
b
 rare allele frequency in 1000 Genomes all populations (1000G_all) in european populations 
(1000G_EUR) and in Tuscans from Italy (1000G_TSI); 
c
 rare allele frequency in Exome Aggregation Consortium (ExAC) Non-Finnish European (NFE) populations; 
d 
PolyPhen-2 HumDiv score; 
B=benign, P=possibly damaging, D=probably damaging, 
e
 CADD v1.3, PHRED-like (-10*log10(rank/total)) scaled C-score 




The most significant result was detected for the MME gene (P value of 2.5 × 10–5), encoding 
for Membrane Metallo Endopeptidase, also called neprilysin. This association result remains 
statistically significant also after the Bonferroni correction for multiple testing (threshold: p < 
6.7 × 10−5). Individually, all MME rare variants included in the gene based analysis had good 
genotyping cluster properties and genotyping rate > 99.9 %.  
The missense variant rs14756488 (p.G225A) is the most significant (p-value= 2.03 × 10−5) in 
the gene based analysis. It causes a substitution of amino acid glycine with alanine at 
position 225 (Gly225Ala). This variant was found in 7 out of 99 CH patients and in none of 
the 359 control smokers.  
The rs14756488 genotypes are represented in Figure 7.5, grouped in two different 
Geneplots based on different batches of Illumina Infinium® PsychArray microarrays (A: v1.0 
and B: v1.1) used for SNPs genotyping. The red cluster is empty in both Geneplots indicating 
the absence of homozygous individuals for rs14756488 risk allele. Instead, in the purple 
cluster we observed 7 dots in graph B indicating the presence of heterozygous individuals for 
rs14756488, which are all CH patients. These genotyping results were confirmed by Sanger 
sequencing (paragraph 7.8). 





Figure 7.5: Plots for rs14756488 genotype in CH and controls sample genotyped by  PsychArray-24 v1.0.(A) and by  
PsychArray-24 v1.1 (B). Genotype are called for each sample (dots) by their signal intensity (Norm-R; y-axis) and Allele 
Frequency (Norm Theta; x-axis) relative canonical cluster position for a given SNP marker. The colours indicate the 
genotype: red= CC; purple= GC and blue= GG. 
 
Analysis of rs14756488 frequency in the public databases “1000 Genome Project” 
(http://www.1000genomes.org/) and Exome Aggregation Consortium (ExAC) 
(http://exac.broadinstitute.org/) showed that this missense variant is very rare in the 
general population: MAF = 0.1% in all 1000 Genome Project phase 3 individuals and 0.2% in 
60706 individuals of ExAC. We used two online bioinformatic tools to predict the 
deleteriousness of variant rs14756488 in the human proteins: PolyPhen-2 and CADD270. This 
variant is predicted to be damaging by PolyPhen‐2 (PolyPhen score=1), and  the phred-CADD 
score is 21 indicating that the variant is predicted to be among the 1% most deleterious 
SNVs present in the human genome (Table 7.6).  
The clinical details of individuals with CH carrying rs14756488 are reported in Table 7.7. 
These subjects did not present significant differences in clinical signs that allow to distinguish 
them to the rest of subjects with CH.  



























56 F 64 40 chronic CH 4 No Yes 15 4 12 
61 M 48 43 1 3 No Yes 14 5 30 
71 M 67 35 1 3 No Yes 15 4 20 
80 F 38 6 chronic CH 4 No Yes 16 5 20 
81 M 33 20 1 3 No Yes 17 4 5 
92 M 81 46 1 1 Yes (CH) Yes NA NA 0 
G002 M 68 50 1 2 Yes (CH) Yes 13 0 20 
Table 7.7: Clinical features of CH patients with the p.G225A MME variant 
 
The other suggestive results (p<0.01) from SKAT analysis have been identified in genes 
encoding for  Neuropeptide Y receptor type 1 (NPY1R), B1 bradykinin receptor (BDKRB1), 
Sodium/myo-inositol cotransporter (SLC5A3) C-C motif chemokine 26 (CCL26) and 
Metabotropic glutamate receptor 1 (GRM1) (Table 7.6).  
7.8 MME mutation screening  
In order to test the presence of other rare protein altering variants in MME gene, we 
performed a mutation screening of the entire MME coding region in all 99 CH patients by 
Sanger sequencing. 
This mutation screening allowed to confirm the two rare variants identified by gene-based 
analysis and to detect a rare synonymous SNP (rs200455903) in one subject with CH (Table 



























exm360204 rs61762319 G 0.03/0.021 0.0072(0.023) 0.016(0.0226) Missense 
p.M8V 
exm360241 rs147564881 C 0.035/0 0.001(0.002) 0.002(0.0033) Missense 
p.G225A 




Table 7.8: Rare variants identified in MME  mutation screening, the first two variants were previously detected by Illumina 
Infinium® PsychArray microarrays and confirmed by mutation screening. In red is indicated a new rare synonymous variant 
detected by mutation screening.   




CHAPTER 8  
 
8.1 Role of α7 nAChR in nicotine dependence 
The World Health Organization (WHO) has defined cigarette smoking as “the single most 
preventable cause of death in the world today”2. Tobacco dependence is caused by nicotine, 
a substance found in high concentration in cigarette smoke. Nicotine produces physical and 
mood-altering effects in the brain that are temporarily pleasing. At the same time, stopping 
tobacco use causes withdrawal symptoms, including irritability and anxiety. Yet, despite the 
widespread awareness of the harms of smoking, millions continue to smoke around the 
world partly due to the difficulty it takes to quit smoking. It has been shown that 
approximately 80% of smokers who attempt to quit on their own relapse within the first 
month of abstinence and only about 3-5% remain abstinent for 6 months273. 
Pharmacological treatment and behavioural counselling have been shown to increase the 
rate of successful smoking cessation. According to the latest estimate from the U.S. 
Preventive Services Task Force (USPSTF), behavioural interventions resulted in 7%-13% 
smoking cessation rates, versus cessation rates in controls of 5%-11%. Nicotine replacement 
therapy (NRT), bupropion, and varenicline all increased smoking cessation rates versus 
control therapy; varenicline showed the greatest rates of cessation (28%), followed by 
bupropion SR (19%) and NRT (17%) at 6 to 12 months167. Combination of both medication 
and behavioural counselling has been shown to be more effective than either intervention 
alone274. Tobacco addiction (like other drug addictions) involves the interplay of 
pharmacology, genetics, and social and environmental factors. Heritability estimates for 
different nicotine addiction traits (such as the level of dependence, the number of cigarettes 
smoked per day and smoking persistence) are in the range of 50% to 60%46,47.  
Recently, several large genetic studies have started to shed some light on genetic 
susceptibility to nicotine dependence. 
The CHRNA5-CHRNA3-CHRNB4 gene cluster on chromosome 15 encoding for nicotinic 
receptor (nAChR) subunits harbours the strongest and most replicated genetic risk factor for 
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several smoking behaviours61,98. In addition, genome-wide association studies (GWAS) of 
smoking phenotypes and nicotine dependence reported associations for other genes 
encoding nAChR subunits, including CHRNB3-CHRNA65 gene cluster and the CHRNA4 
gene243. 
Preclinical studies demonstrated that the activation of heteropentameric ß2 subunit-
containing nicotinic receptors (ß2∗ nAChRs) have a role in promoting nicotine addiction 
phenotypes3,275,276. Moreover, recent functional studies have suggested that 7 nAChRs, 
encoded by CHRNA7 gene, may be involved in addiction mechanisms161,162, possibly by 
modulating the activity of ß2∗ nAChRs in the VTA163. GWAS studies for nicotine addiction 
have not identified a significant association in CHRNA7, but this lack of association could be 
due to the complex genetic architecture of this genomic region, which is among the most 
unstable regions of the human genome. The presence of a chimeric gene, CHRFAM7A, 
deriving from the fusion between a duplication of CHRNA7 exons 5–10 and FAM7A exons A–
E, and the very high C+G content of CHRNA7 promoter region, hampers genetic analysis of 
this region by standard genotyping chips or next generation sequencing. In particular, no 
SNP probes are present in the CHRNA7 promoter in the most commonly used genotyping 
arrays (including Illumina 1M array or Affymetrix 6.0) (Figura5.1). Likewise, the 2bp 
CHRFAM7A variant (rs67158670) is not represented in commercial SNPs arrays and SNPs 
located in the duplicated portion of CHRNA7 and CHRFAM7A are not reliable. 
The CHRFAM7A function is still unknown, however in vitro studies have suggested that it 
encodes for a truncated form of the α7 subunit, called dupα7, which could act as a dominant 
negative regulator of CHRNA7 function, as it assembles with α7 subunits and causes a 
decrease of acetylcholine-stimulated current140,141. 
The aim of this study was to examine the hypothesis that genetic variation affecting α7 
nAChR function may influence smoking behaviors and the effectiveness of varenicline in 
smoking cessation. We performed a comprehensive analysis of the CHRNA7 and CHRFAM7A 
loci, considering sequence and copy number variants in these two genes, in a cohort of 408 
treatment-seeking smokers, which included a subgroup of 142 individuals who were treated 
with varenicline.  
Sequence analysis of the CHRNA7 promoter region in the entire cohort of smokers led to the 
identification of an association of rs28531779 with smoking dependence (FNTD and CPD). To 
our knowledge, this is the first study reporting a significant association of a CHRNA7 
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promoter variant with smoking quantity and nicotine dependence. Interestingly, a previous 
study150 reported that, in luciferase assay, the minor allele of rs28531779 (C) may reduce 
CHRNA7 promoter activity. We attempted to confirm this result using the luciferase assay, 
and we observed the same trend reported by Leonard et al.150, but without reaching the 
threshold of statistical significance. It should be noted that the main disadvantage of 
luciferase assay is the analysis of variant effects outside their normal environment; thus, we 
cannot exclude that the associated variant could have a stronger effect when the DNA is in 
its normal cellular context and/or it could be influenced by other variants in the genome. 
Analysis of CHRNA7 expression in cells of subjects carrying the rs28531779 minor allele could 
help to better understand the role of this variant on CHRNA7 expression.  Therefore, we are 
currently recruiting blood samples from smokers to test CHRNA7 expression in monocytes 
and macrophages, as CHRNA7 has been shown to be specifically expressed in these blood 
cell types277,278.  
Interestingly, the same rs28531779 promoter variant has been previously associated to the 
schizophrenia endophenotype P50 inhibitory deficit150, and to schizophrenia151. Therefore, 
these data suggest that rs28531779, possibly by decreasing the expression of 7 nAChR, 
could be involved in susceptibility to both nicotine dependence and schizophrenia. This 
hypothesis is also supported by post-mortem studies showing reduced levels of 7 nAChR in 
the brain of individuals with schizophrenia279,280, and in vivo studies in rodents which report 
that reductions in 7 nAChR function promote nicotine use161. Moreover, the high 
prevalence of tobacco consumption in schizophrenic subjects is in line with the presence of a 
shared genetic background between these two disorders.  There are increasing evidences for 
cross-disorder effects of genetic variation: first, genomic studies have showed that the same 
CNVs may influence risk for different neuropsychiatric disorders, such as schizophrenia, ASD, 
intellectual disability (ID), developmental delay and ADHD281; second, analysis of GWAS data 
has demonstrated the existence of substantial sharing of genetic risk factors represented by 
common SNPs across five major neuropsychiatric disorders (schizophrenia, bipolar disorder, 
major depressive disorder, autism spectrum disorders and attention-deficit/hyperactivity 
disorder)282. 
A second interesting finding of our study is the observation that CHRFAM7A copy number, 
seems to influence the success of smoking cessation in subjects treated with varenicline. In 
particular, CHRFAM7A copy number positively correlates with smoking cessation success, 
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with higher abstinence rates in subjects carrying two or three copies in comparison to 
subjects with 0-1 copies. The effect of CHRFAM7A copy number on smoking abstinence was 
not detected in the remaining sample of 266 individuals who were not treated with 
varenicline, according to the hypothesis that CHRFAM7A copy number influences smoking 
cessation by interacting with varenicline treatment. Testing for interaction between the 
varenicline treatment and CHRFAM7A copy number provided a p value of 0.04.  
Even if the biological basis for this effect is presently unknown, some evidence in 
reconstituted systems suggests that incorporation of dup7 in 7 receptors modestly 
increases the sensitivity of 7 receptors to varenicline.283 Our study thus supports the 
hypothesis of an involvement of 7 nAChRs activation in the varenicline mode of action for 
smoking cessation treatment.  
The product of CHRFAM7A, 7dup has been hypothesized to be a negative regulator of 7 
receptor function140, and a link between 7 receptor and varenicline also comes from the 
association of CHRNA7/CHRFAM7A variants to schizophrenia142,151 and the effects of 
varenicline treatment in schizophrenic subjects165,166. More specifically, CHRFAM7A copy 
number and 2bp deletion polymorphisms have been associated to schizophrenia. Moreover, 
alterations in the CHRFAM7A/CHRNA7 expression ratios have been detected in 
schizophrenia and bipolar disorder, due mainly to overexpression of CHRFAM7A149. 
Interestingly, varenicline treatment in schizophrenic subjects leads to cognitive 
improvements and anti-smoking effect165,166, suggesting that 7 nAChRs may mediate the 
action of varenicline as a treatment for smoking cessation and schizophrenia.  
By contrast, in our study we found no evidence for an effect on smoking phenotypes of the 
CHRFAM7A Δ2bp polymorphism, previously shown to be associated to schizophrenia and 
the P50 sensory gating deficit.  This could be explained by the small sample size of our study, 
thus lacking an adequate power to detect a significant association for this variant; 
alternatively the CHRFAM7A Δ2bp may specifically influence psychiatric phenotypes. 
The major limitation of this study is the relatively small sample size that does not ensure 
sufficient power to draw definitive conclusions on the association results obtained, as none 
of our significant values would survive multiple testing correction. Replication of CHRNA7 
and CHRFAM7A genetic analysis in larger and independent cohorts is therefore required to 
confirm our initial results.  
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In conclusion, this study is the first one to report a significant association of CHRNA7 
promoter variants with smoking quantity and nicotine dependence, suggesting that variation 
in CHRNA7 expression could have a critical role in tobacco addiction mechanisms. 
Furthermore, our work provides the first evidence that CHRFAM7A copy number variation 
could affect the response to varenicline treatment. 
 It has been estimated that 50% of the risk for a failed attempt at smoking cessation can be 
attributed to genetic factors48,49. Therefore, the identification of genetic factors that could 
improve the effectiveness of pharmacologic approaches to smoking cessation may represent 
a very important finding. Altogether, these results point to a critical role for the 
CHRFAM7A/CHRNA7 locus in tobacco addiction mechanisms. 
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8.2 Genetic analysis of cluster headache 
Cluster Headache (CH) is a rare primary headache characterized by recurrent unilateral 
short-lasting attacks of excruciating orbitotemporal pain, often appearing with a clockwise 
regularity. Despite its clear clinical presentation CH biology is poorly understood. Because of 
the typical rhythmicity of attacks the involvement of the biological clock has been proposed. 
Evidence for activation of the trigeminovascular (CGRP) and cranial parasympathetic (VIP) 
nervous systems, which are involved in controlling cranial vascular reactivity, has also been 
reported197. Smoking is the most consistent lifetime habit reported in CH patients240, but the 
link between CH and cigarette consumption is not clear. Tobacco use could be an 
environmental trigger for CH in genetically predisposed subjects, or specific genetic risk 
factors for CH may also predispose individuals to tobacco smoking. 
Family and twin studies indicate that complex genetic factors play an important, but still 
unknown, role in CH188. Molecular genetic investigations have been in part hampered by the 
complex nature of the disorder and its low prevalence. Most studies investigated the 
involvement of variants in candidate genes thought to be involved in CH pathophysiology. 
Association studies suggested a role for the hypocretin system in CH susceptibility218,239. No 
associations or conflicting results were found for variants in CACNA1A230, NOS229, MTHFR235 , 
PER3226, SERPINA236, and ADH4221,223. 
In contrast to candidate gene studies, genome-wide association studies (GWAS), take a 
hypothesis-free approach to identifying genetic variants for disease. Over recent years, 
GWAS provided novel suggestion into the biological and genetic factors involved in many 
complex traits, including migraine272.  
In general, GWAS focus on common SNPs (MAF > 5% in the general population) with modest 
effects on disease risk or quantitative trait variation, therefore large samples are needed. 
The advent of whole-exome next-generation sequencing allowed to highlight the role of rare 
coding variants in the aetiology of many complex diseases. Thus, more recently, “exome 
genotyping arrays” were introduced as a cost effective alternative to exome sequencing. 
These arrays were created to genotype rare coding variants identified by exome sequencing 
of thousands of individuals284. 
Therefore, to identify genetic variants involved in CH, we decided to use this kind of array, 
specifically the Infinium PsychArray (Illumina)257 that allows testing genome-wide common 
variants as well as low frequency protein-coding variants in exons, with a particular focus on 
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genes implicated in neuropsychiatric disorders: the combination of these two characteristics 
results in a gain in power, given the unknown genetic architecture of CH. Genotype data 
were used to perform a single marker genome-wide association analysis using common SNP 
and a gene-based association analysis considering only rare exonic variants in candidate 
genes with a possible role in CH.  
The GWAS provided an interesting suggestive association of CH with a common 
polymorphism in the ADCYAP1R1 encoding for pituitary adenylate cyclase activating peptide 
(PACAP) receptor gene 1 (PAC1). Moreover, from the gene-based analysis, we identified an 
interesting association with a rare coding variant in the MME gene.  Both ADCYAP1R1 and 
MME are genes known to be involved in pain mechanisms.  
PACAP is a member of the vasoactive intestinal peptide-like peptide family, it is expressed in 
the trigeminal ganglia, the pituitary gland, cerebral cortex, the trigeminal nucleus caudalis285. 
PACAP binds to and activates 3 different receptors:  the PAC1 receptor, activated only by 
PACAP, and the VPAC1 and VPAC2 receptors, activated by PACAP and the vasoactive 
intestinal polypeptide (VIP)286.Studies performed on animal models demonstrated that 
PACAP and its receptors are present in the spinal dorsal horn and dorsal root ganglia and 
suggested a critical role of PACAP receptors signalling system in the regulation of pain 
transmission287.  More specifically, administration of PACAP to rodents sensitized neurons to 
pain287, while PACAP antagonists reduced pain sensitivity288. Futhermore, mice deficient in 
PAC1 receptors displayed a decreased chronic responses to chemical, thermal and 
mechanical stimuli and did not show neuropathic pain after carrageenan-induced 
inflammation or nerve transection289,290. PACAP has been recently reported to induce  
migraine-like attacks likely acting in the trigeminovascular system286, in contrast, the infusion 
of VIP does not cause migraine attacks291,292.  Thus, the PAC1 receptor seems to be the likely 
pathophysiological target of PACAP in migraine. Moreover, a recent study measured the 
plasma PACAP levels during different phases of CH, revealing that PACAP plasma level were 
higher during ictal phase compare to inter-bout periods293. Finally, recent evidence 
suggested that PACAP/PAC1 signalling is important for circadian rhythms294 and, 
interestingly, CH attacks show a circadian regularity.   
Considering these findings, the PAC1 receptor could be the target for new drug development 
to treat migraine and CH. There is large interest in evaluating if antibodies against the PACAP 
peptide and PAC1 receptor have an effect in preventing migraine attacks285.  
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From our gene-based analysis we also identified a significant association in the MME gene. 
MME encodes for a zinc-dependent metallopeptidases, also named neprilysin or neutral 
endopeptidase (NEP). Neprilysin hydrolyzes different peptide hormones including glucagon, 
enkephalins, substance P, neurotensin, atrial and brain natriuretic peptides, oxytocin, and 
bradykinin295. These peptides are implied in pain modulation in the central nervous system, 
in regulation of trigeminal nociceptive inputs and, moreover, in stress and circadian rhythms. 
Interestingly, alteration in all these mechanisms are thought to have a role in the clinical 
features of CH296-298. NEP knockout mice showed enhanced pain behaviour and neurogenic 
inflammation after injury of sciatic nerve299.  
The associated MME missense variant from our gene-based analysis (p.G225A) was not 
identified in control subjects without CH, but it is reported in public control databases with 
low frequency (MAF=0.02%). Therefore, even if the frequency of primary headache in public 
databases is not known, this data could reflect the incomplete penetrance and/or the 
interplay with other genetic and/or environmental factors. Moreover, recent studies 
reported that rare loss-of-function and missense variants in MME predispose individuals to 
late-onset axonal neuropathies, the Charcot–Marie–Tooth disease type 2 (CMT2)300,301 and 
to a rare autosomal recessive form of CMT2302. Patients with this neuropathy have not been 
reported to suffer from migraine or CH, but subjects carrying MME variants were reported 
to manifest neuropathic pain300. Considering the different peptides hydrolysed by neprilysin 
and their wide expression pattern, it is possible that pathogenic mutations in MME genes 
could have a role in the etiology of different neurological traits. Further studies are 
warranted in order to explore the molecular mechanisms predisposing to different 
phenotypes.  We can speculate that severe, very rare deleterious variants contribute to 
axonal neuropathies, while, the more frequent p.G225A missense mutation could have a 
slighter damaging effect, leading to an increased risk for CH susceptibility by interaction with 
other genetic or environmental factors. 
Very recently, a Swedish study attempted to replicate the most significant association results 
emerged from our study (rs1006417 in intergenic region, rs12668955 in ADCYAP1R1, 
rs147564881 in MME) in a cohort of 542 CH patients and 581 controls, but no significant 
result was detected at any of the tested variants303. 
The contrasting results coming from our study and the Swedish replication study might have 
several reasons. For example, the control samples employed by the two studies have 
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different characteristics: in our study we genotyped 360 individuals matched for age and 
smoking status with the case group, while in the Swedish study used DNA from anonymous 
donors as controls. Furthermore, the gender ratio is significantly different among our sample 
and the Swedish sample: our CH cohort has an higher percentage of males (84%) in 
comparison with the Swedish cohort (68,3%).  
We should also considerer that there could be a different genetic background between the 
Italian and Swedish population; in fact, the associated variant have different MAF in the two 
populations. Lastly, the replication study only tested the three single top variants without 
testing additional SNPs in the same loci. Therefore, the lack of replication could also be due 
to the potential diversity of linkage-disequilibrium structure across populations. 
Furthermore, the lack of the specific rare missense mutation rs147564881 in MME in the 
Swedish cohort does not exclude that other rare functional variants in the same gene might 
contribute to CH risk.  
The principal limitation of this study is the small sample size that does not provide enough 
power to detect genome-wide significant associations. Moreover, the suggestive association 
detected in the ADCYAP1R1 gene is supported only by a single intronic variant (rs12668955). 
To exclude the presence of genotyping errors that might have affected this result, we have 
carefully double checked the genotyping data in our case-control sample. Only 11 common 
variants in ADCYAP1R1, spanning about 59 Kb, are present on the Psychiatric array 
(Illumina)257,  and no other variants in LD with rs12668955 is present. Therefore, more 
comprehensive analysis of this gene is warranted in order to fine map the association signal 
and better understand the role of  ADCYAP1R1 in CH susceptibility.  
To address these issues, we are currently recruiting an additional larger independent sample 
of CH subjects to confirm our preliminary association results. In particular, we are planning 
to test additional SNPs in ADCYAP1R1 to obtain an adequate higher coverage of this genetic 
region and to extend the MME mutation screening in this new larger CH cohort.   
Moreover, given the established importance of CNVs in the clinical manifestation of many 
complex disorders, we wold like to explore the role of structural variants in CH susceptibility. 
To date, no CNVs studies have been performed in CH subjects, except a very small analysis in 
10 CH subjects using comparative genomic hybridization (array-CGH)221, leaving this field 
completely unexplored. Therefore, we will exploit the SNPs genotyping data to perform a 
CNV analysis on CH sample.   
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In spite of these limitations, our study provides the first evidence that genetic variation in 
genes related to pain processing might have a role in CH susceptibility, and it acts as pilot 
study to provide preliminary insights into the genetic architecture of CH. A better 
understanding of the molecular pathways involved in the disease, could lead to better 







1. Shaik SS, Doshi D, Bandari SR, Madupu PR, Kulkarni S. Tobacco Use Cessation and Prevention 
- A Review. J Clin Diagn Res. 2016;10(5):ZE13-17. 
2. WHO. WHO global report on mortality attributable to tobacco. Geneva: World Health 
Organization. 2012. 
3. Changeux JP. Nicotine addiction and nicotinic receptors: lessons from genetically modified 
mice. Nat Rev Neurosci. 2010;11(6):389-401. 
4. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur 
J Pharmacol. 2000;393(1-3):295-314. 
5. Greenbaum L, Lerer B. Differential contribution of genetic variation in multiple brain nicotinic 
cholinergic receptors to nicotine dependence: recent progress and emerging open questions. 
Mol Psychiatry. 2009;14(10):912-945. 
6. Stolerman IP, Shoaib M. The neurobiology of tobacco addiction. Trends Pharmacol Sci. 
1991;12(12):467-473. 
7. Corrigall WA. Nicotine self-administration in animals as a dependence model. Nicotine Tob 
Res. 1999;1(1):11-20. 
8. Dani JA, Harris RA. Nicotine addiction and comorbidity with alcohol abuse and mental illness. 
Nat Neurosci. 2005;8(11):1465-1470. 
9. Baldwin PR, Alanis R, Salas R. The Role of the Habenula in Nicotine Addiction. J Addict Res 
Ther. 2011;S1(2). 
10. Corringer PJ, Le Novere N, Changeux JP. Nicotinic receptors at the amino acid level. Annu Rev 
Pharmacol Toxicol. 2000;40:431-458. 
11. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine 
receptors: from structure to function. Physiol Rev. 2009;89(1):73-120. 
12. Nashmi R, Lester HA. CNS localization of neuronal nicotinic receptors. J Mol Neurosci. 
2006;30(1-2):181-184. 
13. Laviolette SR, van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from 
molecules to behaviour. Nat Rev Neurosci. 2004;5(1):55-65. 
14. Kalamida D, Poulas K, Avramopoulou V, et al. Muscle and neuronal nicotinic acetylcholine 
receptors. Structure, function and pathogenicity. FEBS J. 2007;274(15):3799-3845. 
15. Hogg RC, Raggenbass M, Bertrand D. Nicotinic acetylcholine receptors: from structure to 
brain function. Rev Physiol Biochem Pharmacol. 2003;147:1-46. 
16. Buisson B, Bertrand D. Nicotine addiction: the possible role of functional upregulation. 
Trends Pharmacol Sci. 2002;23(3):130-136. 
17. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. Hippocampal synaptic transmission 
enhanced by low concentrations of nicotine. Nature. 1996;383(6602):713-716. 
18. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms 
of the central nervous system. Annu Rev Pharmacol Toxicol. 2007;47:699-729. 
19. Albuquerque EX, Alkondon M, Pereira EF, et al. Properties of neuronal nicotinic acetylcholine 
receptors: pharmacological characterization and modulation of synaptic function. J 
Pharmacol Exp Ther. 1997;280(3):1117-1136. 
20. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997;20(2):92-98. 
21. Sher E, Chen Y, Sharples TJ, et al. Physiological roles of neuronal nicotinic receptor subtypes: 
new insights on the nicotinic modulation of neurotransmitter release, synaptic transmission 
and plasticity. Curr Top Med Chem. 2004;4(3):283-297. 
22. Vijayaraghavan S, Pugh PC, Zhang ZW, Rathouz MM, Berg DK. Nicotinic receptors that bind 
alpha-bungarotoxin on neurons raise intracellular free Ca2+. Neuron. 1992;8(2):353-362. 
23. Rathouz MM, Berg DK. Synaptic-type acetylcholine receptors raise intracellular calcium levels 




24. Vernino S, Rogers M, Radcliffe KA, Dani JA. Quantitative measurement of calcium flux 
through muscle and neuronal nicotinic acetylcholine receptors. J Neurosci. 1994;14(9):5514-
5524. 
25. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory 
synaptic transmission in CNS by presynaptic receptors. Science. 1995;269(5231):1692-1696. 
26. Coggan JS, Paysan J, Conroy WG, Berg DK. Direct recording of nicotinic responses in 
presynaptic nerve terminals. J Neurosci. 1997;17(15):5798-5806. 
27. Radcliffe KA, Dani JA. Nicotinic stimulation produces multiple forms of increased 
glutamatergic synaptic transmission. J Neurosci. 1998;18(18):7075-7083. 
28. Fisher JL, Dani JA. Nicotinic receptors on hippocampal cultures can increase synaptic 
glutamate currents while decreasing the NMDA-receptor component. Neuropharmacology. 
2000;39(13):2756-2769. 
29. Hu M, Liu QS, Chang KT, Berg DK. Nicotinic regulation of CREB activation in hippocampal 
neurons by glutamatergic and nonglutamatergic pathways. Mol Cell Neurosci. 
2002;21(4):616-625. 
30. Ji D, Lape R, Dani JA. Timing and location of nicotinic activity enhances or depresses 
hippocampal synaptic plasticity. Neuron. 2001;31(1):131-141. 
31. Ge S, Dani JA. Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term 
depression or potentiation. J Neurosci. 2005;25(26):6084-6091. 
32. Lena C, Changeux JP, Mulle C. Evidence for "preterminal" nicotinic receptors on GABAergic 
axons in the rat interpeduncular nucleus. J Neurosci. 1993;13(6):2680-2688. 
33. Zarei MM, Radcliffe KA, Chen D, Patrick JW, Dani JA. Distributions of nicotinic acetylcholine 
receptor alpha7 and beta2 subunits on cultured hippocampal neurons. Neuroscience. 
1999;88(3):755-764. 
34. Gotti C, Clementi F, Fornari A, et al. Structural and functional diversity of native brain 
neuronal nicotinic receptors. Biochem Pharmacol. 2009;78(7):703-711. 
35. Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog 
Neurobiol. 2004;74(6):363-396. 
36. Gotti C, Riganti L, Vailati S, Clementi F. Brain neuronal nicotinic receptors as new targets for 
drug discovery. Curr Pharm Des. 2006;12(4):407-428. 
37. Govind AP, Vezina P, Green WN. Nicotine-induced upregulation of nicotinic receptors: 
underlying mechanisms and relevance to nicotine addiction. Biochem Pharmacol. 
2009;78(7):756-765. 
38. Salas R, Orr-Urtreger A, Broide RS, Beaudet A, Paylor R, De Biasi M. The nicotinic 
acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo. Mol 
Pharmacol. 2003;63(5):1059-1066. 
39. Kedmi M, Beaudet AL, Orr-Urtreger A. Mice lacking neuronal nicotinic acetylcholine receptor 
beta4-subunit and mice lacking both alpha5- and beta4-subunits are highly resistant to 
nicotine-induced seizures. Physiol Genomics. 2004;17(2):221-229. 
40. Mao D, Perry DC, Yasuda RP, Wolfe BB, Kellar KJ. The alpha4beta2alpha5 nicotinic cholinergic 
receptor in rat brain is resistant to up-regulation by nicotine in vivo. J Neurochem. 
2008;104(2):446-456. 
41. Nguyen HN, Rasmussen BA, Perry DC. Binding and functional activity of nicotinic cholinergic 
receptors in selected rat brain regions are increased following long-term but not short-term 
nicotine treatment. J Neurochem. 2004;90(1):40-49. 
42. Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW. Molecular cloning, functional 
properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable 
to calcium. J Neurosci. 1993;13(2):596-604. 
43. Levy RB, Aoki C. Alpha7 nicotinic acetylcholine receptors occur at postsynaptic densities of 





44. Li S, Li Z, Pei L, Le AD, Liu F. The alpha7nACh-NMDA receptor complex is involved in cue-
induced reinstatement of nicotine seeking. J Exp Med. 2012;209(12):2141-2147. 
45. Batra V, Patkar AA, Berrettini WH, Weinstein SP, Leone FT. The genetic determinants of 
smoking. Chest. 2003;123(5):1730-1739. 
46. Sullivan PF, Kendler KS. The genetic epidemiology of smoking. Nicotine Tob Res. 1999;1 Suppl 
2:S51-57; discussion S69-70. 
47. Broms U, Silventoinen K, Madden PA, Heath AC, Kaprio J. Genetic architecture of smoking 
behavior: a study of Finnish adult twins. Twin Res Hum Genet. 2006;9(1):64-72. 
48. Xian H, Scherrer JF, Madden PA, et al. The heritability of failed smoking cessation and 
nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob Res. 
2003;5(2):245-254. 
49. Lessov CN, Martin NG, Statham DJ, et al. Defining nicotine dependence for genetic research: 
evidence from Australian twins. Psychol Med. 2004;34(5):865-879. 
50. Yang J, Li MD. Converging findings from linkage and association analyses on susceptibility 
genes for smoking and other addictions. Mol Psychiatry. 2016;21(8):992-1008. 
51. Fagerstrom KO. Measuring degree of physical dependence to tobacco smoking with 
reference to individualization of treatment. Addict Behav. 1978;3(3-4):235-241. 
52. Rustin TA. Assessing nicotine dependence. Am Fam Physician. 2000;62(3):579-584, 591-572. 
53. Ott J, Wang J, Leal SM. Genetic linkage analysis in the age of whole-genome sequencing. Nat 
Rev Genet. 2015;16(5):275-284. 
54. Gelernter J. Genetics of complex traits in psychiatry. Biol Psychiatry. 2015;77(1):36-42. 
55. Li MD. Identifying susceptibility loci for nicotine dependence: 2008 update based on recent 
genome-wide linkage analyses. Hum Genet. 2008;123(2):119-131. 
56. Hardin J, He Y, Javitz HS, et al. Nicotine withdrawal sensitivity, linkage to chr6q26, and 
association of OPRM1 SNPs in the SMOking in FAMilies (SMOFAM) sample. Cancer Epidemiol 
Biomarkers Prev. 2009;18(12):3399-3406. 
57. Swan GE, Hops H, Wilhelmsen KC, et al. A genome-wide screen for nicotine dependence 
susceptibility loci. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(4):354-360. 
58. Han S, Gelernter J, Luo X, Yang BZ. Meta-analysis of 15 genome-wide linkage scans of 
smoking behavior. Biol Psychiatry. 2010;67(1):12-19. 
59. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 
1996;273(5281):1516-1517. 
60. Loukola A, Hallfors J, Korhonen T, Kaprio J. Genetics and smoking. Curr Addict Rep. 
2014;1(1):75-82. 
61. Saccone SF, Hinrichs AL, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in 
a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum 
Mol Genet. 2007;16(1):36-49. 
62. Gelernter J, Yu Y, Weiss R, et al. Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 
and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American 
populations. Hum Mol Genet. 2006;15(24):3498-3507. 
63. Ducci F, Kaakinen M, Pouta A, et al. TTC12-ANKK1-DRD2 and CHRNA5-CHRNA3-CHRNB4 
influence different pathways leading to smoking behavior from adolescence to mid-
adulthood. Biol Psychiatry. 2011;69(7):650-660. 
64. Ma Y, Yuan W, Jiang X, Cui WY, Li MD. Updated findings of the association and functional 
studies of DRD2/ANKK1 variants with addictions. Mol Neurobiol. 2015;51(1):281-299. 
65. Ella E, Sato N, Nishizawa D, et al. Association between dopamine beta hydroxylase rs5320 
polymorphism and smoking behaviour in elderly Japanese. J Hum Genet. 2012;57(6):385-390. 
66. Leventhal AM, Lee W, Bergen AW, et al. Nicotine dependence as a moderator of genetic 





67. Hirvonen K, Korhonen T, Salomaa V, Mannisto S, Kaprio J. Association of the DBH 
Polymorphism rs3025343 With Smoking Cessation in a Large Population-Based Sample. 
Nicotine Tob Res. 2017;19(9):1112-1115. 
68. Yu Y, Panhuysen C, Kranzler HR, et al. Intronic variants in the dopa decarboxylase (DDC) gene 
are associated with smoking behavior in European-Americans and African-Americans. Hum 
Mol Genet. 2006;15(14):2192-2199. 
69. Ma JZ, Beuten J, Payne TJ, Dupont RT, Elston RC, Li MD. Haplotype analysis indicates an 
association between the DOPA decarboxylase (DDC) gene and nicotine dependence. Hum 
Mol Genet. 2005;14(12):1691-1698. 
70. Berrettini WH, Wileyto EP, Epstein L, et al. Catechol-O-methyltransferase (COMT) gene 
variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry. 
2007;61(1):111-118. 
71. Munafo MR, Freathy RM, Ring SM, St Pourcain B, Smith GD. Association of COMT 
Val(108/158)Met genotype and cigarette smoking in pregnant women. Nicotine Tob Res. 
2011;13(2):55-63. 
72. Tobacco, Genetics C. Genome-wide meta-analyses identify multiple loci associated with 
smoking behavior. Nat Genet. 2010;42(5):441-447. 
73. Stapleton JA, Sutherland G, O'Gara C. Association between dopamine transporter genotypes 
and smoking cessation: a meta-analysis. Addict Biol. 2007;12(2):221-226. 
74. Duck CH, Gyoon SW. Meta-analysis update of association between dopamine transporter 
SLC6A3 gene polymorphism and smoking cessation. J Health Psychol. 
2016:1359105316648479. 
75. Verhagen M, Kleinjan M, Engels RC. A systematic review of the A118G (Asn40Asp) variant of 
OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation. 
Pharmacogenomics. 2012;13(8):917-933. 
76. Beuten J, Ma JZ, Payne TJ, et al. Single- and multilocus allelic variants within the GABA(B) 
receptor subunit 2 (GABAB2) gene are significantly associated with nicotine dependence. Am 
J Hum Genet. 2005;76(5):859-864. 
77. Li MD, Mangold JE, Seneviratne C, et al. Association and interaction analyses of GABBR1 and 
GABBR2 with nicotine dependence in European- and African-American populations. PLoS 
One. 2009;4(9):e7055. 
78. Beuten J, Ma JZ, Payne TJ, et al. Association of specific haplotypes of neurotrophic tyrosine 
kinase receptor 2 gene (NTRK2) with vulnerability to nicotine dependence in African-
Americans and European-Americans. Biol Psychiatry. 2007;61(1):48-55. 
79. Li MD, Sun D, Lou XY, Beuten J, Payne TJ, Ma JZ. Linkage and association studies in African- 
and Caucasian-American populations demonstrate that SHC3 is a novel susceptibility locus 
for nicotine dependence. Mol Psychiatry. 2007;12(5):462-473. 
80. Lou XY, Ma JZ, Sun D, Payne TJ, Li MD. Fine mapping of a linkage region on chromosome 
17p13 reveals that GABARAP and DLG4 are associated with vulnerability to nicotine 
dependence in European-Americans. Hum Mol Genet. 2007;16(2):142-153. 
81. Agrawal A, Pergadia ML, Saccone SF, et al. Gamma-aminobutyric acid receptor genes and 
nicotine dependence: evidence for association from a case-control study. Addiction. 
2008;103(6):1027-1038. 
82. Agrawal A, Pergadia ML, Balasubramanian S, et al. Further evidence for an association 
between the gamma-aminobutyric acid receptor A, subunit 4 genes on chromosome 4 and 
Fagerstrom Test for Nicotine Dependence. Addiction. 2009;104(3):471-477. 
83. Iordanidou M, Tavridou A, Petridis I, et al. Association of polymorphisms of the serotonergic 
system with smoking initiation in Caucasians. Drug Alcohol Depend. 2010;108(1-2):70-76. 
84. Kremer I, Bachner-Melman R, Reshef A, et al. Association of the serotonin transporter gene 




85. Daw J, Boardman JD, Peterson R, et al. The interactive effect of neighborhood peer cigarette 
use and 5HTTLPR genotype on individual cigarette use. Addict Behav. 2014;39(12):1804-
1810. 
86. Bidwell LC, Garrett ME, McClernon FJ, et al. A preliminary analysis of interactions between 
genotype, retrospective ADHD symptoms, and initial reactions to smoking in a sample of 
young adults. Nicotine Tob Res. 2012;14(2):229-233. 
87. Yang Z, Seneviratne C, Wang S, et al. Serotonin transporter and receptor genes significantly 
impact nicotine dependence through genetic interactions in both European American and 
African American smokers. Drug Alcohol Depend. 2013;129(3):217-225. 
88. Ma JZ, Payne TJ, Nussbaum J, Li MD. Significant association of glutamate receptor, ionotropic 
N-methyl-D-aspartate 3A (GRIN3A), with nicotine dependence in European- and African-
American smokers. Hum Genet. 2010;127(5):503-512. 
89. Grucza RA, Johnson EO, Krueger RF, et al. Incorporating age at onset of smoking into genetic 
models for nicotine dependence: evidence for interaction with multiple genes. Addict Biol. 
2010;15(3):346-357. 
90. Vink JM, Smit AB, de Geus EJ, et al. Genome-wide association study of smoking initiation and 
current smoking. Am J Hum Genet. 2009;84(3):367-379. 
91. Nussbaum J, Xu Q, Payne TJ, et al. Significant association of the neurexin-1 gene (NRXN1) 
with nicotine dependence in European- and African-American smokers. Hum Mol Genet. 
2008;17(11):1569-1577. 
92. Sato N, Kageyama S, Chen R, et al. Association between neurexin 1 (NRXN1) polymorphisms 
and the smoking behavior of elderly Japanese. Psychiatr Genet. 2010;20(3):135-136. 
93. Docampo E, Ribases M, Gratacos M, et al. Association of neurexin 3 polymorphisms with 
smoking behavior. Genes Brain Behav. 2012;11(6):704-711. 
94. Portugal GS, Gould TJ. Genetic variability in nicotinic acetylcholine receptors and nicotine 
addiction: converging evidence from human and animal research. Behav Brain Res. 
2008;193(1):1-16. 
95. Weiss RB, Baker TB, Cannon DS, et al. A candidate gene approach identifies the CHRNA5-A3-
B4 region as a risk factor for age-dependent nicotine addiction. PLoS Genet. 
2008;4(7):e1000125. 
96. Wessel J, McDonald SM, Hinds DA, et al. Resequencing of nicotinic acetylcholine receptor 
genes and association of common and rare variants with the Fagerstrom test for nicotine 
dependence. Neuropsychopharmacology. 2010;35(12):2392-2402. 
97. Thorgeirsson TE, Gudbjartsson DF, Surakka I, et al. Sequence variants at CHRNB3-CHRNA6 
and CYP2A6 affect smoking behavior. Nat Genet. 2010;42(5):448-453. 
98. Bierut LJ. Genetic vulnerability and susceptibility to substance dependence. Neuron. 
2011;69(4):618-627. 
99. Lou XY, Ma JZ, Payne TJ, Beuten J, Crew KM, Li MD. Gene-based analysis suggests association 
of the nicotinic acetylcholine receptor beta1 subunit (CHRNB1) and M1 muscarinic 
acetylcholine receptor (CHRM1) with vulnerability for nicotine dependence. Hum Genet. 
2006;120(3):381-389. 
100. Ehringer MA, Clegg HV, Collins AC, et al. Association of the neuronal nicotinic receptor beta2 
subunit gene (CHRNB2) with subjective responses to alcohol and nicotine. Am J Med Genet B 
Neuropsychiatr Genet. 2007;144B(5):596-604. 
101. Wang S, A DvdV, Xu Q, et al. Significant associations of CHRNA2 and CHRNA6 with nicotine 
dependence in European American and African American populations. Hum Genet. 
2014;133(5):575-586. 
102. Bergen AW, Javitz HS, Krasnow R, et al. Nicotinic acetylcholine receptor variation and 
response to smoking cessation therapies. Pharmacogenet Genomics. 2013;23(2):94-103. 
103. King DP, Paciga S, Pickering E, et al. Smoking cessation pharmacogenetics: analysis of 





104. Chen LS, Baker TB, Piper ME, et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-
CHRNB4) and cessation treatments in smoking cessation success. Am J Psychiatry. 
2012;169(7):735-742. 
105. Chen LS, Baker TB, Jorenby D, et al. Genetic variation (CHRNA5), medication (combination 
nicotine replacement therapy vs. varenicline), and smoking cessation. Drug Alcohol Depend. 
2015;154:278-282. 
106. Chen LS, Baker TB, Grucza R, et al. Dissection of the phenotypic and genotypic associations 
with nicotinic dependence. Nicotine Tob Res. 2012;14(4):425-433. 
107. Carter B, Long T, Cinciripini P. A meta-analytic review of the CYP2A6 genotype and smoking 
behavior. Nicotine Tob Res. 2004;6(2):221-227. 
108. Chen LS, Bloom AJ, Baker TB, et al. Pharmacotherapy effects on smoking cessation vary with 
nicotine metabolism gene (CYP2A6). Addiction. 2014;109(1):128-137. 
109. Johnson GC, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common 
disease genes. Nat Genet. 2001;29(2):233-237. 
110. Carlson CS, Eberle MA, Rieder MJ, Smith JD, Kruglyak L, Nickerson DA. Additional SNPs and 
linkage-disequilibrium analyses are necessary for whole-genome association studies in 
humans. Nat Genet. 2003;33(4):518-521. 
111. Goldstein DB, Ahmadi KR, Weale ME, Wood NW. Genome scans and candidate gene 
approaches in the study of common diseases and variable drug responses. Trends Genet. 
2003;19(11):615-622. 
112. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med. 
1996;47:387-400. 
113. Fijnheer R, Horbach DA, Donders RC, et al. Factor V Leiden, antiphospholipid antibodies and 
thrombosis in systemic lupus erythematosus. Thromb Haemost. 1996;76(4):514-517. 
114. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. 
Nature. 2009;461(7265):747-753. 
115. Bierut LJ, Madden PA, Breslau N, et al. Novel genes identified in a high-density genome wide 
association study for nicotine dependence. Hum Mol Genet. 2007;16(1):24-35. 
116. Berrettini W, Yuan X, Tozzi F, et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase 
risk for heavy smoking. Mol Psychiatry. 2008;13(4):368-373. 
117. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung 
cancer and peripheral arterial disease. Nature. 2008;452(7187):638-642. 
118. Liu JZ, Tozzi F, Waterworth DM, et al. Meta-analysis and imputation refines the association of 
15q25 with smoking quantity. Nat Genet. 2010;42(5):436-440. 
119. Wang JC, Cruchaga C, Saccone NL, et al. Risk for nicotine dependence and lung cancer is 
conferred by mRNA expression levels and amino acid change in CHRNA5. Hum Mol Genet. 
2009;18(16):3125-3135. 
120. Wang JC, Grucza R, Cruchaga C, et al. Genetic variation in the CHRNA5 gene affects mRNA 
levels and is associated with risk for alcohol dependence. Mol Psychiatry. 2009;14(5):501-
510. 
121. Wang JC, Kapoor M, Goate AM. The genetics of substance dependence. Annu Rev Genomics 
Hum Genet. 2012;13:241-261. 
122. Rice JP, Hartz SM, Agrawal A, et al. CHRNB3 is more strongly associated with Fagerstrom test 
for cigarette dependence-based nicotine dependence than cigarettes per day: phenotype 
definition changes genome-wide association studies results. Addiction. 2012;107(11):2019-
2028. 
123. Loukola A, Buchwald J, Gupta R, et al. A Genome-Wide Association Study of a Biomarker of 
Nicotine Metabolism. PLoS Genet. 2015;11(9):e1005498. 
124. Johnstone E, Benowitz N, Cargill A, et al. Determinants of the rate of nicotine metabolism 
and effects on smoking behavior. Clin Pharmacol Ther. 2006;80(4):319-330. 





126. Olfson E, Saccone NL, Johnson EO, et al. Rare, low frequency and common coding variants in 
CHRNA5 and their contribution to nicotine dependence in European and African Americans. 
Mol Psychiatry. 2016;21(5):601-607. 
127. Xie P, Kranzler HR, Krauthammer M, et al. Rare nonsynonymous variants in alpha-4 nicotinic 
acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry. 
2011;70(6):528-536. 
128. Haller G, Druley T, Vallania FL, et al. Rare missense variants in CHRNB4 are associated with 
reduced risk of nicotine dependence. Hum Mol Genet. 2012;21(3):647-655. 
129. Slimak MA, Ables JL, Frahm S, et al. Habenular expression of rare missense variants of the 
beta4 nicotinic receptor subunit alters nicotine consumption. Front Hum Neurosci. 
2014;8:12. 
130. Yang J, Wang S, Yang Z, et al. The contribution of rare and common variants in 30 genes to 
risk nicotine dependence. Mol Psychiatry. 2015;20(11):1467-1478. 
131. Gillentine MA, Schaaf CP. The human clinical phenotypes of altered CHRNA7 copy number. 
Biochem Pharmacol. 2015;97(4):352-362. 
132. Lowther C, Costain G, Stavropoulos DJ, et al. Delineating the 15q13.3 microdeletion 
phenotype: a case series and comprehensive review of the literature. Genet Med. 
2015;17(2):149-157. 
133. Shinawi M, Schaaf CP, Bhatt SS, et al. A small recurrent deletion within 15q13.3 is associated 
with a range of neurodevelopmental phenotypes. Nat Genet. 2009;41(12):1269-1271. 
134. Mikhail FM, Lose EJ, Robin NH, et al. Clinically relevant single gene or intragenic deletions 
encompassing critical neurodevelopmental genes in patients with developmental delay, 
mental retardation, and/or autism spectrum disorders. Am J Med Genet A. 
2011;155A(10):2386-2396. 
135. Hoppman-Chaney N, Wain K, Seger PR, Superneau DW, Hodge JC. Identification of single 
gene deletions at 15q13.3: further evidence that CHRNA7 causes the 15q13.3 microdeletion 
syndrome phenotype. Clin Genet. 2013;83(4):345-351. 
136. Masurel-Paulet A, Andrieux J, Callier P, et al. Delineation of 15q13.3 microdeletions. Clin 
Genet. 2010;78(2):149-161. 
137. Helbig I, Mefford HC, Sharp AJ, et al. 15q13.3 microdeletions increase risk of idiopathic 
generalized epilepsy. Nat Genet. 2009;41(2):160-162. 
138. Gault J, Robinson M, Berger R, et al. Genomic organization and partial duplication of the 
human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics. 
1998;52(2):173-185. 
139. Sinkus ML, Graw S, Freedman R, Ross RG, Lester HA, Leonard S. The human CHRNA7 and 
CHRFAM7A genes: A review of the genetics, regulation, and function. Neuropharmacology. 
2015;96(Pt B):274-288. 
140. Araud T, Graw S, Berger R, et al. The chimeric gene CHRFAM7A, a partial duplication of the 
CHRNA7 gene, is a dominant negative regulator of alpha7*nAChR function. Biochem 
Pharmacol. 2011;82(8):904-914. 
141. de Lucas-Cerrillo AM, Maldifassi MC, Arnalich F, et al. Function of partially duplicated human 
alpha77 nicotinic receptor subunit CHRFAM7A gene: potential implications for the 
cholinergic anti-inflammatory response. J Biol Chem. 2011;286(1):594-606. 
142. Sinkus ML, Lee MJ, Gault J, et al. A 2-base pair deletion polymorphism in the partial 
duplication of the alpha7 nicotinic acetylcholine gene (CHRFAM7A) on chromosome 15q14 is 
associated with schizophrenia. Brain Res. 2009;1291:1-11. 
143. Flomen RH, Shaikh M, Walshe M, et al. Association between the 2-bp deletion polymorphism 
in the duplicated version of the alpha7 nicotinic receptor gene and P50 sensory gating. Eur J 
Hum Genet. 2013;21(1):76-81. 
144. Gjini K, Burroughs S, Boutros NN. Relevance of attention in auditory sensory gating 




145. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD. Neurophysiological evidence for a 
defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free 
patients. Biol Psychiatry. 1983;18(5):537-551. 
146. Raux G, Bonnet-Brilhault F, Louchart S, et al. The -2 bp deletion in exon 6 of the 'alpha 7-like' 
nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit. Mol 
Psychiatry. 2002;7(9):1006-1011. 
147. Rozycka A, Dorszewska J, Steinborn B, et al. Association study of the 2-bp deletion 
polymorphism in exon 6 of the CHRFAM7A gene with idiopathic generalized epilepsy. DNA 
Cell Biol. 2013;32(11):640-647. 
148. Flomen RH, Collier DA, Osborne S, et al. Association study of CHRFAM7A copy number and 2 
bp deletion polymorphisms with schizophrenia and bipolar affective disorder. Am J Med 
Genet B Neuropsychiatr Genet. 2006;141B(6):571-575. 
149. Kunii Y, Zhang W, Xu Q, et al. CHRNA7 and CHRFAM7A mRNAs: co-localized and their 
expression levels altered in the postmortem dorsolateral prefrontal cortex in major 
psychiatric disorders. Am J Psychiatry. 2015;172(11):1122-1130. 
150. Leonard S, Gault J, Hopkins J, et al. Association of promoter variants in the alpha7 nicotinic 
acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch 
Gen Psychiatry. 2002;59(12):1085-1096. 
151. Bertelsen B, Oranje B, Melchior L, et al. Association Study of CHRNA7 Promoter Variants with 
Sensory and Sensorimotor Gating in Schizophrenia Patients and Healthy Controls: A Danish 
Case-Control Study. Neuromolecular Med. 2015;17(4):423-430. 
152. Stephens SH, Logel J, Barton A, et al. Association of the 5'-upstream regulatory region of the 
alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. Schizophr 
Res. 2009;109(1-3):102-112. 
153. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased 
numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 1995;38(1):22-
33. 
154. Guillozet-Bongaarts AL, Hyde TM, Dalley RA, et al. Altered gene expression in the dorsolateral 
prefrontal cortex of individuals with schizophrenia. Mol Psychiatry. 2014;19(4):478-485. 
155. Marutle A, Zhang X, Court J, et al. Laminar distribution of nicotinic receptor subtypes in 
cortical regions in schizophrenia. J Chem Neuroanat. 2001;22(1-2):115-126. 
156. Court J, Spurden D, Lloyd S, et al. Neuronal nicotinic receptors in dementia with Lewy bodies 
and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem. 
1999;73(4):1590-1597. 
157. Mexal S, Berger R, Logel J, Ross RG, Freedman R, Leonard S. Differential regulation of alpha7 
nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J Mol Neurosci. 
2010;40(1-2):185-195. 
158. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association 
between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2-3):135-
157. 
159. De Luca V, Wong AH, Muller DJ, Wong GW, Tyndale RF, Kennedy JL. Evidence of association 
between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. 
Neuropsychopharmacology. 2004;29(8):1522-1526. 
160. Zammit S, Spurlock G, Williams H, et al. Genotype effects of CHRNA7, CNR1 and COMT in 
schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry. 2007;191:402-
407. 
161. Brunzell DH, McIntosh JM. Alpha7 nicotinic acetylcholine receptors modulate motivation to 
self-administer nicotine: implications for smoking and schizophrenia. 
Neuropsychopharmacology. 2012;37(5):1134-1143. 
162. Harenza JL, Muldoon PP, De Biasi M, Damaj MI, Miles MF. Genetic variation within the 





163. Brunzell DH, McIntosh JM, Papke RL. Diverse strategies targeting alpha7 homomeric and 
alpha6beta2* heteromeric nicotinic acetylcholine receptors for smoking cessation. Ann N Y 
Acad Sci. 2014;1327:27-45. 
164. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full 
agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006;70(3):801-805. 
165. Smith RC, Lindenmayer JP, Davis JM, et al. Cognitive and antismoking effects of varenicline in 
patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2009;110(1-3):149-
155. 
166. Hong LE, Thaker GK, McMahon RP, et al. Effects of moderate-dose treatment with 
varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with 
schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 2011;68(12):1195-1206. 
167. Siu AL, Force USPST. Behavioral and Pharmacotherapy Interventions for Tobacco Smoking 
Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force 
Recommendation Statement. Ann Intern Med. 2015;163(8):622-634. 
168. Parrott S, Godfrey C, Raw M, West R, McNeill A. Guidance for commissioners on the cost 
effectiveness of smoking cessation interventions. Health Educational Authority. Thorax. 
1998;53 Suppl 5 Pt 2:S1-38. 
169. West R. The clinical significance of "small" effects of smoking cessation treatments. 
Addiction. 2007;102(4):506-509. 
170. Michie S, Hyder N, Walia A, West R. Development of a taxonomy of behaviour change 
techniques used in individual behavioural support for smoking cessation. Addict Behav. 
2011;36(4):315-319. 
171. Rabius V, Pike KJ, Hunter J, Wiatrek D, McAlister AL. Effects of frequency and duration in 
telephone counselling for smoking cessation. Tob Control. 2007;16 Suppl 1:i71-74. 
172. Clinical Practice Guideline Treating Tobacco U, Dependence Update Panel L, Staff. A clinical 
practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public 
Health Service report. Am J Prev Med. 2008;35(2):158-176. 
173. Patnode CD, Henderson JT, Thompson JH, Senger CA, Fortmann SP, Whitlock EP. Behavioral 
Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including 
Pregnant Women: A Review of Reviews for the U.S. Preventive Services Task Force. Ann 
Intern Med. 2015;163(8):608-621. 
174. Casella G, Caponnetto P, Polosa R. Therapeutic advances in the treatment of nicotine 
addiction: present and future. Ther Adv Chronic Dis. 2010;1(3):95-106. 
175. Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM. Advances in pharmacotherapy for 
tobacco dependence. Expert Opin Emerg Drugs. 2004;9(1):39-53. 
176. Benowitz NL. Nicotine replacement therapy. What has been accomplished--can we do 
better? Drugs. 1993;45(2):157-170. 
177. Benowitz NL, Porchet H, Sheiner L, Jacob P, 3rd. Nicotine absorption and cardiovascular 
effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin 
Pharmacol Ther. 1988;44(1):23-28. 
178. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. 
Cochrane Database Syst Rev. 2012;11:CD000146. 
179. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and 
reverses the affective and somatic aspects of nicotine withdrawal in the rat. 
Psychopharmacology (Berl). 2003;168(3):347-358. 
180. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 
2000;295(1):321-327. 
181. John R. Hughes JKSN. Shape of the relapse curve and long-term abstinence among untreated 
smokers. Society for the Study of Addiction.99:29-38. 
182. Haddad A, Davis AM. Tobacco Smoking Cessation in Adults and Pregnant Women: Behavioral 




183. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the alpha4beta2 nicotinic 
acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. 
Neuropharmacology. 2007;52(3):985-994. 
184. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial 
agonist for smoking cessation. J Med Chem. 2005;48(10):3474-3477. 
185. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine 
receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a 
randomized controlled trial. JAMA. 2006;296(1):47-55. 
186. Jorenby D.E. HJT, Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., et al. Efficacy of 
varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-
release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–
63. 
187. Administration USFaD. FDA Approves Novel Medication for Smoking Cessation. 2006. 
188. Russell MB. Epidemiology and genetics of cluster headache. Lancet Neurol. 2004;3(5):279-
283. 
189. Headache Classification Committee of the International Headache S. The International 
Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629-
808. 
190. Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic 
implications. Neurology. 2002;58(3):354-361. 
191. Goadsby PJ, Cittadini E, Burns B, Cohen AS. Trigeminal autonomic cephalalgias: diagnostic 
and therapeutic developments. Curr Opin Neurol. 2008;21(3):323-330. 
192. Torelli P, Manzoni GC. Behavior during cluster headache. Curr Pain Headache Rep. 
2005;9(2):113-119. 
193. Ekbom K. Nitrolglycerin as a provocative agent in cluster headache. Arch Neurol. 
1968;19(5):487-493. 
194. Dodick DW, Rozen TD, Goadsby PJ, Silberstein SD. Cluster headache. Cephalalgia. 
2000;20(9):787-803. 
195. Costa F AF, Ramusino MC, Nappi G. The Neuropharmacology of Cluster Headache and other 
Trigeminal Autonomic Cephalalgias. Current Neuropharmacology. 2015;13:304-323. 
196. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster 
headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117 ( Pt 
3):427-434. 
197. Sjostrand C. Genetic aspects of cluster headache. Expert Rev Neurother. 2009;9(3):359-368. 
198. Tfelt-Hansen P, Le H. Calcitonin gene-related peptide in blood: is it increased in the external 
jugular vein during migraine and cluster headache? A review. J Headache Pain. 
2009;10(3):137-143. 
199. Buture A, Gooriah R, Nimeri R, Ahmed F. Current Understanding on Pain Mechanism in 
Migraine and Cluster Headache. Anesth Pain Med. 2016;6(3):e35190. 
200. Hayes DJ, Northoff G. Common brain activations for painful and non-painful aversive stimuli. 
BMC Neurosci. 2012;13:60. 
201. Olesen J, Thomsen LL, Iversen H. Nitric oxide is a key molecule in migraine and other vascular 
headaches. Trends Pharmacol Sci. 1994;15(5):149-153. 
202. D'Amico D, Leone M, Ferraris A, et al. Role of nitric oxide in cluster headache. Ital J Neurol 
Sci. 1999;20(2 Suppl):S25-27. 
203. Luo ZD, Cizkova D. The role of nitric oxide in nociception. Curr Rev Pain. 2000;4(6):459-466. 
204. Meller ST, Gebhart GF. Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain. 
1993;52(2):127-136. 
205. Tassorelli C, Greco R, Wang D, Sandrini M, Sandrini G, Nappi G. Nitroglycerin induces 




206. Strosznajder J, Chalimoniuk M, Samochocki M. Activation of serotonergic 5-HT1A receptor 
reduces Ca(2+)- and glutamatergic receptor-evoked arachidonic acid and No/cGMP release in 
adult hippocampus. Neurochem Int. 1996;28(4):439-444. 
207. Strecker T, Dux M, Messlinger K. Nitric oxide releases calcitonin-gene-related peptide from 
rat dura mater encephali promoting increases in meningeal blood flow. J Vasc Res. 
2002;39(6):489-496. 
208. Schwenger N, Dux M, de Col R, Carr R, Messlinger K. Interaction of calcitonin gene-related 
peptide, nitric oxide and histamine release in neurogenic blood flow and afferent activation 
in the rat cranial dura mater. Cephalalgia. 2007;27(6):481-491. 
209. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336(3):186-195. 
210. May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ. Hypothalamic activation in cluster 
headache attacks. Lancet. 1998;352(9124):275-278. 
211. Morelli N, Pesaresi I, Cafforio G, et al. Functional magnetic resonance imaging in episodic 
cluster headache. J Headache Pain. 2009;10(1):11-14. 
212. Holland P, Goadsby PJ. The hypothalamic orexinergic system: pain and primary headaches. 
Headache. 2007;47(6):951-962. 
213. Russell MB, Andersson PG, Thomsen LL. Familial occurrence of cluster headache. J Neurol 
Neurosurg Psychiatry. 1995;58(3):341-343. 
214. Rainero I, Rubino E, Paemeleire K, et al. Genes and primary headaches: discovering new 
potential therapeutic targets. J Headache Pain. 2013;14:61. 
215. Aridon P, D'Andrea G, Rigamonti A, Leone M, Casari G, Bussone G. Elusive amines and cluster 
headache: mutational analysis of trace amine receptor cluster on chromosome 6q23. Neurol 
Sci. 2004;25 Suppl 3:S279-280. 
216. D’Andrea G TS, Leon A, Fortin D, Perini F, Granella F, Bussone G. Elevated levels of circulating 
trace amines in primary headaches. Neurology. 2004;62(10):1701-1705. 
217. Baumber L, Sjostrand C, Leone M, et al. A genome-wide scan and HCRTR2 candidate gene 
analysis in a European cluster headache cohort. Neurology. 2006;66(12):1888-1893. 
218. Rainero I, Gallone S, Valfre W, et al. A polymorphism of the hypocretin receptor 2 gene is 
associated with cluster headache. Neurology. 2004;63(7):1286-1288. 
219. Sutcliffe JG, de Lecea L. The hypocretins: excitatory neuromodulatory peptides for multiple 
homeostatic systems, including sleep and feeding. J Neurosci Res. 2000;62(2):161-168. 
220. Schurks M, Kurth T, Geissler I, Tessmann G, Diener HC, Rosskopf D. Cluster headache is 
associated with the G1246A polymorphism in the hypocretin receptor 2 gene. Neurology. 
2006;66(12):1917-1919. 
221. Zarrilli F, Tomaiuolo R, Ceglia C, et al. Molecular analysis of cluster headache. Clin J Pain. 
2015;31(1):52-57. 
222. Weller CM, Wilbrink LA, Houwing-Duistermaat JJ, et al. Cluster headache and the hypocretin 
receptor 2 reconsidered: a genetic association study and meta-analysis. Cephalalgia. 
2015;35(9):741-747. 
223. Fourier C, Ran C, Steinberg A, Sjostrand C, Waldenlind E, Carmine Belin A. Screening of Two 
ADH4 Variations in a Swedish Cluster Headache Case-Control Material. Headache. 2016. 
224. Cevoli S, Mochi M, Pierangeli G, et al. Investigation of the T3111C CLOCK gene polymorphism 
in cluster headache. J Neurol. 2008;255(2):299-300. 
225. Zhang EE, Kay SA. Clocks not winding down: unravelling circadian networks. Nat Rev Mol Cell 
Biol. 2010;11(11):764-776. 
226. Ofte HK, Tronvik E, Alstadhaug KB. Lack of association between cluster headache and PER3 
clock gene polymorphism. J Headache Pain. 2015;17:18. 
227. Gupta S, Nahas SJ, Peterlin BL. Chemical mediators of migraine: preclinical and clinical 
observations. Headache. 2011;51(6):1029-1045. 





229. Sjostrand C, Modin H, Masterman T, Ekbom K, Waldenlind E, Hillert J. Analysis of nitric oxide 
synthase genes in cluster headache. Cephalalgia. 2002;22(9):758-764. 
230. Sjostrand C, Giedratis V, Ekbom K, Waldenlind E, Hillert J. CACNA1A gene polymorphisms in 
cluster headache. Cephalalgia. 2001;21(10):953-958. 
231. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic 
ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 
1996;87(3):543-552. 
232. Tietjen GE. Migraine as a systemic vasculopathy. Cephalalgia. 2009;29(9):987-996. 
233. Rubino E, Ferrero M, Rainero I, Binello E, Vaula G, Pinessi L. Association of the C677T 
polymorphism in the MTHFR gene with migraine: a meta-analysis. Cephalalgia. 
2009;29(8):818-825. 
234. Schurks M, Rist PM, Kurth T. MTHFR 677C>T and ACE D/I polymorphisms in migraine: a 
systematic review and meta-analysis. Headache. 2010;50(4):588-599. 
235. Schurks M, Neumann FA, Kessler C, et al. MTHFR 677C>T polymorphism and cluster 
headache. Headache. 2011;51(2):201-207. 
236. Summ O, Gregor N, Marziniak M, Gralow I, Husstedt IW, Evers S. Cluster headache and Alpha 
1-antitrypsin deficiency. Cephalalgia. 2010;30(1):113-117. 
237. Rainero I, Rivoiro C, Rubino E, et al. Prevalence of HFE (hemochromatosis) gene mutations in 
patients with cluster headache. Headache. 2005;45(9):1219-1223. 
238. Hagen K, Stovner LJ, Asberg A, Thorstensen K, Bjerve KS, Hveem K. High headache prevalence 
among women with hemochromatosis: the Nord-Trondelag health study. Ann Neurol. 
2002;51(6):786-789. 
239. Schurks M. Genetics of cluster headache. Curr Pain Headache Rep. 2010;14(2):132-139. 
240. Schurks M, Diener HC. Cluster headache and lifestyle habits. Curr Pain Headache Rep. 
2008;12(2):115-121. 
241. Rozen TD. Cluster headache as the result of secondhand cigarette smoke exposure during 
childhood. Headache. 2010;50(1):130-132. 
242. Thorgeirsson TE, Steinberg S, Reginsson GW, et al. A rare missense mutation in CHRNA4 
associates with smoking behavior and its consequences. Mol Psychiatry. 2016;21(5):594-600. 
243. Hancock DB, Reginsson GW, Gaddis NC, et al. Genome-wide meta-analysis reveals common 
splice site acceptor variant in CHRNA4 associated with nicotine dependence. Transl 
Psychiatry. 2015;5:e651. 
244. Bekkelund SI, Ofte HK, Alstadhaug KB. Patient satisfaction with conventional, 
complementary, and alternative treatment for cluster headache in a Norwegian cohort. 
Scand J Prim Health Care. 2014;32(3):111-116. 
245. Schurks M, Kurth T, Stude P, et al. G protein beta3 polymorphism and triptan response in 
cluster headache. Clin Pharmacol Ther. 2007;82(4):396-401. 
246. Helyes Z, Pinter E, Nemeth J, et al. Anti-inflammatory effect of synthetic somatostatin 
analogues in the rat. Br J Pharmacol. 2001;134(7):1571-1579. 
247. Matharu MS, Levy MJ, Meeran K, Goadsby PJ. Subcutaneous octreotide in cluster headache: 
randomized placebo-controlled double-blind crossover study. Ann Neurol. 2004;56(4):488-
494. 
248. Kittrelle JP, Grouse DS, Seybold ME. Cluster headache. Local anesthetic abortive agents. Arch 
Neurol. 1985;42(5):496-498. 
249. Robbins L. Intranasal lidocaine for cluster headache. Headache. 1995;35(2):83-84. 
250. Fogan L. Treatment of cluster headache. A double-blind comparison of oxygen v air 
inhalation. Arch Neurol. 1985;42(4):362-363. 
251. Andersson PG, Jespersen LT. Dihydroergotamine nasal spray in the treatment of attacks of 
cluster headache. A double-blind trial versus placebo. Cephalalgia. 1986;6(1):51-54. 





253. Ito Y, Mitsufuji T, Asano Y, et al. Naratriptan in the Prophylactic Treatment of Cluster 
Headache. Intern Med. 2017;56(19):2579-2582. 
254. Eekers PJ, Koehler PJ. Naratriptan prophylactic treatment in cluster headache. Cephalalgia. 
2001;21(1):75-76. 
255. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a 
diagnostic interview for caregivers of individuals with possible pervasive developmental 
disorders. J Autism Dev Disord. 1994;24(5):659-685. 
256. Lord C, Risi S, Lambrecht L, et al. The autism diagnostic observation schedule-generic: a 
standard measure of social and communication deficits associated with the spectrum of 
autism. J Autism Dev Disord. 2000;30(3):205-223. 
257. Kit IP-. Psychiatric predisposition microarray. 
http://wwwilluminacom/products/psycharrayhtml. 2016. 
258. Peiffer DA, Le JM, Steemers FJ, et al. High-resolution genomic profiling of chromosomal 
aberrations using Infinium whole-genome genotyping. Genome Res. 2006;16(9):1136-1148. 
259. Wang K, Li M, Hadley D, et al. PennCNV: an integrated hidden Markov model designed for 
high-resolution copy number variation detection in whole-genome SNP genotyping data. 
Genome Res. 2007;17(11):1665-1674. 
260. Colella S, Yau C, Taylor JM, et al. QuantiSNP: an Objective Bayes Hidden-Markov Model to 
detect and accurately map copy number variation using SNP genotyping data. Nucleic Acids 
Res. 2007;35(6):2013-2025. 
261. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408. 
262. Korbie DJ, Mattick JS. Touchdown PCR for increased specificity and sensitivity in PCR 
amplification. Nat Protoc. 2008;3(9):1452-1456. 
263. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising 
to the challenge of larger and richer datasets. Gigascience. 2015;4:7. 
264. Ionita-Laza I LS, Makarov V, Buxbaum JD, Lin X. Sequence kernel association tests for the 
combined effect of rare and common variants. Am J Hum Genet. 2013;92:841-853. 
265. Guo Y, He J, Zhao S, et al. Illumina human exome genotyping array clustering and quality 
control. Nat Protoc. 2014;9(11):2643-2662. 
266. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and 
population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-575. 
267. Buchmann R HS. Creating Structure Plots - Genesis Manual 0.1. 
http://wwwbioinfwitsacza/software/genesis. 2016. 
268. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide 
association scan results. Bioinformatics. 2010;26(18):2336-2337. 
269. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense 
mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;Chapter 7:Unit7 20. 
270. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for 
estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310-
315. 
271. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 
schizophrenia-associated genetic loci. Nature. 2014;511(7510):421-427. 
272. Gormley P, Anttila V, Winsvold BS, et al. Meta-analysis of 375,000 individuals identifies 38 
susceptibility loci for migraine. Nat Genet. 2016;48(8):856-866. 
273. Hughes JR KJ, Naud S. Shape of the relapse curve and long-term abstinence among untreated 
smokers. Addiction. 2004;99:29-38. 
274. Rigotti NA. Strategies to help a smoker who is struggling to quit. JAMA. 2012;308(15):1573-
1580. 
275. Picciotto MR, Kenny PJ. Molecular mechanisms underlying behaviors related to nicotine 




276. Gotti C, Guiducci S, Tedesco V, et al. Nicotinic acetylcholine receptors in the mesolimbic 
pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating 
systemic nicotine effects on dopamine release, locomotion, and reinforcement. J Neurosci. 
2010;30(15):5311-5325. 
277. Olofsson PS, Katz DA, Rosas-Ballina M, et al. alpha7 nicotinic acetylcholine receptor 
(alpha7nAChR) expression in bone marrow-derived non-T cells is required for the 
inflammatory reflex. Mol Med. 2012;18:539-543. 
278. Cedillo JL, Arnalich F, Martin-Sanchez C, et al. Usefulness of alpha7 nicotinic receptor 
messenger RNA levels in peripheral blood mononuclear cells as a marker for cholinergic 
antiinflammatory pathway activity in septic patients: results of a pilot study. J Infect Dis. 
2015;211(1):146-155. 
279. Martin-Ruiz CM, Haroutunian VH, Long P, et al. Dementia rating and nicotinic receptor 
expression in the prefrontal cortex in schizophrenia. Biol Psychiatry. 2003;54(11):1222-1233. 
280. Young JW, Geyer MA. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in 
the pathophysiology and treatment of schizophrenia. Biochem Pharmacol. 2013;86(8):1122-
1132. 
281. Kirov G, Rees E, Walters JT, et al. The penetrance of copy number variations for 
schizophrenia and developmental delay. Biol Psychiatry. 2014;75(5):378-385. 
282. Cross-Disorder Group of the Psychiatric Genomics C, Lee SH, Ripke S, et al. Genetic 
relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat 
Genet. 2013;45(9):984-994. 
283. Wang Y, Xiao C, Indersmitten T, Freedman R, Leonard S, Lester HA. The duplicated alpha7 
subunits assemble and form functional nicotinic receptors with the full-length alpha7. J Biol 
Chem. 2014;289(38):26451-26463. 
284. Nievergelt CM, Wineinger NE, Libiger O, et al. Chip-based direct genotyping of coding 
variants in genome wide association studies: utility, issues and prospects. Gene. 
2014;540(1):104-109. 
285. Vollesen ALH, Ashina M. PACAP38: Emerging Drug Target in Migraine and Cluster Headache. 
Headache. 2017;57 Suppl 2:56-63. 
286. Sundrum T, Walker CS. Pituitary adenylate cyclase-activating polypeptide receptors in the 
trigeminovascular system: implications for migraine. Br J Pharmacol. 2017. 
287. Yokai M, Kurihara T, Miyata A. Spinal astrocytic activation contributes to both induction and 
maintenance of pituitary adenylate cyclase-activating polypeptide type 1 receptor-induced 
long-lasting mechanical allodynia in mice. Mol Pain. 2016;12. 
288. Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and 
sensitization of trigeminocervical neurons: Relevance to migraine. Sci Transl Med. 
2015;7(308):308ra157. 
289. Jongsma H, Pettersson LM, Zhang Y, et al. Markedly reduced chronic nociceptive response in 
mice lacking the PAC1 receptor. Neuroreport. 2001;12(10):2215-2219. 
290. Mabuchi T, Shintani N, Matsumura S, et al. Pituitary adenylate cyclase-activating polypeptide 
is required for the development of spinal sensitization and induction of neuropathic pain. J 
Neurosci. 2004;24(33):7283-7291. 
291. Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Brain Res Rev. 
2005;48(3):438-456. 
292. Hansen JM, Sitarz J, Birk S, et al. Vasoactive intestinal polypeptide evokes only a minimal 
headache in healthy volunteers. Cephalalgia. 2006;26(8):992-1003. 
293. Tuka B, Szabo N, Toth E, et al. Release of PACAP-38 in episodic cluster headache patients - an 
exploratory study. J Headache Pain. 2016;17(1):69. 
294. Racz B, Horvath G, Faluhelyi N, et al. Effects of PACAP on the circadian changes of signaling 
pathways in chicken pinealocytes. J Mol Neurosci. 2008;36(1-3):220-226. 
295. Bayes-Genis A, Barallat J, Richards AM. A Test in Context: Neprilysin: Function, Inhibition, and 




296. Barloese MC. A Review of Cardiovascular Autonomic Control in Cluster Headache. Headache. 
2016;56(2):225-239. 
297. Barloese M, Lund N, Petersen A, Rasmussen M, Jennum P, Jensen R. Sleep and chronobiology 
in cluster headache. Cephalalgia. 2015;35(11):969-978. 
298. Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet 
Neurol. 2002;1(4):251-257. 
299. Kramer HH, He L, Lu B, Birklein F, Sommer C. Increased pain and neurogenic inflammation in 
mice deficient of neutral endopeptidase. Neurobiol Dis. 2009;35(2):177-183. 
300. Auer-Grumbach M, Toegel S, Schabhuttl M, et al. Rare Variants in MME, Encoding 
Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal 
Polyneuropathies. Am J Hum Genet. 2016;99(3):607-623. 
301. Depondt C, Donatello S, Rai M, et al. MME mutation in dominant spinocerebellar ataxia with 
neuropathy (SCA43). Neurol Genet. 2016;2(5):e94. 
302. Higuchi Y, Hashiguchi A, Yuan J, et al. Mutations in MME cause an autosomal-recessive 
Charcot-Marie-Tooth disease type 2. Ann Neurol. 2016;79(4):659-672. 
303. Ran C, Fourier C, Michalska JM, et al. Screening of genetic variants in ADCYAP1R1, MME and 






Table S1: list  of selected candidate genes used in CH gene-based analysis  
GENE 
N of rare 
PAV/gene 
SKAT          
P-value 
GO term 
MME 3 2.55E-05 GO:0019233 
NPY1R 2 1.18E-03 GO:0004983|GO:0007218|GO:0008015|GO:0008217|GO:0019233|GO:0045907 
BDKRB1 2 3.30E-03 GO:0019233 
SLC5A3 2 4.94E-03 GO:0006814 
CCL26 1 7.02E-03 GO:0071356 
GRM1 5 9.45E-03 GO:0019233|GO:0051930 
KCNJ16 6 1.11E-02 GO:0006813 
OPN4 2 1.47E-02 GO:0042752 
KCND3 3 1.52E-02 GO:0006813 
NPR3 2 1.64E-02 GO:0008217 
SERPINE1 1 1.67E-02 GO:0007623 
SCN11A 6 1.83E-02 GO:0001518|GO:0006814|GO:0051930 
HRH1 4 2.13E-02 GO:0019229|GO:0045907 
COL4A3 11 2.19E-02 GO:0008015 
HCRTR2 3 2.41E-02 GO:0007218|GO:0008188|GO:0045187 
KDM5A 5 2.61E-02 GO:0032922 
HOXB2 2 2.66E-02 GO:0008015 
SORCS1 6 3.13E-02 GO:0007218|GO:0008188 
ATP7B 11 3.19E-02 GO:0007623 
RAI1 5 3.49E-02 GO:0032922 
APOE 2 3.49E-02 GO:0042311 
TNFRSF11B 2 3.49E-02 GO:0005031|GO:0033209 
SLC38A8 6 3.50E-02 GO:0006814 
RBM4B 1 3.62E-02 GO:0007623|GO:0032922|GO:0043153 
EDA2R 2 3.91E-02 GO:0005031|GO:0033209 
STXBP5 2 3.92E-02 GO:0005892 
GSTP1 2 3.94E-02 GO:0010804 
DBH 9 4.43E-02 GO:0045907|GO:0048265 
SLC24A4 7 4.53E-02 GO:0005262|GO:0006813 
GIT2 2 5.25E-02 GO:0048266 
ANKRD1 2 5.41E-02 GO:0071356 
TRPM2 15 5.51E-02 GO:0005262 
SLC24A2 1 5.65E-02 GO:0005262|GO:0006813 
ASS1 3 5.68E-02 GO:0071356 
CASP8 3 5.68E-02 GO:0005164|GO:0010803 
HMOX1 3 5.68E-02 GO:0008217|GO:0045909 
MEOX2 3 5.68E-02 GO:0008015 
CACNG4 1 5.69E-02 GO:0005262|GO:0005891 
CACNG6 1 5.69E-02 GO:0005891 
CNR1 1 5.69E-02 GO:0019233 
COMMD9 1 5.69E-02 GO:0006814 
CXCL16 1 5.69E-02 GO:0034612 
FAM19A4 1 5.69E-02 GO:0051930 
GJA4 1 5.69E-02 GO:0048265 
IL18BP 1 5.69E-02 GO:0071356 
MAP3K14 1 5.69E-02 GO:0033209 
MAPK9 1 5.69E-02 GO:0042752|GO:0071356 
NR1D2 1 5.69E-02 GO:0042752 
NXPH2 1 5.69E-02 GO:0007218 
P2RX1 1 5.69E-02 GO:0008217|GO:0042310 
PRKAA2 1 5.69E-02 GO:0042752 
PRKCG 1 5.69E-02 GO:0042752|GO:0048265 
SLC9A1 1 5.69E-02 GO:0051930 
TAC3 1 5.69E-02 GO:0007218 
TRADD 1 5.69E-02 GO:0005164|GO:0010803|GO:0033209 
ZC3H12A 1 5.69E-02 GO:0071356 
ADH1C 1 5.70E-02 GO:0004022|GO:0004024 
CCL25 1 5.70E-02 GO:0071356 
PTGER3 1 5.75E-02 GO:0045907|GO:0046010 




AVPR2 3 6.07E-02 GO:0045907 
MTNR1B 3 6.17E-02 GO:0007623|GO:0045909|GO:0046010 
OPN3 3 6.42E-02 GO:0042752 
NMUR1 2 7.26E-02 GO:0007218|GO:0008188 
SLC6A4 2 7.26E-02 GO:0007623|GO:0042310 
KCNA5 3 7.29E-02 GO:0006813|GO:0019229 
CCL23 1 7.89E-02 GO:0071356 
RELN 17 8.27E-02 GO:0048265 
NFIL3 2 8.49E-02 GO:0007623 
SLC38A7 2 8.50E-02 GO:0006814 
ECE1 4 8.58E-02 GO:0003100|GO:0019229|GO:0042312 
NPPA 2 8.77E-02 GO:0005184|GO:0007218 
ALOX12 4 9.18E-02 GO:0045909 
FBXL21 4 9.20E-02 GO:0043153 
GRIN3A 11 9.31E-02 GO:0005262 
KCNK7 1 9.32E-02 GO:0005267|GO:0006813 
PSMB6 1 9.32E-02 GO:0033209 
ADM 1 9.35E-02 GO:0008015 
ARNTL2 6 9.44E-02 GO:0007623|GO:0009649|GO:0042753 
PROKR1 1 9.62E-02 GO:0004983|GO:0007218|GO:0007623 
TRPV3 8 9.91E-02 GO:0005262 
QRFP 3 9.99E-02 GO:0005184|GO:0007218 
NPFFR2 6 1.01E-01 GO:0007218|GO:0008188 
CD34 2 1.03E-01 GO:0008217 
NPSR1 5 1.04E-01 GO:0007218|GO:0008188 
SETX 12 1.04E-01 GO:0007623 
TNFRSF1B 1 1.10E-01 GO:0005031|GO:0033209 
TIMELESS 11 1.10E-01 GO:0007623|GO:0042752 
A2M 6 1.11E-01 GO:0043120 
PSME4 2 1.12E-01 GO:0033209 
CHGA 5 1.12E-01 GO:0008217|GO:0045908 
BAG4 3 1.16E-01 GO:0033209|GO:0071356 
ALDH3B2 9 1.20E-01 GO:0006066 
HMGCR 2 1.21E-01 GO:0045908 
MC1R 10 1.21E-01 GO:0019233 
KCNK18 3 1.25E-01 GO:0005267|GO:0006813 
ALDH3B1 4 1.26E-01 GO:0006066 
OTULIN 2 1.27E-01 GO:0010803 
AGT 7 1.30E-01 GO:0008217|GO:0019229|GO:0042311|GO:0042312 
ADCY6 4 1.30E-01 GO:0042312 
SIK1 3 1.33E-01 GO:0043153 
HTR1B 1 1.34E-01 GO:0042310 
PKD2 5 1.36E-01 GO:0005267 
AFF3 4 1.37E-01 GO:0034612 
F5 10 1.42E-01 GO:0008015 
CHRNA4 2 1.42E-01 GO:0004889|GO:0005892|GO:0019233 
ACVRL1 2 1.42E-01 GO:0008015|GO:0008217 
CACNA1D 2 1.42E-01 GO:0005891 
DRD1 2 1.42E-01 GO:0019229|GO:0042311|GO:0042321 
HTR3E 2 1.42E-01 GO:0004889|GO:0005892 
KCNMB1 2 1.42E-01 GO:0006813 
NLGN1 2 1.42E-01 GO:0010841 
PAX4 2 1.42E-01 GO:0007623 
TRAF3 2 1.42E-01 GO:0005164|GO:0033209 
QRFPR 5 1.46E-01 GO:0004983|GO:0007218 
NPPB 2 1.49E-01 GO:0008217|GO:0042312 
KCNJ11 1 1.54E-01 GO:0071356 
UBE3A 1 1.54E-01 GO:0042752 
CCDC109B 4 1.56E-01 GO:0005262 
NPFFR1 5 1.66E-01 GO:0007218|GO:0008188 
MC4R 1 1.66E-01 GO:0042923 
TNF 1 1.66E-01 GO:0005164|GO:0010803|GO:0033209 
POSTN 3 1.68E-01 GO:0071356 
KCNK5 3 1.74E-01 GO:0005267|GO:0006813 
CRHR2 3 1.79E-01 GO:0019233 
HTR3C 3 1.80E-01 GO:0004889|GO:0005892 
MBP 3 1.83E-01 GO:0034612 
AHR 7 1.84E-01 GO:0032922 
CACNA1E 5 1.86E-01 GO:0005262|GO:0005891 




TRIM32 3 1.89E-01 GO:0034612 
TNFRSF10D 2 1.95E-01 GO:0005031|GO:0033209 
ASIC4 1 1.96E-01 GO:0005272 
METTL3 1 1.96E-01 GO:0007623 
NXPH3 2 1.96E-01 GO:0007218 
SLC5A6 2 1.96E-01 GO:0006814 
ID1 2 1.98E-01 GO:0007623 
SSTR4 2 1.99E-01 GO:0042923 
SSTR5 5 2.00E-01 GO:0042923 
KEL 4 2.03E-01 GO:0042310 
P2RX4 3 2.05E-01 GO:0008217|GO:0019233 
GAS6 2 2.05E-01 GO:0010804 
CACNA2D1 2 2.06E-01 GO:0005891 
PSMD13 2 2.06E-01 GO:0033209 
KCNC4 2 2.13E-01 GO:0005267|GO:0006813 
APOB 36 2.19E-01 GO:0071356 
TRPM3 7 2.20E-01 GO:0005262 
SLC10A5 5 2.24E-01 GO:0006814 
SMTNL1 3 2.24E-01 GO:0045907|GO:0045908 
TRHDE 3 2.24E-01 GO:0008217 
F2RL1 2 2.26E-01 GO:0045909|GO:0010804 
RELA 2 2.28E-01 GO:0071356 
KCNMB3 1 2.30E-01 GO:0006813 
CHD7 7 2.30E-01 GO:0008015 
GUCY1B3 1 2.34E-01 GO:0008015 
KCNJ6 1 2.38E-01 GO:0006813 
NTSR2 3 2.41E-01 GO:0007218 
GUCY1A3 3 2.43E-01 GO:0008015|GO:0008217 
DHRS9 3 2.47E-01 GO:0004022 
AGTR1 3 2.48E-01 GO:0019229|GO:0042312 
MC2R 3 2.52E-01 GO:0007218 
NOS3 8 2.54E-01 GO:0003100|GO:0008217|GO:0045909 
OCSTAMP 2 2.54E-01 GO:0071356 
NOS1 9 2.54E-01 GO:0045906|GO:0051930 
NISCH 6 2.54E-01 GO:0008217 
SLC17A2 3 2.56E-01 GO:0006814 
HCRTR1 3 2.59E-01 GO:0007218|GO:0008188|GO:0045187 
BRS3 1 2.59E-01 GO:0008217 
RAD51L3-RFFL 4 2.61E-01 GO:0010804 
MTHFR 5 2.62E-01 GO:0008015 
SLC5A11 3 2.62E-01 GO:0006814 
LGR4 5 2.63E-01 GO:0032922 
KCNK6 3 2.64E-01 GO:0005267|GO:0006813 
SELE 3 2.64E-01 GO:0034612 
RET 2 2.71E-01 GO:0048265 
MRGPRX2 3 2.71E-01 GO:0019233|GO:0042923 
HS3ST2 1 2.71E-01 GO:0007623 
MCHR1 5 2.73E-01 GO:0007218|GO:0008188 
SSTR3 5 2.73E-01 GO:0042923 
IKBKB 3 2.77E-01 GO:0010803|GO:0033209|GO:0071356 
PTPRM 3 2.77E-01 GO:0045909 
ADRB2 1 2.82E-01 GO:0045909|GO:0051930 
SLC12A8 7 2.85E-01 GO:0006813 
GPR1 2 2.87E-01 GO:0007218|GO:0042923 
KCNK10 2 2.87E-01 GO:0005267 
NEDD4L 2 2.87E-01 GO:0006814 
PSME1 2 2.87E-01 GO:0033209 
HTR3A 3 2.88E-01 GO:0004889|GO:0005892 
CACNA2D4 10 2.90E-01 GO:0005891 
NPY4R 3 2.90E-01 GO:0007218|GO:0008015 
GRIN2A 4 2.91E-01 GO:0005262|GO:0019233|GO:0051930 
KCNIP3 1 2.91E-01 GO:0005267 
COL1A1 5 2.92E-01 GO:0071356 
CD40LG 1 2.92E-01 GO:0005164|GO:0033209 
EDAR 1 2.92E-01 GO:0033209 
KCNMA1 1 2.92E-01 GO:0006813 
NPY 1 2.92E-01 GO:0005184|GO:0007218|GO:0008015|GO:0008217 
CACNA1B 4 2.94E-01 GO:0005262|GO:0005891|GO:0008217|GO:0071356 
MMP24 2 2.98E-01 GO:0050965 




SLC4A4 8 2.99E-01 GO:0006814 
KCNU1 7 3.01E-01 GO:0005267 
CCL14 2 3.05E-01 GO:0071356 
NTRK1 8 3.06E-01 GO:0007623|GO:0050965|GO:0050966 
MGLL 3 3.06E-01 GO:0051930 
SLC9B2 3 3.06E-01 GO:0006814 
GHRHR 1 3.08E-01 GO:0046010 
HYAL3 2 3.10E-01 GO:0071356 
SLC9C2 4 3.10E-01 GO:0006814 
HTR3B 4 3.16E-01 GO:0004889|GO:0005892 
LRP5 4 3.16E-01 GO:0008217 
SLC5A4 10 3.18E-01 GO:0006814 
KCNH4 4 3.18E-01 GO:0006813 
NPR1 4 3.20E-01 GO:0008217|GO:0042312 
HTR2A 2 3.22E-01 GO:0045907|GO:0050965|GO:0050966 
IL12B 3 3.25E-01 GO:0019233 
RORC 3 3.25E-01 GO:0032922 
FAM134B 4 3.27E-01 GO:0019233 
KCNH1 2 3.28E-01 GO:0006813 
KCNJ8 1 3.29E-01 GO:0006813|GO:0042311 
KCNS1 1 3.29E-01 GO:0006813 
NOCT 1 3.29E-01 GO:0007623|GO:0032922|GO:0042752 
NPBWR1 1 3.29E-01 GO:0007218|GO:0008188|GO:0042923 
PTGS2 1 3.29E-01 GO:0008217|GO:0019233|GO:0045907|GO:0034612 
PYY 1 3.29E-01 GO:0005184|GO:0007218 
SREBF1 1 3.29E-01 GO:0007623 
CACNA1H 12 3.29E-01 GO:0005891 
ADAM9 4 3.29E-01 GO:0034612 
TRPC6 1 3.30E-01 GO:0005262 
TNFRSF21 4 3.31E-01 GO:0005031|GO:0033209|GO:0071356 
KNG1 4 3.32E-01 GO:0042311 
NOL3 4 3.32E-01 GO:0010804 
TRAP1 15 3.32E-01 GO:0005164 
CCAR2 3 3.33E-01 GO:0042752 
HTR1A 2 3.35E-01 GO:0042310 
ACSM3 5 3.39E-01 GO:0008217 
SLC9C1 5 3.41E-01 GO:0006814 
PER3 7 3.44E-01 GO:0032922|GO:0045187 
PIRT 3 3.44E-01 GO:0048266 
BRCA1 10 3.47E-01 GO:0071356 
DENND5B 2 3.47E-01 GO:0005262 
FYN 2 3.50E-01 GO:0050966 
PKD2L1 13 3.53E-01 GO:0005262|GO:0005272 
TRAF4 2 3.53E-01 GO:0005164 
LSM14B 2 3.55E-01 GO:0033209 
TPH1 2 3.55E-01 GO:0007623 
PRKCQ 2 3.56E-01 GO:0019229 
CCL17 1 3.57E-01 GO:0071356 
SORT1 2 3.57E-01 GO:0007218 
GRIN3B 5 3.59E-01 GO:0005262 
NTS 1 3.61E-01 GO:0005184 
EPHB1 1 3.62E-01 GO:0050965|GO:0045909 
HYAL2 1 3.62E-01 GO:0071356 
KCNQ2 1 3.62E-01 GO:0005267|GO:0006813 
LTB4R 1 3.62E-01 GO:0007218 
PAWR 1 3.62E-01 GO:0050965|GO:0050966 
PROX1 1 3.62E-01 GO:0007623|GO:0042752 
PSMF1 1 3.62E-01 GO:0033209 
TMEM37 1 3.62E-01 GO:0005262 
TNFRSF18 1 3.62E-01 GO:0005031|GO:0033209 
ZNF675 1 3.62E-01 GO:0010804 
GPD1 5 3.62E-01 GO:0071356 
KMT2A 8 3.64E-01 GO:0032922 
CPS1 7 3.67E-01 GO:0045909 
ADIPOQ 4 3.67E-01 GO:0007623|GO:0010804|GO:0034612 
CARD14 11 3.67E-01 GO:0033209 
TRPV5 5 3.69E-01 GO:0005262 
CACNA2D2 2 3.71E-01 GO:0005891|GO:0060024 
HTR7 2 3.72E-01 GO:0007623|GO:0008015|GO:0042310 




MYOF 16 3.76E-01 GO:0008015 
SLC22A5 4 3.79E-01 GO:0006814 
NONO 1 3.81E-01 GO:0007623|GO:0042752 
VCAM1 2 3.82E-01 GO:0071356 
SLC17A4 3 3.82E-01 GO:0006814 
CARTPT 3 3.82E-01 GO:0007218|GO:0032922 
CYSLTR2 8 3.85E-01 GO:0007218 
KCNA4 2 3.86E-01 GO:0006813 
NPBWR2 4 3.86E-01 GO:0007218|GO:0008188|GO:0042923 
KCNQ3 3 3.87E-01 GO:0005267|GO:0006813 
AQP1 4 3.88E-01 GO:0005267|GO:0006813 
CHRNE 3 3.88E-01 GO:0004889|GO:0005892 
PSMB9 3 3.89E-01 GO:0033209 
ADAM10 3 3.91E-01 GO:0034612 
SCN2A 5 3.93E-01 GO:0001518 
NFKB1 6 3.95E-01 GO:0071356 
TRPM8 5 3.95E-01 GO:0005262 
SLC24A1 2 3.97E-01 GO:0005262 
KCNK16 5 4.00E-01 GO:0005267|GO:0006813 
CHRND 6 4.04E-01 GO:0004889|GO:0005892 
ADAMTS12 7 4.07E-01 GO:0071356 
NUB1 2 4.08E-01 GO:0034612 
TOP2A 5 4.09E-01 GO:0042752 
PSMD6 2 4.09E-01 GO:0033209 
SLC24A3 5 4.10E-01 GO:0005262|GO:0006813 
RPE65 2 4.11E-01 GO:0007623 
LOXHD1 16 4.14E-01 GO:0005262 
SCN1A 6 4.16E-01 GO:0001518|GO:0006814 
CACNB2 3 4.16E-01 GO:0005262|GO:0005891 
KLF9 2 4.20E-01 GO:0007623 
CHRNA10 3 4.20E-01 GO:0004889|GO:0005262|GO:0005892 
PLVAP 2 4.24E-01 GO:0033209 
TRPA1 3 4.31E-01 GO:0005262|GO:0019233|GO:0048265|GO:0050966|GO:0050968 
SCN4B 1 4.32E-01 GO:0001518|GO:0006814 
TNFRSF17 1 4.32E-01 GO:0033209 
ENTPD2 3 4.34E-01 GO:0071356 
AVPR1A 2 4.35E-01 GO:0008015|GO:0045907 
KCNJ3 1 4.40E-01 GO:0006813 
DAB2IP 3 4.41E-01 GO:0071356 
GLRA1 4 4.41E-01 GO:0007218 
EPHX2 3 4.49E-01 GO:0008217 
OPRM1 5 4.49E-01 GO:0007218|GO:0019233|GO:0051930 
DCSTAMP 5 4.52E-01 GO:0071356 
CNR2 2 4.53E-01 GO:0019233 
HTR3D 1 4.56E-01 GO:0004889|GO:0005892 
PSMD9 1 4.56E-01 GO:0033209 
ROCK2 1 4.56E-01 GO:0042752 
ADH4 1 4.57E-01 GO:0004022|GO:0004024|GO:0006066 
ALB 1 4.57E-01 GO:0046010 
ATOH7 1 4.57E-01 GO:0007623|GO:0009649 
CACNG2 1 4.57E-01 GO:0005262|GO:0005891 
CALCRL 1 4.57E-01 GO:0004948 
CCL11 1 4.57E-01 GO:0071356 
CD58 1 4.57E-01 GO:0071356 
CPT1A 1 4.57E-01 GO:0007623 
DRD2 1 4.57E-01 GO:0032922|GO:0042321 
EZH2 1 4.57E-01 GO:0042752 
GPR84 1 4.57E-01 GO:0007218 
KCNAB3 1 4.57E-01 GO:0006813 
KLF10 1 4.57E-01 GO:0007623|GO:0042752 
LEP 1 4.57E-01 GO:0007623|GO:0008217|GO:0045906 
PDE4D 1 4.57E-01 GO:0005891 
PPARD 1 4.57E-01 GO:0045909 
PSMB2 1 4.57E-01 GO:0033209 
RBCK1 1 4.57E-01 GO:0010803 
SLC17A8 1 4.57E-01 GO:0006814 
TNFSF14 1 4.57E-01 GO:0005164|GO:0033209 
TPH2 1 4.57E-01 GO:0007623 
CCL24 1 4.58E-01 GO:0071356 




CASQ2 2 4.61E-01 GO:0005891 
CHRNA2 2 4.61E-01 GO:0004889|GO:0005892 
ENDOG 2 4.61E-01 GO:0034612 
POMK 2 4.63E-01 GO:0019233 
CHRNA6 2 4.63E-01 GO:0004889|GO:0005892 
MCOLN1 2 4.63E-01 GO:0005262 
SLC10A1 2 4.63E-01 GO:0006814 
MKKS 3 4.63E-01 GO:0042311 
KCNN4 2 4.63E-01 GO:0005267|GO:0006813 
MYBBP1A 25 4.65E-01 GO:0032922 
KCNK13 4 4.66E-01 GO:0005267 
AHCY 3 4.68E-01 GO:0042745 
NFE2L2 2 4.71E-01 GO:0071356 
CALCA 4 4.71E-01 GO:0007218|GO:0048265|GO:0050965|GO:0071356 
ZACN 4 4.76E-01 GO:0004889|GO:0005892 
MTNR1A 6 4.77E-01 GO:0007623 
ADRA1A 6 4.77E-01 GO:0045907 
NTSR1 10 4.77E-01 GO:0007218|GO:0050965|GO:0051930 
TRAPPC10 4 4.80E-01 GO:0006814 
LTB 1 4.81E-01 GO:0005164|GO:0033209 
NLGN3 1 4.81E-01 GO:0060024 
TNFRSF13B 6 4.82E-01 GO:0033209 
ALOXE3 5 4.82E-01 GO:0019233 
TNFRSF14 1 4.83E-01 GO:0005031|GO:0033209 
GAL 2 4.85E-01 GO:0005184|GO:0007218 
CHUK 2 4.86E-01 GO:0010803|GO:0071356 
PROKR2 4 4.90E-01 GO:0004983|GO:0007218|GO:0007623 
SIRT1 3 4.92E-01 GO:0032922|GO:0071356 
EPB41 2 4.92E-01 GO:0008015 
MAGEL2 7 4.95E-01 GO:0042752 
TRPM1 9 4.95E-01 GO:0005262 
YTHDC2 4 4.96E-01 GO:0034612 
HDAC4 5 4.99E-01 GO:0071356 
SCN8A 4 5.00E-01 GO:0001518|GO:0006814 
ADH7 5 5.02E-01 GO:0004022|GO:0004024 
NPS 4 5.03E-01 GO:0007218|GO:0010841 
SCNN1G 3 5.04E-01 GO:0005272|GO:0006814 
CACNA1C 5 5.05E-01 GO:0005891 
KCNA10 7 5.07E-01 GO:0006813 
EP300 7 5.08E-01 GO:0007623|GO:0034612 
STK39 2 5.09E-01 GO:0008217 
CX3CL1 3 5.12E-01 GO:0045906|GO:0071356 
CYB5R3 3 5.12E-01 GO:0008015 
TAX1BP1 4 5.13E-01 GO:0010803 
EPO 3 5.13E-01 GO:0008015 
FXYD4 1 5.17E-01 GO:0005267 
SLC9A3 5 5.21E-01 GO:0007623 
TRPV1 9 5.22E-01 GO:0005262 
TNFRSF10C 3 5.23E-01 GO:0005031|GO:0033209 
SLC38A4 2 5.31E-01 GO:0006814 
PSMB11 7 5.34E-01 GO:0033209 
SLC5A10 2 5.37E-01 GO:0006814 
DENND5A 4 5.39E-01 GO:0005262 
FAS 2 5.41E-01 GO:0007623|GO:0005031|GO:0033209 
NOS2 3 5.44E-01 GO:0007623|GO:0045909 
CCL8 3 5.45E-01 GO:0071356 
PRKCDBP 2 5.52E-01 GO:0032922 
TRIM37 3 5.53E-01 GO:0005164 
TRDN 3 5.55E-01 GO:0005891 
SLC38A10 7 5.55E-01 GO:0006814 
MADD 9 5.60E-01 GO:0010803 
IL6 2 5.61E-01 GO:0045188|GO:0071356 
GALR2 4 5.63E-01 GO:0007218|GO:0042923 
PKD1L3 9 5.69E-01 GO:0005262 
NDUFA9 2 5.71E-01 GO:0006814 
CALCR 3 5.71E-01 GO:0004948 
HTR1D 3 5.71E-01 GO:0042310 
TRPM7 3 5.71E-01 GO:0005262 
TSC1 3 5.73E-01 GO:0006813 




KAT2B 7 5.76E-01 GO:0045909 
CACNA1F 2 5.76E-01 GO:0005891 
ATP1A4 11 5.77E-01 GO:0006813|GO:0006814 
COL1A2 4 5.78E-01 GO:0008217 
BBS2 1 5.80E-01 GO:0042311 
SLC6A15 4 5.81E-01 GO:0006814 
BMPR2 1 5.83E-01 GO:0045906 
PSMB8 3 5.86E-01 GO:0033209 
TMEM38B 5 5.96E-01 GO:0005267 
PPARA 3 5.96E-01 GO:0032922|GO:0042752 
NCOA2 1 5.96E-01 GO:0032922 
PTGDR2 1 5.97E-01 GO:0007218|GO:0042923 
PTEN 1 5.98E-01 GO:0060024 
SLC13A2 2 5.98E-01 GO:0006814 
BTRC 1 5.99E-01 GO:0042752|GO:0042753 
PDE4B 1 5.99E-01 GO:0005891 
PSMB3 1 5.99E-01 GO:0033209 
TRPC1 1 5.99E-01 GO:0005262 
LTB4R2 3 5.99E-01 GO:0007218 
OPRL1 3 5.99E-01 GO:0007218|GO:0019233|GO:0042923 
ACPP 1 5.99E-01 GO:0051930 
ADORA1 1 5.99E-01 GO:0045908|GO:0050965|GO:0051930 
ADORA2A 2 5.99E-01 GO:0008015 
ADRA1D 1 5.99E-01 GO:0045907 
ADRA2B 1 5.99E-01 GO:0019229 
AGTRAP 1 5.99E-01 GO:0008217 
ALDH2 2 5.99E-01 GO:0006066 
ALOX5 1 5.99E-01 GO:0019233|GO:0045907 
BDKRB2 1 5.99E-01 GO:0008015|GO:0019229|GO:0042310|GO:0042311 
BIRC2 1 5.99E-01 GO:0010803|GO:0033209 
CACFD1 1 5.99E-01 GO:0005262 
CCL4 1 5.99E-01 GO:0071356 
CD38 1 5.99E-01 GO:0045907 
CD40 2 5.99E-01 GO:0005031|GO:0033209 
CHI3L1 1 5.99E-01 GO:0034612|GO:0071356 
COMT 1 5.99E-01 GO:0048265|GO:0051930 
CRCP 1 5.99E-01 GO:0007218 
CRHBP 1 5.99E-01 GO:0071356 
CSNK1D 1 5.99E-01 GO:0032922|GO:0042752 
CXCL12 1 5.99E-01 GO:0008015 
DBP 1 5.99E-01 GO:0007623 
DRD3 1 5.99E-01 GO:0032922|GO:0045187 
DRD4 1 5.99E-01 GO:0007623|GO:0042752 
EDA 1 5.99E-01 GO:0005164|GO:0033209 
EDN3 1 5.99E-01 GO:0003100|GO:0008015|GO:0019229|GO:0042310 
ENOX2 1 5.99E-01 GO:0007624 
FASLG 1 5.99E-01 GO:0005164 
FGA 1 5.99E-01 GO:0045907 
FLI1 1 5.99E-01 GO:0008015 
GJA1 1 5.99E-01 GO:0045907|GO:0045909 
GLRA2 1 5.99E-01 GO:0007218 
GLRB 1 5.99E-01 GO:0007218 
GNB3 1 5.99E-01 GO:0008217 
GPER1 1 5.99E-01 GO:0045909|GO:0071356 
GSS 1 5.99E-01 GO:0034612 
HDAC2 1 5.99E-01 GO:0032922 
HEBP1 1 5.99E-01 GO:0007623 
HIPK1 1 5.99E-01 GO:0010803 
HOXB8 1 5.99E-01 GO:0019233 
IAPP 1 5.99E-01 GO:0019233 
IMMP2L 1 5.99E-01 GO:0008015 
INPP5K 1 5.99E-01 GO:0071356 
KCNC1 1 5.99E-01 GO:0006813 
KCNK15 1 5.99E-01 GO:0005267 
KCNK3 1 5.99E-01 GO:0005267|GO:0006813 
KCNQ4 1 5.99E-01 GO:0005267|GO:0006813 
MAPK3 1 5.99E-01 GO:0019233 
MTA1 1 5.99E-01 GO:0032922|GO:0043153 
NDN 1 5.99E-01 GO:0019233 




NGFR 1 5.99E-01 GO:0019233|GO:0032922|GO:0005031|GO:0033209 
NMU 1 5.99E-01 GO:0007218 
NPFF 1 5.99E-01 GO:0005184 
NPY5R 1 5.99E-01 GO:0004983|GO:0007218 
NR1H3 1 5.99E-01 GO:0042752 
NTRK2 1 5.99E-01 GO:0007623|GO:0071356 
OXTR 1 5.99E-01 GO:0045907 
PDE2A 1 5.99E-01 GO:0005262 
PELI3 1 5.99E-01 GO:0010804 
PIAS4 1 5.99E-01 GO:0010804 
POMC 1 5.99E-01 GO:0005184|GO:0007218 
PPY 1 5.99E-01 GO:0005184|GO:0007218 
PSMC5 1 5.99E-01 GO:0033209 
PSMD3 1 5.99E-01 GO:0033209 
PSMD8 1 5.99E-01 GO:0033209 
RBM14 1 5.99E-01 GO:0043153 
RPS6KB1 1 5.99E-01 GO:0034612 
RXFP3 1 5.99E-01 GO:0007218 
SCN1B 1 5.99E-01 GO:0001518 
SERPING1 1 5.99E-01 GO:0008015 
SHC1 1 5.99E-01 GO:0045907 
SLC10A4 1 5.99E-01 GO:0006814 
SLC23A2 1 5.99E-01 GO:0006814 
SLC4A11 1 5.99E-01 GO:0005272|GO:0006814 
SLC5A7 1 5.99E-01 GO:0006814 
SPX 1 5.99E-01 GO:0005184 
TBX20 1 5.99E-01 GO:0008015 
THBS1 1 5.99E-01 GO:0048266 
TMEM100 1 5.99E-01 GO:0051930 
TNFRSF6B 1 5.99E-01 GO:0005031|GO:0033209 
TOP1 1 5.99E-01 GO:0007623|GO:0032922 
TRAIP 1 5.99E-01 GO:0010804 
TRPC7 1 5.99E-01 GO:0005262 
VPS4B 1 5.99E-01 GO:0006813 
YBX3 1 5.99E-01 GO:0071356 
PANX1 1 5.99E-01 GO:0005262 
SCN3A 7 6.00E-01 GO:0001518 
CXCL8 1 6.00E-01 GO:0071356 
KCNK1 4 6.01E-01 GO:0005267|GO:0005272|GO:0006814 
GALP 1 6.02E-01 GO:0007218 
PSMB7 1 6.02E-01 GO:0033209 
NPVF 2 6.04E-01 GO:0007218 
TENM1 4 6.07E-01 GO:0007218 
P2RX7 11 6.08E-01 GO:0019233 
CDKN1B 2 6.09E-01 GO:0006813 
HCN4 2 6.10E-01 GO:0008015 
MCOLN2 2 6.10E-01 GO:0005262 
MCOLN3 2 6.10E-01 GO:0005262 
NMS 2 6.10E-01 GO:0007218 
PRLH 2 6.10E-01 GO:0005184 
PSMD1 2 6.10E-01 GO:0033209 
SLC12A2 2 6.10E-01 GO:0006813|GO:0006814 
TH 2 6.10E-01 GO:0042745 
THRAP3 2 6.10E-01 GO:0007623|GO:0042753 
GHRH 1 6.14E-01 GO:0046005 
INSR 3 6.18E-01 GO:0034612 
AVPR1B 1 6.21E-01 GO:0045907 
DLL1 1 6.21E-01 GO:0008217 
PSMB10 1 6.21E-01 GO:0033209 
PTPN2 1 6.21E-01 GO:0010804 
TNFSF18 1 6.21E-01 GO:0032813|GO:0033209 
PTGS1 4 6.22E-01 GO:0008217|GO:0019233|GO:0045907 
KCNJ13 1 6.23E-01 GO:0006813 
PROK1 1 6.23E-01 GO:0007623 
SLC38A11 1 6.23E-01 GO:0006814 
JAK2 4 6.23E-01 GO:0033209|GO:0034612 
NMUR2 4 6.24E-01 GO:0007218|GO:0048265 
PDYN 1 6.35E-01 GO:0005184|GO:0007218 
LPA 15 6.37E-01 GO:0008015 




TNFRSF19 4 6.37E-01 GO:0005031|GO:0033209 
TNFSF9 2 6.37E-01 GO:0005164|GO:0032813 
PML 8 6.39E-01 GO:0032922|GO:0042752|GO:0043153 
ERAP1 4 6.40E-01 GO:0008217|GO:0043120 
CACTIN 1 6.45E-01 GO:0071356 
NOX1 3 6.45E-01 GO:0008217 
SLC38A2 4 6.47E-01 GO:0006814 
ERBB2IP 4 6.48E-01 GO:0071356 
ECEL1 4 6.48E-01 GO:0007218 
TRAF1 2 6.49E-01 GO:0005164|GO:0010803 
CCL15 4 6.50E-01 GO:0071356 
RNF31 5 6.50E-01 GO:0010803 
PER2 5 6.50E-01 GO:0007623|GO:0019229|GO:0032922 
P2RY2 3 6.51E-01 GO:0019233|GO:0042312 
SLC10A6 3 6.51E-01 GO:0006814 
TNFRSF8 4 6.51E-01 GO:0005031|GO:0033209 
SLC10A7 4 6.52E-01 GO:0006814 
SGK1 1 6.53E-01 GO:0006814|GO:0008217 
DDC 4 6.53E-01 GO:0007623 
PSMD5 3 6.58E-01 GO:0033209 
HTR2B 4 6.58E-01 GO:0042310 
TRPV2 4 6.59E-01 GO:0005262 
ZFHX3 27 6.60E-01 GO:0032922 
P2RX2 4 6.63E-01 GO:0048266 
SCN7A 8 6.71E-01 GO:0001518|GO:0006814 
MECP2 3 6.72E-01 GO:0019233 
NRIP1 5 6.73E-01 GO:0007623|GO:0032922 
ADAM17 7 6.76E-01 GO:0033209 
ADH6 3 6.76E-01 GO:0004022|GO:0004024 
CHRNA9 3 6.76E-01 GO:0004889|GO:0005262|GO:0005892 
GPR149 3 6.76E-01 GO:0007218|GO:0042923 
TNFRSF10B 3 6.76E-01 GO:0005031|GO:0033209 
SCNN1B 3 6.77E-01 GO:0006814 
PTK2B 5 6.78E-01 GO:0033209 
CIART 3 6.79E-01 GO:0032922 
PER1 8 6.84E-01 GO:0007623|GO:0009649|GO:0032922|GO:0042752|GO:0043153 
ADCY1 4 6.84E-01 GO:0007623|GO:0042752 
GLRA4 6 6.86E-01 GO:0007218 
SORCS3 2 6.87E-01 GO:0007218|GO:0008188 
PKD2L2 5 6.94E-01 GO:0005262 
CHRNG 5 6.94E-01 GO:0004889|GO:0005892 
SCN4A 12 6.94E-01 GO:0001518|GO:0006813|GO:0006814 
CACNA1G 8 6.96E-01 GO:0005891 
SLC5A9 7 6.96E-01 GO:0006814 
NRG1 9 6.97E-01 GO:0008217 
PRKDC 14 6.97E-01 GO:0042752 
SLC38A6 2 6.98E-01 GO:0006814 
UBD 2 7.00E-01 GO:0034612 
ACE2 3 7.03E-01 GO:0019229|GO:0042312 
DLG2 5 7.04E-01 GO:0019233 
CACNA1S 11 7.05E-01 GO:0005891 
PKD1L2 52 7.12E-01 GO:0005262 
ABCC8 4 7.18E-01 GO:0005267|GO:0006813 
NCOR1 5 7.21E-01 GO:0007623 
SLC10A2 9 7.31E-01 GO:0006814 
SLC34A3 10 7.31E-01 GO:0006814 
CHRNB1 3 7.34E-01 GO:0004889|GO:0005892 
SLC17A3 3 7.34E-01 GO:0006814 
CASP3 3 7.34E-01 GO:0034612 
CPE 3 7.34E-01 GO:0007218 
CHRNA3 2 7.39E-01 GO:0004889|GO:0005892 
ACE 10 7.41E-01 GO:0008217 
SORCS2 7 7.45E-01 GO:0007218|GO:0008188 
F7 3 7.50E-01 GO:0007623 
GJA5 2 7.58E-01 GO:0006813|GO:0045907|GO:0045909 
SPHK1 4 7.58E-01 GO:0010803 
NPB 2 7.59E-01 GO:0007218 
PENK 2 7.59E-01 GO:0005184|GO:0007218 
TNFRSF4 2 7.59E-01 GO:0005031|GO:0033209 




ATP1A2 2 7.59E-01 GO:0006813|GO:0006814|GO:0008217|GO:0019229 
BIRC3 2 7.59E-01 GO:0010803|GO:0033209 
CACNG1 2 7.59E-01 GO:0005891 
CAV1 2 7.59E-01 GO:0042310|GO:0045907 
CRTC1 2 7.59E-01 GO:0043153 
EDN1 2 7.59E-01 GO:0003100|GO:0019229|GO:0019233|GO:0042310|GO:0051930|GO:0071356 
ESR2 2 7.59E-01 GO:0045909 
GPR83 2 7.59E-01 GO:0004983|GO:0007218 
HNF1B 2 7.59E-01 GO:0032922 
TNFSF10 2 7.59E-01 GO:0005164 
TRH 2 7.59E-01 GO:0005184 
ID3 2 7.61E-01 GO:0007623 
ADH1B 4 7.61E-01 GO:0004024 
ASIC2 2 7.61E-01 GO:0019229 
TMEM38A 2 7.61E-01 GO:0005267 
TRAF2 2 7.61E-01 GO:0005164|GO:0010803|GO:0033209 
THBS4 7 7.61E-01 GO:0048266 
ITGA2 5 7.65E-01 GO:0050966 
SCNN1D 10 7.66E-01 GO:0006814 
CYBA 1 7.67E-01 GO:0071356 
KCNJ1 1 7.67E-01 GO:0006813 
PTAFR 1 7.67E-01 GO:0045907|GO:0045909 
PYDC2 1 7.67E-01 GO:0010804 
AIM2 3 7.70E-01 GO:0033209 
ERAP2 6 7.72E-01 GO:0008217 
TBC1D8 5 7.72E-01 GO:0008015 
USP2 4 7.72E-01 GO:0032922 
ICAM1 7 7.72E-01 GO:0045907|GO:0071356 
SLC5A12 2 7.78E-01 GO:0006814 
HYAL1 6 7.79E-01 GO:0071356 
LTBR 1 7.80E-01 GO:0005031|GO:0033209 
PKD1L1 23 7.84E-01 GO:0005262 
ELN 10 7.91E-01 GO:0008015 
CACNA2D3 4 7.92E-01 GO:0005262|GO:0005891 
GALR3 2 7.92E-01 GO:0007218 
CIB1_GDPGP1 6 7.97E-01 GO:0071356 
ADAMTS7 2 7.97E-01 GO:0071356 
RYR2 7 8.07E-01 GO:0005262 
LVRN 8 8.07E-01 GO:0008217 
CACNB1 2 8.11E-01 GO:0005891 
PSEN1 1 8.15E-01 GO:0005262 
TNFAIP3 5 8.15E-01 GO:0010803 
CHRNA1 3 8.43E-01 GO:0004889 
CORIN 3 8.43E-01 GO:0008217 
FGFR1 3 8.43E-01 GO:0051930 
LXN 7 8.43E-01 GO:0050965 
KCNJ10 3 8.46E-01 GO:0006813 
NALCN 1 8.52E-01 GO:0005272 
C3AR1 1 8.53E-01 GO:0008015|GO:0008217 
PLA2G6 5 8.55E-01 GO:0045909 
CACNA1I 6 8.65E-01 GO:0005891 
KCNB2 1 8.69E-01 GO:0006813 
KCNJ15 1 8.69E-01 GO:0006813 
CRP 1 8.71E-01 GO:0045908 
HBB 1 8.71E-01 GO:0008217 
GHRL 3 8.71E-01 GO:0042322|GO:0046010 
GPR139 3 8.74E-01 GO:0007218|GO:0008188 
SLC13A3 3 8.74E-01 GO:0006814 
TRPC4AP 3 8.74E-01 GO:0005262 
TNFRSF13C 1 8.77E-01 GO:0033209 
TRPV6 3 8.85E-01 GO:0005262 
TRPV4 2 8.86E-01 GO:0005262 
GCGR 2 8.87E-01 GO:0008217 
CATSPER3 5 8.91E-01 GO:0006814 
SLC23A1 4 8.91E-01 GO:0006814 
SLC12A3 6 8.93E-01 GO:0006814 
SCN9A 19 8.94E-01 GO:0001518|GO:0006814|GO:0019233|GO:0048266 
RELT 6 8.99E-01 GO:0005031|GO:0033209 
ITGA1 4 9.06E-01 GO:0042311 




RIPK1 3 9.09E-01 GO:0010803|GO:0033209|GO:0034612|GO:0071356 
SLC6A2 4 9.16E-01 GO:0048265 
PKDREJ 15 9.20E-01 GO:0005262 
ADCYAP1R1 2 9.24E-01 GO:0042923 
SLC5A2 4 9.27E-01 GO:0006814 
EDARADD 1 9.29E-01 GO:0033209 
NPNT 6 9.30E-01 GO:0071356 
CHRNB3 1 9.30E-01 GO:0004889|GO:0005892 
CXCL10 1 9.30E-01 GO:0008015 
KCNS2 1 9.30E-01 GO:0006813 
PPARGC1A 5 9.31E-01 GO:0007623|GO:0032922|GO:0042752|GO:0071356 
HIF1A 5 9.32E-01 GO:0045906 
UTS2 2 9.38E-01 GO:0008217|GO:0010841|GO:0045909|GO:0046005 
TRPM6 7 9.39E-01 GO:0005262 
TXNDC17 2 9.39E-01 GO:0033209 
SCN10A 12 9.41E-01 GO:0001518|GO:0019233 
ATP1A1 1 9.42E-01 GO:0008217 
LIPC 4 9.44E-01 GO:0007623 
CACNA1A 5 9.46E-01 GO:0005262|GO:0005891|GO:0071356|GO:0060024 
TNFRSF10A 4 9.47E-01 GO:0005031 
ATP4B 3 9.52E-01 GO:0006813|GO:0006814 
RYR1 23 9.52E-01 GO:0005262 
GALR1 4 9.52E-01 GO:0007218|GO:0042923 
CHRNB4 6 9.54E-01 GO:0004889|GO:0005892 
SLC12A1 4 9.55E-01 GO:0006813|GO:0006814 
KCNH3 2 9.62E-01 GO:0006813 
FGB 4 9.63E-01 GO:0045907 
AANAT 1 9.64E-01 GO:0007623 
PHLPP1 4 9.68E-01 GO:0009649 
PKD1 9 9.72E-01 GO:0005262 
SLC5A8 5 9.75E-01 GO:0006814 
SLC17A6 2 9.76E-01 GO:0006814 
SCN5A 11 9.77E-01 GO:0001518|GO:0006814 
MCHR2 1 9.81E-01 GO:0007218 
SLC5A1 6 9.83E-01 GO:0006814 
TNFRSF9 2 9.86E-01 GO:0005031|GO:0033209 
TRPM5 8 9.90E-01 GO:0005267 
CCL22 3 9.97E-01 GO:0071356 
ABCC9 2 1.00E+00 GO:0005267|GO:0006813 
ADAMTS13 3 1.00E+00 GO:0034612 
AGTR2 2 1.00E+00 GO:0008217|GO:0045909 
ASIC3 3 1.00E+00 GO:0005272|GO:0050965|GO:0050966|GO:0050968 
BRE 2 1.00E+00 GO:0005164 
CD27 2 1.00E+00 GO:0005031|GO:0033209 
CHRNA5 2 1.00E+00 GO:0004889|GO:0005892 
CLOCK 3 1.00E+00 GO:0007623|GO:0009649 
EDNRB 3 1.00E+00 GO:0008217|GO:0019233|GO:0042310|GO:0042311|GO:0048265|GO:0051930 
FGG 3 1.00E+00 GO:0045907 
HOXD1 2 1.00E+00 GO:0019233 
PSME2 2 1.00E+00 GO:0033209 
PTGER4 2 1.00E+00 GO:0042322|GO:0046010 
RELB 2 1.00E+00 GO:0032922 
TNFRSF11A 3 1.00E+00 GO:0060086|GO:0005031|GO:0033209|GO:0034612 
TNFRSF1A 3 1.00E+00 GO:0005031|GO:0010803|GO:0033209|GO:0005164 
TNFSF15 3 1.00E+00 GO:0005164|GO:0033209 
A0A0G2JLG4 0 #N/D GO:0005272 
ACTA2 0 #N/D GO:0008217 
ADCYAP1 0 #N/D GO:0005184|GO:0007218|GO:0019233|GO:0045909 
ADH1A 0 #N/D GO:0004022|GO:0004024|GO:0006066 
ADH5 0 #N/D GO:0004022 
ADK 0 #N/D GO:0032922 
ADRA1B 0 #N/D GO:0045907 
ADRA2A 0 #N/D GO:0019229|GO:0045909 
ADRA2C 0 #N/D GO:0045907|GO:0051930 
AGRP 0 #N/D GO:0005184|GO:0007218|GO:0007623 
AKT1 0 #N/D GO:0045907 
APLN 0 #N/D GO:0045906|GO:0045909 
APOA1 0 #N/D GO:0010804 
ARHGEF2 0 #N/D GO:0071356 




ARRB2 0 #N/D GO:0050965 
ASIC1 0 #N/D GO:0006814 
ATF4 0 #N/D GO:0032922 
ATF5 0 #N/D GO:0007623 
ATG5 0 #N/D GO:0042311 
AVP 0 #N/D GO:0005184|GO:0042310|GO:0045907 
BHLHE40 0 #N/D GO:0032922|GO:0043153 
BHLHE41 0 #N/D GO:0032922 
CACNB3 0 #N/D GO:0005262|GO:0005891 
CACNB4 0 #N/D GO:0005262|GO:0005891 
CACNG3 0 #N/D GO:0005891 
CACNG7 0 #N/D GO:0005891 
CACNG8 0 #N/D GO:0005891 
CALCB 0 #N/D GO:0005184 
CCK 0 #N/D GO:0005184|GO:0051930 
CCL1 0 #N/D GO:0071356 
CCL13 0 #N/D GO:0071356 
CCL16 0 #N/D GO:0071356 
CCL18 0 #N/D GO:0071356 
CCL19 0 #N/D GO:0071356 
CCL2 0 #N/D GO:0071356 
CCL20 0 #N/D GO:0071356 
CCL21 0 #N/D GO:0071356 
CCL3 0 #N/D GO:0051930|GO:0071356 
CCL3L1 0 #N/D GO:0071356 
CCL4L1 0 #N/D GO:0071356 
CCL5 0 #N/D GO:0071356 
CCL7 0 #N/D GO:0071356 
CD14 0 #N/D GO:0034612 
CD70 0 #N/D GO:0005164|GO:0033209 
CDIP1 0 #N/D GO:0033209 
CDK2 0 #N/D GO:0006813 
CDK4 0 #N/D GO:0007623 
CDK5 0 #N/D GO:0019233 
CHP1 0 #N/D GO:0006813 
CHRNA7 0 #N/D GO:0004889|GO:0005892 
CHRNB2 0 #N/D GO:0004889|GO:0005892|GO:0019233|GO:0042320|GO:0045188 
CLCA3P 0 #N/D GO:0005262 
CLDN4 0 #N/D GO:0007623 
CLIP3 0 #N/D GO:0010803 
COMMD3 0 #N/D GO:0006814 
COMMD7 0 #N/D GO:0033209 
CORT 0 #N/D GO:0005184 
CREB1 0 #N/D GO:0007623|GO:0042752 
CREM 0 #N/D GO:0032922|GO:0042752 
CRH 0 #N/D GO:0005184|GO:0010841|GO:0046005|GO:0048265 
CRX 0 #N/D GO:0007623 
CRY1 0 #N/D GO:0032922|GO:0042752|GO:0043153 
CRY2 0 #N/D GO:0007623|GO:0032922|GO:0042752|GO:0043153 
CSNK1E 0 #N/D GO:0032922|GO:0042752 
CUL5 0 #N/D GO:0005262 
CYLD 0 #N/D GO:0010803 
CYP11B1 0 #N/D GO:0008217 
CYP4F2 0 #N/D GO:0008217 
CYSLTR1 0 #N/D GO:0007218 
DAXX 0 #N/D GO:0071356 
DHRS4 0 #N/D GO:0006066 
DLL4 0 #N/D GO:0008015 
DYRK1A 0 #N/D GO:0007623 
E2F4 0 #N/D GO:0008015 
EDN2 0 #N/D GO:0003100|GO:0019229|GO:0042310 
EDNRA 0 #N/D GO:0008217|GO:0019233|GO:0042310 
EGR2 0 #N/D GO:0007622 
EGR3 0 #N/D GO:0007623 
F2R 0 #N/D GO:0045907|GO:0051930 
FADD 0 #N/D GO:0005164|GO:0032813 
FBXL3 0 #N/D GO:0042752|GO:0043153 
FBXW11 0 #N/D GO:0042753 
FOXO3 0 #N/D GO:0033209 




GCH1 0 #N/D GO:0008217|GO:0042311|GO:0071356|GO:0034612 
GFPT1 0 #N/D GO:0032922 
GIP 0 #N/D GO:0019233 
GLRA3 0 #N/D GO:0007218 
GNA11 0 #N/D GO:0009649 
GNAQ 0 #N/D GO:0009649 
GPM6A 0 #N/D GO:0005262 
GPR143 0 #N/D GO:0007218 
GPX1 0 #N/D GO:0042311 
GRIN1 0 #N/D GO:0005262|GO:0019233 
GRIN2D 0 #N/D GO:0051930 
GRP 0 #N/D GO:0005184|GO:0007218 
GSK3B 0 #N/D GO:0007623 
H0Y8X5 0 #N/D GO:0007623 
HAS2 0 #N/D GO:0071356 
HCN1 0 #N/D GO:0005267|GO:0006813 
HCRT 0 #N/D GO:0005184|GO:0007218 
HDAC1 0 #N/D GO:0032922 
HDAC3 0 #N/D GO:0007623 
HNRNPD 0 #N/D GO:0042752 
HNRNPR 0 #N/D GO:0007623 
HNRNPU 0 #N/D GO:0032922 
HRH2 0 #N/D GO:0045907 
ID2 0 #N/D GO:0032922|GO:0042752|GO:0043153 
ID4 0 #N/D GO:0007623 
IGBP1 0 #N/D GO:0034612 
IKBKG 0 #N/D GO:0010803 
IL10 0 #N/D GO:0051930 
INS 0 #N/D GO:0045908|GO:0045909 
IRG1 0 #N/D GO:0071356 
JUN 0 #N/D GO:0007623 
JUND 0 #N/D GO:0007623 
KAT2A 0 #N/D GO:0071356 
KCNA1 0 #N/D GO:0005267|GO:0006813|GO:0050966 
KCNA2 0 #N/D GO:0005267|GO:0006813|GO:0019233|GO:0045188 
KCNA3 0 #N/D GO:0006813 
KCNA6 0 #N/D GO:0006813 
KCNAB1 0 #N/D GO:0006813 
KCND2 0 #N/D GO:0019233 
KCNF1 0 #N/D GO:0005267|GO:0006813 
KCNG1 0 #N/D GO:0005267|GO:0006813 
KCNG2 0 #N/D GO:0006813 
KCNIP1 0 #N/D GO:0005267 
KCNIP2 0 #N/D GO:0006813 
KCNIP4 0 #N/D GO:0005267 
KCNJ12 0 #N/D GO:0006813 
KCNJ2 0 #N/D GO:0006813 
KCNJ4 0 #N/D GO:0006813 
KCNJ5 0 #N/D GO:0006813 
KCNK4 0 #N/D GO:0005267|GO:0006813|GO:0019233 
KCNK9 0 #N/D GO:0005267|GO:0006813 
KCNMB2 0 #N/D GO:0006813|GO:0019229 
KCNMB4 0 #N/D GO:0006813|GO:0019229 
KCNN1 0 #N/D GO:0006813 
KCNN2 0 #N/D GO:0006813 
KCNS3 0 #N/D GO:0006813 
KCNV1 0 #N/D GO:0006813 
KISS1R 0 #N/D GO:0007218|GO:0008188|GO:0042923 
KLF2 0 #N/D GO:0071356 
KRT18 0 #N/D GO:0033209 
KRT8 0 #N/D GO:0033209 
LTA 0 #N/D GO:0005164|GO:0033209 
MAGED1 0 #N/D GO:0032922|GO:0042752 
MAP2K7 0 #N/D GO:0034612 
MAP4K3 0 #N/D GO:0034612 
MAPK1 0 #N/D GO:0019233 
MAPK10 0 #N/D GO:0042752 
MAPK8 0 #N/D GO:0042752 
MC3R 0 #N/D GO:0008217|GO:0032922|GO:0042923 




MFSD4B 0 #N/D GO:0006814 
NAMPT 0 #N/D GO:0007623|GO:0032922 
NFE2 0 #N/D GO:0008015 
NIPSNAP1 0 #N/D GO:0019233 
NKX2-1 0 #N/D GO:0042753 
NKX3-1 0 #N/D GO:0071356 
NLGN2 0 #N/D GO:0019233 
NLRP2P 0 #N/D GO:0010804 
NMB 0 #N/D GO:0007218 
NPAS2 0 #N/D GO:0007623|GO:0032922 
NPPC 0 #N/D GO:0045909 
NPR2 0 #N/D GO:0008217 
NPW 0 #N/D GO:0007218 
NPY2R 0 #N/D GO:0004983|GO:0007218|GO:0046005|GO:0051930 
NPY6R 0 #N/D GO:0004983|GO:0007218|GO:0008015 
NR1D1 0 #N/D GO:0007623|GO:0032922|GO:0042752|GO:0060086 
NR2F6 0 #N/D GO:0043153|GO:0050965 
NSF 0 #N/D GO:0006813 
NTRK3 0 #N/D GO:0007623 
NXPH4 0 #N/D GO:0007218 
OGT 0 #N/D GO:0032922 
OLR1 0 #N/D GO:0008015 
OPRD1 0 #N/D GO:0007218|GO:0019233|GO:0042923 
OPRK1 0 #N/D GO:0007218|GO:0019233|GO:0042923|GO:0051930 
OSM 0 #N/D GO:0048266 
P2RY1 0 #N/D GO:0019233|GO:0042312 
PCSK1N 0 #N/D GO:0007218 
PID1 0 #N/D GO:0071356 
PLN 0 #N/D GO:0008015 
PLOD3 0 #N/D GO:0042311 
PMCH 0 #N/D GO:0007218 
PNOC 0 #N/D GO:0005184|GO:0007218 
PPARG 0 #N/D GO:0008217|GO:0042752 
PPP1CA 0 #N/D GO:0032922|GO:0042752|GO:0043153 
PPP1CB 0 #N/D GO:0032922|GO:0042752|GO:0043153 
PPP1CC 0 #N/D GO:0032922|GO:0042752|GO:0043153 
PRKAA1 0 #N/D GO:0042752 
PRLHR 0 #N/D GO:0004983|GO:0007218|GO:0008188 
PRMT5 0 #N/D GO:0032922 
PROK2 0 #N/D GO:0007218|GO:0007623|GO:0019233 
PROL1 0 #N/D GO:0051930 
PRPF8 0 #N/D GO:0071356 
PSMA1 0 #N/D GO:0033209 
PSMA2 0 #N/D GO:0033209 
PSMA3 0 #N/D GO:0033209 
PSMA4 0 #N/D GO:0033209 
PSMA5 0 #N/D GO:0033209 
PSMA6 0 #N/D GO:0033209 
PSMA8 0 #N/D GO:0033209 
PSMB1 0 #N/D GO:0033209 
PSMB4 0 #N/D GO:0033209 
PSMB5 0 #N/D GO:0033209 
PSMC1 0 #N/D GO:0033209 
PSMC2 0 #N/D GO:0033209 
PSMC3 0 #N/D GO:0033209 
PSMC4 0 #N/D GO:0033209 
PSMC6 0 #N/D GO:0033209 
PSMD10 0 #N/D GO:0033209 
PSMD11 0 #N/D GO:0033209 
PSMD12 0 #N/D GO:0033209 
PSMD14 0 #N/D GO:0033209 
PSMD2 0 #N/D GO:0033209 
PSMD4 0 #N/D GO:0033209 
PSMD7 0 #N/D GO:0033209 
PSME3 0 #N/D GO:0033209 
PSPC1 0 #N/D GO:0042752 
PTGDS 0 #N/D GO:0045187 
PTH2 0 #N/D GO:0007218 
PYCARD 0 #N/D GO:0010803|GO:0033209|GO:0071356 




PYY2 0 #N/D GO:0005184|GO:0007218 
PYY3 0 #N/D GO:0005184|GO:0007218 
RACK1 0 #N/D GO:0010803 
RAMP1 0 #N/D GO:0004948 
RAMP2 0 #N/D GO:0008217 
RAPGEF2 0 #N/D GO:0007218 
RCAN1 0 #N/D GO:0008015 
REN 0 #N/D GO:0008217 
RORA 0 #N/D GO:0032922|GO:0042753|GO:0071356 
RORB 0 #N/D GO:0007623|GO:0042752|GO:0042753 
RPS27A 0 #N/D GO:0010803|GO:0033209 
SCG5 0 #N/D GO:0007218 
SCN2B 0 #N/D GO:0001518 
SCN3B 0 #N/D GO:0001518|GO:0006814|GO:0019233 
SCPEP1 0 #N/D GO:0045909 
SFPQ 0 #N/D GO:0042752 
SFRP1 0 #N/D GO:0071356 
SHARPIN 0 #N/D GO:0010803 
SLC13A5 0 #N/D GO:0006814 
SLC22A4 0 #N/D GO:0006814 
SLC24A5 0 #N/D GO:0005262|GO:0006813 
SLC38A1 0 #N/D GO:0006814 
SLC38A3 0 #N/D GO:0006814 
SLC4A10 0 #N/D GO:0006814 
SLC4A8 0 #N/D GO:0006814 
SLC6A8 0 #N/D GO:0006814 
SMPD4 0 #N/D GO:0071356 
SOD1 0 #N/D GO:0008217 
SOD2 0 #N/D GO:0008217 
SOX14 0 #N/D GO:0009649 
SSTR1 0 #N/D GO:0007218|GO:0042923 
SSTR2 0 #N/D GO:0007218|GO:0042923 
STAT1 0 #N/D GO:0008015|GO:0043120|GO:0033209 
SYNCRIP 0 #N/D GO:0007623 
TAC1 0 #N/D GO:0007218|GO:0008217|GO:0019233|GO:0048265 
TAC4 0 #N/D GO:0008217 
TACR1 0 #N/D GO:0019233|GO:0045907|GO:0048265 
TBXA2R 0 #N/D GO:0045907 
TDGF1 0 #N/D GO:0071356 
TNFRSF12A 0 #N/D GO:0033209 
TNFRSF25 0 #N/D GO:0005031|GO:0033209 
TNFSF11 0 #N/D GO:0005164|GO:0032813|GO:0033209 
TNFSF12 0 #N/D GO:0005164|GO:0033209 
TNFSF12-
TNFSF13 
0 #N/D GO:0005164 
0 #N/D GO:0005164|GO:0033209 
TNFSF13B 0 #N/D GO:0005164|GO:0033209 
TNFSF4 0 #N/D GO:0005164|GO:0032813|GO:0033209 
TNFSF8 0 #N/D GO:0005164 
TP53 0 #N/D GO:0043153 
TRAF6 0 #N/D GO:0005164 
TRPC3 0 #N/D GO:0005262 
TRPC4 0 #N/D GO:0005262 
TRPC5 0 #N/D GO:0005262 
TSPO 0 #N/D GO:0048266 
TYMS 0 #N/D GO:0007623 
UBA52 0 #N/D GO:0010803|GO:0033209 
UBB 0 #N/D GO:0010803|GO:0033209 
UBC 0 #N/D GO:0010803|GO:0033209 
UCHL1 0 #N/D GO:0019233 
UCN 0 #N/D GO:0005184|GO:0007218 
UTS2B 0 #N/D GO:0008217|GO:0042312 
UTS2R 0 #N/D GO:0007218|GO:0008015|GO:0010841|GO:0042312|GO:0045906|GO:0010841 
VGF 0 #N/D GO:0005184 
VIP 0 #N/D GO:0005184|GO:0051930 
VWA1 0 #N/D GO:0048266 
XCL1 0 #N/D GO:0071356 
XCL2 0 #N/D GO:0008015|GO:0071356 






Table S2: GO terms annotations  
 Go_term description GO term 
voltage-gated_sodium_channel_complex GO:0001518 
regulation_of_systemic_arterial_blood_pressure_by_endothelin GO:0003100 
alcohol_dehydrogenase_(NAD)_activity GO:0004022 
alcohol_dehydrogenase_activity,_zinc-dependent GO:0004024 
nicotinic_acetylcholine-activated_cation-selective_channel_activity GO:0004889 
calcitonin_receptor_activity GO:0004948 
neuropeptide_Y_receptor_activity GO:0004983 
tumor_necrosis_factor_receptor_activity GO:0005031 
tumor_necrosis_factor_receptor_binding GO:0005164 
neuropeptide_hormone_activity GO:0005184 
calcium_channel_activity GO:0005262 
potassium_channel_activity GO:0005267 
sodium_channel_activity GO:0005272 
voltage-gated_calcium_channel_complex GO:0005891 
nicotinic_acetylcholine-gated_receptor-channel_complex GO:0005892 
alcohol_metabolic_process GO:0006066 
potassium_ion_transport GO:0006813 
sodium_ion_transport GO:0006814 
neuropeptide_signaling_pathway GO:0007218 
rhythmic_behavior GO:0007622 
circadian_rhythm GO:0007623 
ultradian_rhythm GO:0007624 
blood_circulation GO:0008015 
neuropeptide_receptor_activity GO:0008188 
regulation_of_blood_pressure GO:0008217 
entrainment_of_circadian_clock GO:0009649 
regulation_of_tumor_necrosis_factor-mediated_signaling_pathway GO:0010803 
negative_regulation_of_tumor_necrosis_factor-mediated_signaling_pathway GO:0010804 
positive_regulation_of_circadian_sleep/wake_cycle,_wakefulness GO:0010841 
regulation_of_vasoconstriction GO:0019229 
sensory_perception_of_pain GO:0019233 
tumor_necrosis_factor_receptor_superfamily_binding GO:0032813 
circadian_regulation_of_gene_expression GO:0032922 
tumor_necrosis_factor-mediated_signaling_pathway GO:0033209 
response_to_tumor_necrosis_factor GO:0034612 
Vasoconstriction GO:0042310 
Vasodilation GO:0042311 
regulation_of_vasodilation GO:0042312 
regulation_of_circadian_sleep/wake_cycle,_REM_sleep GO:0042320 
negative_regulation_of_circadian_sleep/wake_cycle,_sleep GO:0042321 
negative_regulation_of_circadian_sleep/wake_cycle,_REM_sleep GO:0042322 
circadian_sleep/wake_cycle GO:0042745 
regulation_of_circadian_rhythm GO:0042752 
positive_regulation_of_circadian_rhythm GO:0042753 
neuropeptide_binding GO:0042923 
tumor_necrosis_factor_binding GO:0043120 
entrainment_of_circadian_clock_by_photoperiod GO:0043153 
rhythmic_excitation GO:0043179 
regulation_of_circadian_sleep/wake_cycle,_sleep GO:0045187 
regulation_of_circadian_sleep/wake_cycle,_non-REM_sleep GO:0045188 
negative_regulation_of_vasoconstriction GO:0045906 
positive_regulation_of_vasoconstriction GO:0045907 
negative_regulation_of_vasodilation GO:0045908 
positive_regulation_of_vasodilation GO:0045909 
positive_regulation_of_circadian_sleep/wake_cycle,_REM_sleep GO:0046005 
positive_regulation_of_circadian_sleep/wake_cycle,_non-REM_sleep GO:0046010 
alcohol_catabolic_process GO:0046164 
response_to_pain GO:0048265 
behavioral_response_to_pain GO:0048266 
detection_of_temperature_stimulus_involved_in_sensory_perception_of_pain GO:0050965 
detection_of_mechanical_stimulus_involved_in_sensory_perception_of_pain GO:0050966 
detection_of_chemical_stimulus_involved_in_sensory_perception_of_pain GO:0050968 
regulation_of_sensory_perception_of_pain GO:0051930 
rhythmic_synaptic_transmission GO:0060024 
circadian_temperature_homeostasis GO:0060086 
cellular_response_to_tumor_necrosis_factor GO:0071356 
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